L Number	Hits	Search Text	DB	Time stamp
1	439	(544/358).CCLS.	USPAT; US-PGPUB; EPO; JPO	2003/06/14 11:11
2	303	(544/359).CCLS.	USPAT; US-PGPUB; EPO; JPO	2003/06/14 11:12
3	540	(514/252.12).CCLS.	USPAT; US-PGPUB; EPO; JPO	2003/06/14 11:12
4	423	(514/252.13).CCLS.	USPAT; US-PGPUB; EPO; JPO	2003/06/14 11:12

V. Balasubramanian

Welcome to STN International! Enter x:x

LOGINID:ssspta1611bxv

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	Jun 03	New e-mail delivery for search results now available
NEWS 4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 7	Sep 03	JAPIO has been reloaded and enhanced
NEWS 8	Sep 16	Experimental properties added to the REGISTRY file
NEWS 9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 11	Oct 24	BEILSTEIN adds new search fields
NEWS 12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 13	Nov 18	DKILIT has been renamed APOLLIT
NEWS 14	Nov 25	More calculated properties added to REGISTRY
NEWS 15	Dec 04	CSA files on STN
NEWS 16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 17	Dec 17	TOXCENTER enhanced with additional content
NEWS 18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS 20	Feb 13	CANCERLIT is no longer being updated
NEWS 21	Feb 24	METADEX enhancements
NEWS 22	Feb 24	PCTGEN now available on STN
NEWS 23	Feb 24	TEMA now available on STN
NEWS 24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS 25	Feb 26	PCTFULL now contains images
NEWS 26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 27	Mar 20	EVENTLINE will be removed from STN
NEWS 28	Mar 24	PATDPAFULL now available on STN
NEWS 29	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS 30	Apr 11	Display formats in DGENE enhanced
NEWS 31	Apr 14	MEDLINE Reload
NEWS 32	Apr 17	Polymer searching in REGISTRY enhanced
NEWS 33	Jun 13	Indexing from 1947 to 1956 added to records in CA/CAPLUS
NEWS 34	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS 35	Apr 28	RDISCLOSURE now available on STN
NEWS 36	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS 37	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS 38	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 39	May 16	CHEMREACT will be removed from STN
NEWS 40	May 19	Simultaneous left and right truncation added to WSCA

V. Balasubramanian

```
 NEWS 41  May 19  RAPRA enhanced with new search field, simultaneous left and
                  right truncation
 NEWS 42  Jun 06  Simultaneous left and right truncation added to CBNB
 NEWS 43  Jun 06  PASCAL enhanced with additional data

 NEWS EXPRESS  April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
               MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:06:36 ON 14 JUN 2003

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'REGISTRY' ENTERED AT 11:06:46 ON 14 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   13 JUN 2003  HIGHEST RN 530739-23-2
DICTIONARY FILE UPDATES:  13 JUN 2003  HIGHEST RN 530739-23-2

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end
```

V. Balasubramanian

```
=>
Uploading C:\STNEXP4\QUERIES\10039898SP.str

L1      STRUCTURE UPLOADED

=> que L1

L2   QUE L1

=> d l1
L1 HAS NO ANSWERS
L1              STR
```







```
G1 [@1],[@2]

Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss sam
SAMPLE SEARCH INITIATED 11:07:10 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    251 TO ITERATE

100.0% PROCESSED     251 ITERATIONS                          18 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         4070 TO     5970
PROJECTED ANSWERS:             106 TO      614

L3           18 SEA SSS SAM L1

=> d scan

L3   18 ANSWERS   REGISTRY  COPYRIGHT 2003 ACS
```

V. Balasubramanian

IN 2-Piperazinecarboxamide, N-hydroxy-4-[(4-methoxyphenyl)sulfonyl]-1-(1-methylethyl)-6-oxo-, (R)- (9CI)
MF C15 H21 N3 O6 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):17

L3 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Carbamic acid, [3-[1-(N-acetyl-L-tyrosyl-4-fluorophenylalanyl)-4-[2-(methylamino)-1-(2-naphthalenylmethyl)-2-oxoethyl]-3-oxo-2-piperazinyl]propyl]-, phenylmethyl ester (9CI)
SQL 4
MF C49 H53 F N6 O8

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.



V. Balasubramanian

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 1H-Imidazole-1-carboxylic acid, 2-[3-[[1-(cyclohexylmethyl)-2-hydroxy-2-(tetrahydro-4-methyl-2-furanyl)ethyl]amino]-2-[4-[(4-methyl-1-piperazinyl)sulfonyl]-2-oxo-3-(phenylmethyl)-1-piperazinyl]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI)
MF C41 H63 N7 O8 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3,8-Diazabicyclo[3.2.1]octan-2-one, 3-[4-(3,4-dimethoxyphenyl)-1-(3-phenylpropyl)butyl]-8-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, (1S,5R)- (9CI)
MF C38 H46 N2 O8

Absolute stereochemistry.



V. Balasubramanian

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-[[[[[4-(1-methylethyl)-3-oxo-1-piperazinyl]carbonyl]amino]phenylacetyl]amino]-7-oxo-, monosodium salt, [2S-[2.alpha.,5.alpha.,6.beta.(S*)]]- (9CI)
MF C24 H31 N5 O6 S . Na

Absolute stereochemistry.



● Na

L3 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 1-Piperazineacetamide, .alpha.-butyl-N-[1-(cyclohexylmethyl)-4-[[[2-(dimethylamino)ethyl]amino]carbonyl]-2-hydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, [3R-[1[S*(1S*,2S*,4S*)],3R*]]- (9CI)
MF C42 H71 N7 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Carbamic acid, [2-[2-[2-(acetyloxy)ethyl]-4-[2-(methylamino)-1-(2-

naphthalenylmethyl)-2-oxoethyl]-3-oxo-1-piperazinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI)
MF C36 H43 F N4 O7



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 1-Piperazineacetamide, 4-(aminoacetyl)-N-[2-[[2-[4-[1-[[[2-[(2,5-dioxo-1-pyrrolidinyl)oxy]-2-oxoethyl]amino]carbonyl]-3-methylbutyl]-2-(2-methylpropyl)-3-oxo-1-piperazinyl]-2-oxoethyl]amino]-2-oxoethyl]-.alpha.,3-bis(2-methylpropyl)-2-oxo-, monohydrochloride, [2S-[1[R*(R*)],2R*,4(R*)]]-(9CI)
SQL 8
MF C40 H65 N9 O11 . Cl H

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.



● HCl



L3 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 1-Piperazineacetic acid, 3-methyl-4-[(2-nitrophenyl)sulfonyl]-2-oxo-.alpha.-(phenylmethyl)-, (.alpha.S,3S)- (9CI)
MF C20 H21 N3 O7 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 1-Piperazinecarbonyl chloride, 4-(1-methylethyl)-3-oxo- (9CI)
MF C8 H13 Cl N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 1-Piperazineacetic acid, 4-(2,4-dinitrobenzoyl)-.alpha.-[3-[[[(2,4-dinitrobenzoyl)amino][[(4-methylphenyl)sulfonyl]amino]methylene]amino]propyl]-3-(1-hydroxyethyl)-2-oxo-, ethyl ester, [3S-[1(R*),3R*(S*)]]- (9CI)
MF C35 H37 N9 O16 S

Absolute stereochemistry.
Double bond geometry unknown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 1-Piperazineacetic acid, 4-benzoyl-.alpha.-(2-methylpropyl)-2-oxo-5-(phenylmethyl)-, (.alpha.S,5R)- (9CI)
MF C24 H28 N2 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Glycine, N-[2-[4-[[[[[2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]-3-(2-methylpropyl)-2-oxo-1-piperazinyl]-4-methyl-1-oxopentyl]amino]acetyl]amino]acetyl]-3-(2-methylpropyl)-2-oxo-1-piperazinyl]-4-methyl-1-oxopentyl]-, methyl ester, [3S-[1(R*),3R*,4[R*(R*)]]]- (9CI)
SQL 8
MF C42 H72 N8 O11

RELATED SEQUENCES AVAILABLE WITH SEQLINK

PAGE 1-A



PAGE 1-B



L3 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-.alpha.,3-bis[(4-

hydroxyphenyl)methyl]-2-oxo-, ethyl ester, (.alpha.S,3S)- (9CI)
MF C27 H34 N2 O7

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 1-Piperazineacetic acid, 4-[3-(1H-imidazol-4-yl)-1-oxopropyl]-2-oxo-
.alpha.,3-bis(phenylmethyl)-, ethyl ester, (.alpha.S,3S)- (9CI)
MF C28 H32 N4 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 1,3-Piperazinediacetic acid, 4-[[[4-[(aminoiminomethyl)amino]benzoyl]amino
]acetyl]-.alpha.1-methyl-2-oxo-, monohydrochloride, [S-(R*,R*)]- (9CI)
MF C19 H23 N5 O7 . Cl H

Absolute stereochemistry.



● HCl

L3 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 1-Piperazinecarboxylic acid, 4-[(1R)-2-(acetyloxy)-1-[7-methyl-6-[(methylsulfonyl)oxy]-1,3-benzodioxol-4-yl]ethyl]-2-[[2-iodo-4-methoxy-5-methyl-3-(phenylmethoxy)phenyl]methyl]-5-methyl-3,6-dioxo-, 1,1-dimethylethyl ester, (2S)- (9CI)
MF C39 H45 I N2 O13 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 1-Piperazineacetic acid, 4-[[[2-[4-[[[(1,1-dimethylethoxy)carbonyl]methylamino]acetyl]-3-methyl-2-oxo-1-piperazinyl]-1-oxopropyl]methylamino]acetyl]-.alpha.,3-dimethyl-2-oxo-, methyl ester, [3S-[1(R*),3R*,4[2R*(3R*)]]]- (9CI)
SQL 6
MF C28 H46 N6 O9

V. Balasubramanian

Absolute stereochemistry.



RN 474094-77-4 CAPLUS
CN 1-Piperazineacetamide, 3-[2-(acetyloxy)ethyl]-4-(N-acetyl-L-tyrosyl-4-fluorophenylalanyl)-N-methyl-.alpha.-(2-naphthalenylmethyl)-2-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L.. ANSWER 6 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 2002:777909 CAPLUS
DN 137:295253
TI Method for preparing monocyclic N-acyl aminolactam compounds and their combinatorial libraries
IN Cheng, Jie Fei; Chen, Mi; Nadzan, Alex
PA Chugai Seiyaku Kabushiki Kaisha, Japan
SO PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DT Patent
LA English

V. Balasubramanian

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002079172	A1	20021010	WO 2001-US51579	20011210

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2000-255092P P 20001212

OS MARPAT 137:295253

IT **467469-31-4P 467469-32-5P 467469-33-6P**
467469-34-7P 467469-35-8P 467469-36-9P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of monocyclic N-acyl aminolactam compds. by solid-phase four-component reaction)

RN 467469-31-4 CAPLUS

CN Hexanoic acid, 6-[[2-[5-[(butylamino)carbonyl]-3-methyl-2-oxo-4-(1-oxo-3-phenylpropyl)-1-piperazinyl]-1-oxo-4-phenylbutyl]amino]- (9CI) (CA INDEX NAME)



RN 467469-32-5 CAPLUS

CN Hexanoic acid, 6-[[2-[5-[(butylamino)carbonyl]-3-methyl-4-(3-nitrobenzoyl)-2-oxo-1-piperazinyl]-1-oxo-4-phenylbutyl]amino]- (9CI) (CA INDEX NAME)



RN 467469-33-6 CAPLUS

CN Hexanoic acid, 6-[[2-[5-[[(1,1-dimethylethyl)amino]carbonyl]-3-(1-methylethyl)-4-(3-nitrobenzoyl)-2-oxo-1-piperazinyl]-3-methyl-1-

oxobutyl]amino]- (9CI) (CA INDEX NAME)



RN 467469-34-7 CAPLUS
CN Benzoic acid, 4-[[4-[1-[[(5-carboxypentyl)amino]carbonyl]-2-methylpropyl]-6-[[(1,1-dimethylethyl)amino]carbonyl]-2-(1-methylethyl)-3-oxo-1-piperazinyl]carbonyl]-, 1-methyl ester (9CI) (CA INDEX NAME)



RN 467469-35-8 CAPLUS
CN Hexanoic acid, 6-[[cyclohexyl[4-(3-nitrobenzoyl)-2-oxo-5-[[(phenylmethyl)amino]carbonyl]-1-piperazinyl]acetyl]amino]- (9CI) (CA INDEX NAME)



RN 467469-36-9 CAPLUS
CN Hexanoic acid, 6-[[cyclohexyl[2-oxo-4-(1-oxo-3-phenylpropyl)-5-[[(phenylmethyl)amino]carbonyl]-1-piperazinyl]acetyl]amino]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 2002:362728 CAPLUS
DN 137:109413
TI Total Synthesis of Ecteinascidin 743
AU Endo, Atsushi; Yanagisawa, Arata; Abe, Masanao; Tohma, Shigemitsu; Kan, Toshiyuki; Fukuyama, Tohru
CS Graduate School of Pharmaceutical Sciences, The University of Tokyo, CREST, The Japan Science and Technology Cooperation (JST), Bunkyo-ku, Tokyo, 113-0033, Japan
SO Journal of the American Chemical Society (2002), 124(23), 6552-6554
CODEN: JACSAT; ISSN: 0002-7863
PB American Chemical Society
DT Journal
LA English
OS CASREACT 137:109413
IT **442663-32-3P 442663-33-4P 442663-34-5P**
442663-50-5P 442663-51-6P 442663-52-7P
442663-53-8P 442663-54-9P 442663-55-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(total synthesis of ecteinascidin 743)
RN 442663-32-3 CAPLUS
CN 1,5-Imino-3-benzazocine-11-carboxylic acid, 3-[(1R)-2-(acetyloxy)-1-[7-methyl-6-[(methylsulfonyl)oxy]-1,3-benzodioxol-4-yl]ethyl]-1,2,3,4,5,6-hexahydro-9-methoxy-8-methyl-2-methylene-4-oxo-10-(phenylmethoxy)-, 1,1-dimethylethyl ester, (1R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 442663-33-4 CAPLUS
CN 1,5-Imino-3-benzazocine-11-carboxylic acid, 3-[(1R)-2-(acetyloxy)-1-[6-(acetyloxy)-7-methyl-1,3-benzodioxol-4-yl]ethyl]-1,2,3,4,5,6-hexahydro-2-(hydroxymethyl)-2,9-dimethoxy-8-methyl-4-oxo-10-(phenylmethoxy)-, 2,2,2-trichloroethyl ester, (1R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 442663-34-5 CAPLUS
CN 1,5-Imino-3-benzazocine-11-carboxylic acid, 3-[(1R)-2-(acetyloxy)-1-[6-(acetyloxy)-7-methyl-1,3-benzodioxol-4-yl]ethyl]-1,2,3,4,5,6-hexahydro-2-(hydroxymethyl)-9-methoxy-8-methyl-4-oxo-10-(phenylmethoxy)-, 2,2,2-trichloroethyl ester, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 442663-50-5 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[(1R)-2-(acetyloxy)-1-[7-methyl-6-[(methylsulfonyl)oxy]-1,3-benzodioxol-4-yl]ethyl]-2-[[2-iodo-4-methoxy-5-methyl-3-(phenylmethoxy)phenyl]methyl]-5-methyl-3,6-dioxo-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 442663-51-6 CAPLUS
CN 1,5-Imino-3-benzazocine-11-carboxylic acid, 3-[(1R)-2-(acetyloxy)-1-[6-(acetyloxy)-7-methyl-1,3-benzodioxol-4-yl]ethyl]-1,2,3,4,5,6-hexahydro-9-methoxy-8-methyl-2-methylene-4-oxo-10-(phenylmethoxy)-, 1,1-dimethylethyl ester, (1R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 442663-52-7 CAPLUS
CN 1,5-Imino-3-benzazocine-11-carboxylic acid, 3-[(1R)-2-(acetyloxy)-1-[6-(acetyloxy)-7-methyl-1,3-benzodioxol-4-yl]ethyl]-1,2,3,4,5,6-hexahydro-9-methoxy-8-methyl-2-methylene-4-oxo-10-(phenylmethoxy)-, 2,2,2-trichloroethyl ester, (1R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 442663-53-8 CAPLUS
CN 1,5-Imino-3-benzazocine-11-carboxylic acid, 3-[(1R)-2-(acetyloxy)-1-[6-(acetyloxy)-7-methyl-1,3-benzodioxol-4-yl]ethyl]-2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-1,2,3,4,5,6-hexahydro-9-methoxy-8-methyl-4-oxo-10-(phenylmethoxy)-, 2,2,2-trichloroethyl ester, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 442663-54-9 CAPLUS
CN 1,5-Imino-3-benzazocine-11-carboxylic acid, 2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-1,2,3,4,5,6-hexahydro-3-[(1R)-2-hydroxy-1-(6-hydroxy-7-methyl-1,3-benzodioxol-4-yl)ethyl]-9-methoxy-8-methyl-4-oxo-10-(phenylmethoxy)-, 2,2,2-trichloroethyl ester, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 442663-55-0 CAPLUS
CN 1,5-Imino-3-benzazocine-11-carboxylic acid, 2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-1,2,3,4,5,6-hexahydro-3-[(1R)-2-hydroxy-1-[7-methyl-6-(phenylmethoxy)-1,3-benzodioxol-4-yl]ethyl]-9-methoxy-8-methyl-4-oxo-10-(phenylmethoxy)-, 2,2,2-trichloroethyl ester, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 2002:286697 CAPLUS
DN 136:309938
TI Preparation of new piperazinone derivatives by cyclization of N,N'-bis(dicarboxyalkyl)ethylenediamine derivatives
IN Nogami, Hiroyuki; Anzai, Ryuichi; Yoshioka, Akira
PA Mitsubishi Rayon Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 14 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2002114766	A2	20020416	JP 2000-304904	20001004
PRAI	JP 2000-304904		20001004		

OS CASREACT 136:309938; MARPAT 136:309938
IT **410077-31-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of new piperazinone derivs. by cyclization of N,N'-bis(dicarboxyalkyl)ethylenediamine derivs. in presence of .alpha.-hydroxy carboxylic acid)
RN 410077-31-5 CAPLUS
CN Pentanedioic acid, 2-[(3R)-3-(2-carboxyethyl)-2-oxo-4-(1-oxododecyl)-1-piperazinyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

V. Balasubramanian



L5 ANSWER 9 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 2002:197486 CAPLUS
DN 137:155164
TI Synthesis of diastereomerically pure 1,4,5-substituted-2-oxopiperazines on solid-phase
AU Khan, Nawaz M.; Cano, Montserrat; Balasubramanian, Shankar
CS Department of Chemistry, University of Cambridge, Cambridge, CB2 1EW, UK
SO Tetrahedron Letters (2002), 43(13), 2439-2443
CODEN: TELEAY; ISSN: 0040-4039
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 137:155164
IT **445273-93-8P 445273-94-9P 445273-96-1P**
445273-98-3P 445274-02-2P 445274-04-4P
445274-06-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of as peptidomimetics using solid-phase synthesis techniques)
RN 445273-93-8 CAPLUS
CN 1-Piperazineacetic acid, 4-[(4-methylphenyl)sulfonyl]-.alpha.-(2-methylpropyl)-2-oxo-5-(phenylmethyl)-, (.alpha.S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 445273-94-9 CAPLUS
CN 1-Piperazineacetic acid, 5-methyl-4-[(4-methylphenyl)sulfonyl]-.alpha.-(2-methylpropyl)-2-oxo-, (.alpha.S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 445273-96-1 CAPLUS
CN 1-Piperazineacetic acid, .alpha.,5-dimethyl-4-[(4-methylphenyl)sulfonyl]-2-oxo-, (.alpha.S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 445273-98-3 CAPLUS
CN 1-Piperazineacetic acid, 4-acetyl-.alpha.-(2-methylpropyl)-2-oxo-5-(phenylmethyl)-, (.alpha.S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 445274-02-2 CAPLUS
CN 1-Piperazineacetic acid, .alpha.-(2-methylpropyl)-4-[(4-nitrophenyl)sulfonyl]-2-oxo-5-(phenylmethyl)-, (.alpha.S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 445274-04-4 CAPLUS
CN 1-Piperazineacetic acid, 4-benzoyl-.alpha.-(2-methylpropyl)-2-oxo-5-(phenylmethyl)-, (.alpha.S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 445274-06-6 CAPLUS
CN 1-Piperazineacetic acid, 4-[(2S)-2-amino-1-oxopropyl]-.alpha.-(2-methylpropyl)-2-oxo-5-(phenylmethyl)-, (.alpha.S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 2002:136921 CAPLUS
DN 137:93725
TI Synthesis and structure-Activity relationships of M2-Selective muscarinic receptor ligands in the 1-[4-(4-Arylsulfonyl)-phenylmethyl]-4-(4-

piperidinyl)-piperazine family
AU McCombie, Stuart W.; Lin, Sue-Ing; Tagat, Jayaram R.; Nazareno, Dennis; Vice, Susan; Ford, Jennifer; Asberom, Theodros; Leone, Daria; Kozlowski, Joseph A.; Zhou, Guowei; Ruperto, Vilma B.; Duffy, Ruth A.; Lachowicz, Jean E.
CS Department of Chemistry, Schering-Plough Research Institute, Kenilworth, NJ, 07033, USA
SO Bioorganic & Medicinal Chemistry Letters (2002), 12(5), 795-798
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 137:93725
IT **441772-09-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and structure-activity relationships of M2-selective muscarinic receptor ligands in the [[(arylsulfonyl)phenyl]methyl](piperidinyl)piperazine family)
RN 441772-09-4 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[(1S)-1-[4-(1,3-benzodioxol-5-ylsulfonyl)phenyl]ethyl]-3-methyl-2,5-dioxo-, 1,1-dimethylethyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 2002:106262 CAPLUS
DN 136:321186
TI Insights into the Selective Inhibition of Candida albicans Secreted Aspartyl Protease: A Docking Analysis Study
AU Pranav Kumar, S. K.; Kulkarni, Vithal M.
CS Department of Chemical Technology, Pharmaceutical Division, University of Mumbai, Mumbai, 400 019, India
SO Bioorganic & Medicinal Chemistry (2002), 10(4), 1153-1170
CODEN: BMECEP; ISSN: 0968-0896
PB Elsevier Science Ltd.
DT Journal
LA English
IT **142928-23-2 143731-22-0 414896-67-6**
414896-68-7 414896-69-8 414896-70-1
414896-71-2 414896-72-3
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(mol. modeling study reveals hydrogen bonding hydrophobic interactions

and binding energies play role in binding of inhibitors to Candida albicans aspartyl protease)

RN 142928-23-2 CAPLUS

CN 1-Piperazineacetamide, .alpha.-butyl-N-[(1S,2S,4R)-4-[(butylamino)carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, monohydrochloride, (.alpha.S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 143731-22-0 CAPLUS

CN 1-Piperazineacetamide, .alpha.-butyl-N-[(1S,2S,4R)-4-[(butylamino)carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, (.alpha.S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 414896-67-6 CAPLUS
CN 1-Piperazineacetamide, .alpha.-butyl-N-[(1S,2S,4R)-4-[(butylamino)carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, (.alpha.R,3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 414896-68-7 CAPLUS
CN 1-Piperazineacetamide, .alpha.-butyl-N-[(1S,2S,4R)-4-[(butylamino)carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, (.alpha.S,3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 414896-69-8 CAPLUS
CN 1-Piperazineacetamide, .alpha.-butyl-N-[(1S,2S,4R)-4-[(butylamino)carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)sulfonyl]-2-oxo-3-(phenylmethyl)-, (.alpha.S,3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 414896-70-1 CAPLUS
CN 1-Piperazineacetamide, .alpha.-butyl-N-[(1S,2S,4R)-1-(cyclohexylmethyl)-2-hydroxy-5-methyl-4-[[[3-(4-morpholinyl)propyl]amino]carbonyl]hexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, (.alpha.S,3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





RN 414896-71-2 CAPLUS
CN 1-Piperazineacetamide, .alpha.-butyl-N-[(1S,2S,4R)-1-(cyclohexylmethyl)-4-[[[2-(dimethylamino)ethyl]amino]carbonyl]-2-hydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, (.alpha.S,3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 414896-72-3 CAPLUS
CN 1-Piperazineacetamide, .alpha.-butyl-N-[(1S,2S,4R)-1-(cyclohexylmethyl)-4-[[[3-(dimethylamino)propyl]amino]carbonyl]-2-hydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, (.alpha.S,3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



V. Balasubramanian

RE.CNT 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 12 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 2001:545724 CAPLUS
DN 135:147398
TI Peptidomimetic modulators of cell adhesion
IN Gour, Barbara J.; Blaschuk, Orest W.; Ali, Anmar; Ni, Feng; Chen, Zhigang; Michaud, Stephanie Denise; Wang, Shoameng; Hu, Zengjian
PA Adherex Technologies, Inc., Can.
SO PCT Int. Appl., 416 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001053331	A2	20010726	WO 2001-US2508	20010124
	WO 2001053331	A3	20020711		
	WO 2001053331	C2	20021031		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 2000-491078 A 20000124
OS MARPAT 135:147398
IT **351857-32-4 351857-33-5 351857-34-6**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(peptidomimetic modulators of cell adhesion)
RN 351857-32-4 CAPLUS
CN 1-Piperazineacetamide, 4-[(2S)-2-(acetylamino)-3-(1H-imidazol-4-yl)-1-oxopropyl]-3-methyl-.alpha.-(1-methylethyl)-2-oxo-, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 351857-33-5 CAPLUS

V. Balasubramanian

CN 1-Piperazineacetamide, 4-[(2S)-2-(acetylamino)-3-(1H-imidazol-4-yl)-1-oxopropyl]-.alpha.-[(4-hydroxyphenyl)methyl]-3-methyl-2-oxo-, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 351857-34-6 CAPLUS
CN L-Tyrosinamide, N-acetyl-L-histidyl-(.alpha.S,3S)-3-methyl-.alpha.-(1-methylethyl)-2-oxo-1-piperazineacetyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 13 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 2001:435076 CAPLUS
DN 135:46205
TI Preparation of neurotrophic bicyclic diamides with peptidylprolyl isomerase (PPIase or rotamase) inhibitory activity
IN Dubowchik, Gene Michael; Provencal, David Paul
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 91 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001042245	A1	20010614	WO 2000-US32395	20001128

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1999-169600P P 19991208

OS MARPAT 135:46205

IT **344461-77-4P 344461-81-0P 344461-92-3P**
344462-01-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(stereoselective prepn. and biol. activity of bicyclic diamides as neuroprotective agents and peptidylprolyl isomerase (PPIase or rotamase) inhibitors)

RN 344461-77-4 CAPLUS

CN 3,8-Diazabicyclo[3.2.1]octan-2-one, 8-[oxo(3,4,5-trimethoxyphenyl)acetyl]-3-[3-phenyl-1-(2-phenylethyl)propyl]-, (1S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344461-81-0 CAPLUS

CN 3,8-Diazabicyclo[3.2.1]octan-2-one, 3-[4-(3,4-dimethoxyphenyl)-1-(3-phenylpropyl)butyl]-8-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, (1S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344461-92-3 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]nonan-2-one, 3-[4-(3,4-dimethoxyphenyl)-1-(3-phenylpropyl)butyl]-9-[oxo(3,4,5-trimethoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)



RN 344462-01-7 CAPLUS
CN 3,8-Diazabicyclo[3.2.1]octan-2-one, 8-[difluoro(3,4,5-trimethoxyphenyl)acetyl]-3-[3-phenyl-1-(2-phenylethyl)propyl]-, (1S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



V. Balasubramanian

IT **344462-62-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(stereoselective prepn. and biol. activity of bicyclic diamides as neuroprotective agents and peptidylprolyl isomerase (PPIase or rotamase) inhibitors)
RN 344462-62-0 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]nonane-9-carboxylic acid, 3-[4-(3,4-dimethoxyphenyl)-1-(3-phenylpropyl)butyl]-2-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 14 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 2001:59590 CAPLUS
DN 134:237814
TI New analogues of bradykinin containing a conformationally restricted dipeptide fragment in their molecules
AU Derdowska, I.; Prahl, A.; Neubert, K.; Hartrodt, B.; Kania, A.; Dobrowolski, D.; Melhem, S.; Trzeciak, H. I.; Wierzba, T.; Lammek, B.
CS Faculty of Chemistry, University of Gdansk, Gdansk, 80-952, Pol.
SO Journal of Peptide Research (2001), 57(1), 11-18
CODEN: JPERFA; ISSN: 1397-002X
PB Munksgaard International Publishers Ltd.
DT Journal
LA English
OS CASREACT 134:237814
IT **193091-08-6P 193091-09-7P 330184-10-6P**
330184-14-0P 330184-19-5P 330184-23-1P
330184-27-5P 330184-31-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and structure-activity relationship of conformationally restricted bradykinin analogs)
RN 193091-08-6 CAPLUS
CN L-Arginine, D-arginyl-L-arginyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-L-phenylalanyl-L-seryl-(.alpha.S,3S)-2-oxo-.alpha.,3-bis(phenylmethyl)-1-piperazineacetyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

PAGE 1-A



PAGE 1-B



RN 193091-09-7 CAPLUS
CN L-Arginine, N2-(tricyclo[3.3.1.13,7]dec-1-ylacetyl)-D-arginyl-L-arginyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-L-phenylalanyl-L-seryl-(.alpha.S,3S)-2-oxo-.alpha.,3-bis(phenylmethyl)-1-piperazineacetyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

V. Balasubramanian

PAGE 1-A



PAGE 1-B



RN 330184-10-6 CAPLUS
CN L-Arginine, D-arginyl-L-arginyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-(.alpha.S,3S)-2-oxo-.alpha.,3-bis(phenylmethyl)-1-piperazineacetyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

V. Balasubramanian

PAGE 1-A



PAGE 1-B



RN 330184-14-0 CAPLUS
CN L-Arginine, N2-(tricyclo[3.3.1.13,7]dec-1-ylacetyl)-D-arginyl-L-arginyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-(.alpha.S,3S)-2-oxo-.alpha.,3-bis(phenylmethyl)-1-piperazineacetyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

V. Balasubramanian

PAGE 1-A



PAGE 1-B



RN 330184-19-5 CAPLUS
CN L-Arginine, D-arginyl-L-arginyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-L-phenylalanyl-(.alpha.S,3S)-2-oxo-.alpha.,3-bis(phenylmethyl)-1-piperazineacetyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 330184-23-1 CAPLUS
CN L-Arginine, N2-(tricyclo[3.3.1.13,7]dec-1-ylacetyl)-D-arginyl-L-arginyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-L-phenylalanyl-(.alpha.S,3S)-2-oxo-.alpha.,3-bis(phenylmethyl)-1-piperazineacetyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 330184-27-5 CAPLUS

CN L-Arginine, D-arginyl-L-arginyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-(.alpha.S,3S)-2-oxo-.alpha.,3-bis(phenylmethyl)-1-piperazineacetyl- (9CI) (CA INDEX NAME)

V. Balasubramanian

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 330184-31-1 CAPLUS
CN L-Arginine, N2-(tricyclo[3.3.1.13,7]dec-1-ylacetyl)-D-arginyl-L-arginyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-(.alpha.S,3S)-2-oxo-.alpha.,3-bis(phenylmethyl)-1-piperazineacetyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT **193091-13-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of a conformationally restricted PhePhe fragment)
RN 193091-13-3 CAPLUS
CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-2-oxo-.alpha.,3-bis(phenylmethyl)-, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

V. Balasubramanian



RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 15 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 2001:31476 CAPLUS
DN 134:95515
TI Cyclized amino acid derivatives for the treatment of neurological diseases
IN Lauffer, David; Ledford, Brian
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001002372	A1	20010111	WO 2000-US18577	20000706
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1196395	A1	20020417	EP 2000-945224	20000706
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2003503482	T2	20030128	JP 2001-507811	20000706
PRAI	US 1999-142404P	P	19990706		
	WO 2000-US18577	W	20000706		

OS MARPAT 134:95515
IT **318948-03-7 318948-10-6 318948-17-3**
318948-24-2 318948-31-1 318948-38-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclized amino acid derivs. for treatment of neurol. diseases)
RN 318948-03-7 CAPLUS
CN Piperazinone, 4-[oxo(3,4,5-trimethoxyphenyl)acetyl]-1-[4-phenyl-1-(3-phenylpropyl)butyl]- (9CI) (CA INDEX NAME)



RN 318948-10-6 CAPLUS
CN Piperazinone, 4-[oxo(3,4,5-trimethoxyphenyl)acetyl]-3-phenyl-1-[4-phenyl-1-(3-phenylpropyl)butyl]- (9CI) (CA INDEX NAME)



RN 318948-17-3 CAPLUS
CN Piperazinone, 4-[oxo(3,4,5-trimethoxyphenyl)acetyl]-1-[3-phenyl-1-(2-phenylethyl)propyl]- (9CI) (CA INDEX NAME)



RN 318948-24-2 CAPLUS
CN Piperazinone, 4-[oxo(3,4,5-trimethoxyphenyl)acetyl]-3-phenyl-1-[3-phenyl-1-(2-phenylethyl)propyl]- (9CI) (CA INDEX NAME)



RN 318948-31-1 CAPLUS
CN Piperazinone, 1-(diphenylmethyl)-4-[oxo(3,4,5-trimethoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)



RN 318948-38-8 CAPLUS
CN Piperazinone, 1-(diphenylmethyl)-4-[oxo(3,4,5-trimethoxyphenyl)acetyl]-3-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 16 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 2000:591213 CAPLUS
DN 133:261650
TI New bradykinin analogs in contraction of rat uterus
AU Trzeciak, H. I.; Kozik, W.; Melhem, S.; Kania, A.; Dobrowolski, D.; Prahl, A.; Derdowska, I.; Lammek, B.
CS Department of Pharmacology, Silesian Medical University, Katowice, 40-752, Pol.
SO Peptides (New York) (2000), 21(6), 829-834
CODEN: PPTDD5; ISSN: 0196-9781
PB Elsevier Science Inc.
DT Journal
LA English
IT **193091-08-6 297175-25-8**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(new bradykinin analogs in contraction of rat uterus)
RN 193091-08-6 CAPLUS
CN L-Arginine, D-arginyl-L-arginyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-L-phenylalanyl-L-seryl-(.alpha.S,3S)-2-oxo-.alpha.,3-bis(phenylmethyl)-1-piperazineacetyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

PAGE 1-A



PAGE 1-B



RN 297175-25-8 CAPLUS
CN L-Arginine, N2-(phenylacetyl)-D-arginyl-L-arginyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-L-phenylalanyl-L-seryl-(.alpha.S,3S)-2-oxo-.alpha.,3-bis(phenylmethyl)-1-piperazineacetyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 17 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 2000:296186 CAPLUS
DN 133:105336
TI Synthesis of a novel thyrotropin releasing hormone (TRH) analog incorporating a piperazin-2-one ring
AU Bhatt, Ulhas; Just, George
CS Department of Chemistry, McGill University, Montreal, QC, H3A 2K6, Can.
SO Helvetica Chimica Acta (2000), 83(4), 722-727
CODEN: HCACAV; ISSN: 0018-019X
PB Verlag Helvetica Chimica Acta
DT Journal
LA English
IT **282529-03-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis of a piperazinone-contg. peptidomimetic analog of TSH releasing hormone)
RN 282529-03-7 CAPLUS
CN 1-Piperazineacetamide, 3-(1H-imidazol-4-ylmethyl)-.alpha.-(1-methylethyl)-2-oxo-4-[[(2S)-5-oxo-2-pyrrolidinyl]carbonyl]-, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **282529-08-2P 282529-12-8P 282529-13-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of a piperazinone-contg. peptidomimetic analog of TSH releasing hormone)

RN 282529-08-2 CAPLUS
CN 1-Piperazineacetic acid, .alpha.-(1-methylethyl)-4-[(4-nitrophenyl)sulfonyl]-2-oxo-3-[[1-(triphenylmethyl)-1H-imidazol-4-yl]methyl]-, methyl ester, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 282529-12-8 CAPLUS
CN 1-Piperazineacetic acid, .alpha.-(1-methylethyl)-2-oxo-4-[[(2S)-5-oxo-2-pyrrolidinyl]carbonyl]-3-[[1-(triphenylmethyl)-1H-imidazol-4-yl]methyl]-, methyl ester, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 282529-13-9 CAPLUS
CN 1-Piperazineacetamide, .alpha.-(1-methylethyl)-2-oxo-4-[[(2S)-5-oxo-2-pyrrolidinyl]carbonyl]-3-[[1-(triphenylmethyl)-1H-imidazol-4-yl]methyl]-, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 18 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 2000:242935 CAPLUS
DN 133:98608
TI Preparations and Characterizations of Novel N,N'-Ethylene-Bridged-(S)-Histidyl-(S)-Tyrosine Derivatives and Their Copper(II) Complexes as Models of Galactose Oxidase
AU Yamato, Kazuhiro; Inada, Takanori; Doe, Matsumi; Ichimura, Akio; Takui, Takeji; Kojima, Yoshitane; Kikunaga, Toshimitsu; Nakamura, Shin; Yanagihara, Naohisa; Onaka, Tomoko; Yano, Shigenobu
CS Dep. Chem., Grad. Sch. Sci., Osaka City University, Sumiyoshi-ku, Osaka, 558-8585, Japan
SO Bulletin of the Chemical Society of Japan (2000), 73(4), 903-912
CODEN: BCSJA8; ISSN: 0009-2673
PB Chemical Society of Japan
DT Journal

V. Balasubramanian

LA English

IT **280558-83-0P**
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and electrochem. oxidn. and reactant for prepn. of copper N,N'-ethylene-bridged-hystidyltyrosine deriv. complex galactose oxidase model)

RN 280558-83-0 CAPLUS

CN 1-Piperazineacetic acid, 4-[[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]-.alpha.-[(4-hydroxyphenyl)methyl]-3-(1H-imidazol-4-ylmethyl)-2-oxo-, ethyl ester, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **280558-85-2P 280558-87-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reactant for prepn. of copper N,N'-ethylene-bridged-hystidyltyrosine deriv. complex galactose oxidase model)

RN 280558-85-2 CAPLUS

CN 1-Piperazineacetic acid, 4-acetyl-.alpha.-[(4-hydroxyphenyl)methyl]-3-(1H-imidazol-4-ylmethyl)-2-oxo-, ethyl ester, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 280558-87-4 CAPLUS

CN Carbamic acid, [2-[(2S)-4-[(1S)-2-amino-1-[(4-hydroxyphenyl)methyl]-2-oxoethyl]-2-(1H-imidazol-4-ylmethyl)-3-oxo-1-piperazinyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

V. Balasubramanian

Absolute stereochemistry. Rotation (+).



IT **280558-89-6P**
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn., acid dissocn. consts. and reactant for prepn. of copper N,N'-ethylene-bridged-hystidyltyrosine deriv. complex galactose oxidase model)
RN 280558-89-6 CAPLUS
CN 1-Piperazineacetamide, 4-acetyl-.alpha.-[(4-hydroxyphenyl)methyl]-3-(1H-imidazol-4-ylmethyl)-2-oxo-, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 19 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 2000:188697 CAPLUS
DN 133:4959
TI Conformationally constrained substance P analogs: The total synthesis of a constrained peptidomimetic for the Phe7-Phe8 region
AU Tong, Yunsong; Fobian, Yvette M.; Wu, Meiye; Boyd, Norman D.; Moeller, Kevin D.
CS The Department of Chemistry, Washington University, St. Louis, MO, 63130, USA

V. Balasubramanian

SO Journal of Organic Chemistry (2000), 65(8), 2484-2493
CODEN: JOCEAH; ISSN: 0022-3263
PB American Chemical Society
DT Journal
LA English
IT **212612-56-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis of substance P analogs contg. conformationally constrained Phe-Phe peptidomimetic)
RN 212612-56-1 CAPLUS
CN L-Methioninamide, L-arginyl-L-prolyl-L-lysyl-L-prolyl-L-glutaminyl-L-glutaminyl-(.alpha.S,3S)-2-oxo-.alpha.,3-bis(phenylmethyl)-1-piperazineacetylglycyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



V. Balasubramanian

IT **193091-13-3P 270257-61-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of substance P analogs contg. conformationally constrained Phe-Phe peptidomimetic)
RN 193091-13-3 CAPLUS
CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-2-oxo-.alpha.,3-bis(phenylmethyl)-, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 270257-61-9 CAPLUS
CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-5-hydroxy-2-oxo-.alpha.,3-bis(phenylmethyl)-, methyl ester, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 20 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 2000:117072 CAPLUS
DN 132:166522
TI Preparation of depsipeptide derivatives bearing piperazinone rings as enhancers of apolipoprotein E production
IN Yanai, Makoto; Suzuki, Masashi; Oshida, Norio; Kawamura, Koji; Hiramoto, Shigeru; Yasuda, Orie; Kinoshita, Nobuhiro; Shingai, Akiko; Takasu, Masako
PA Nisshin Flour Milling Co., Ltd., Japan
SO PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

PI	WO 2000008047	A1	20000217	WO 1999-JP4205	19990804
	W: JP, US				
	RW: DE, FR, GB, IT				
	EP 1028126	A1	20000816	EP 1999-935054	19990804
	R: DE, FR, GB, IT				
	US 6288038	B1	20010911	US 2000-509132	20000403
PRAI	JP 1998-220398	A	19980804		
	WO 1999-JP4205	W	19990804		

OS MARPAT 132:166522

IT **259087-00-8P 259087-08-6P 259087-24-6P**
259087-25-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of depsipeptide derivs. bearing piperazinone rings as enhancers of apolipoprotein E prodn. for remedies for nerve injury, dementia, and hyperlipidemia)

RN 259087-00-8 CAPLUS

CN 1-Piperazinepropanoic acid, .beta.-[[[(2E)-5-[[(1R)-1-(carboxymethyl)dodecyl]oxy]-5-oxo-2-pentenyl]amino]carbonyl]-4-[(9H-fluoren-9-ylmethoxy)carbonyl]-2-oxo-, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 259087-08-6 CAPLUS

CN 1-Piperazinepropanoic acid, .beta.-[[[(1R)-1-[[[(1R,2R)-1-[[[(1R)-1-(carboxymethyl)dodecyl]oxy]carbonyl]-2-methylbutyl]amino]methyl]-3-methylbutyl]amino]carbonyl]-4-[(9H-fluoren-9-ylmethoxy)carbonyl]-2-oxo-, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 259087-24-6 CAPLUS
CN 1-Piperazinepropanoic acid, .beta.-[[[(1R)-5-[[(1R)-1-(carboxymethyl)dodecyl]oxy]-1-(2-methylpropyl)-2,5-dioxopentyl]amino]carbonyl]-4-[(9H-fluoren-9-ylmethoxy)carbonyl]-2-oxo-, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 259087-25-7 CAPLUS
CN 1-Piperazinepropanoic acid, .beta.-[[[(1R)-1-[[[(1R,2R)-1-[[[(1R)-1-(carboxymethyl)dodecyl]oxy]carbonyl]-2-methylbutyl]amino]methyl]-3-methylbutyl]amino]carbonyl]-4-[(9H-fluoren-9-ylmethoxy)carbonyl]-2-oxo-, (.beta.S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 259087-08-6
CMF C49 H72 N4 O10

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT **259086-94-7P 259086-98-1P 259086-99-2P**
259087-06-4P 259087-07-5P 259087-23-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of depsipeptide derivs. bearing piperazinone rings as enhancers of apolipoprotein E prodn. for remedies for nerve injury, dementia, and hyperlipidemia)

RN 259086-94-7 CAPLUS
CN Butanedioic acid, [4-[(9H-fluoren-9-ylmethoxy)carbonyl]-2-oxo-1-piperazinyl]-, 4-(1,1-dimethylethyl) ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 259086-98-1 CAPLUS
CN 1-Piperazinepropanoic acid, 4-[(9H-fluoren-9-ylmethoxy)carbonyl]-2-oxo-.beta.-[[[(2E)-5-oxo-5-[[(1R)-1-[2-oxo-2-(2-oxo-2-phenylethoxy)ethyl]dodecyl]oxy]-2-pentenyl]amino]carbonyl]-, 1,1-dimethylethyl ester, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





RN 259086-99-2 CAPLUS
CN 1-Piperazinepropanoic acid, .beta.-[[[(2E)-5-[[(1R)-1-(carboxymethyl)dodecyl]oxy]-5-oxo-2-pentenyl]amino]carbonyl]-4-[(9H-fluoren-9-ylmethoxy)carbonyl]-2-oxo-, .alpha.-(1,1-dimethylethyl) ester, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 259087-06-4 CAPLUS
CN 1-Piperazinepropanoic acid, 4-[(9H-fluoren-9-ylmethoxy)carbonyl]-.beta.-[(3R,6R,9R)-6-[(1R)-1-methylpropyl]-3-(2-methylpropyl)-1,7,11-trioxo-13-phenyl-5-[(phenylmethoxy)carbonyl]-9-undecyl-8,12-dioxa-2,5-diazatridec-1-yl]-2-oxo-, 1,1-dimethylethyl ester, (.beta.S)- (9CI) (CA INDEX NAME)

V. Balasubramanian

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 259087-07-5 CAPLUS
CN 1-Piperazinepropanoic acid, .beta.-[[[(1R)-1-[[[(1R,2R)-1-[[[(1R)-1-(carboxymethyl)dodecyl]oxy]carbonyl]-2-methylbutyl]amino]methyl]-3-methylbutyl]amino]carbonyl]-4-[(9H-fluoren-9-ylmethoxy)carbonyl]-2-oxo-, .alpha.-(1,1-dimethylethyl) ester, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

V. Balasubramanian



RN 259087-23-5 CAPLUS
CN 1-Piperazinepropanoic acid, .beta.-[[[(1R)-5-[[(1R)-1-[2-(1,1-dimethylethoxy)-2-oxoethyl]dodecyl]oxy]-1-(2-methylpropyl)-2,5-dioxopentyl]amino]carbonyl]-4-[(9H-fluoren-9-ylmethoxy)carbonyl]-2-oxo-, 1,1-dimethylethyl ester, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 21 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 2000:68456 CAPLUS
DN 132:107945
TI Preparation of 9-trimethoxyphenyloxalyl-2-oxo-3,9-diaza[3.3.1]nonanes and

V. Balasubramanian

analogs as FKBP rotamase inhibitors

IN Katoh, Susumu; Kawakami, Hiroshi; Tada, Hiroki; Linton, Maria Angelica; Kalish, Vincent; Tatlock, John Howard; Villafranca, J. Ernest

PA Agouron Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 130 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000004020	A1	20000127	WO 1999-US15965	19990715
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2337377	AA	20000127	CA 1999-2337377	19990715
	AU 9949963	A1	20000207	AU 1999-49963	19990715
	AU 756912	B2	20030123		
	EP 1098897	A1	20010516	EP 1999-934043	19990715
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9912423	A	20010605	BR 1999-12423	19990715
	SI 20638	C	20020228	SI 1999-20067	19990715
	EE 200100032	A	20020617	EE 2001-32	19990715
	JP 2002520413	T2	20020709	JP 2000-560126	19990715
	NZ 509211	A	20021025	NZ 1999-509211	19990715
	NO 2001000191	A	20010316	NO 2001-191	20010112
	LT 4850	B	20011025	LT 2001-12	20010215
	BG 105268	A	20011130	BG 2001-105268	20010216
	LV 12665	B	20011120	LV 2001-23	20010313
PRAI	US 1998-93299P	P	19980717		
	US 1999-132884P	P	19990506		
	WO 1999-US15965	W	19990715		

OS MARPAT 132:107945

IT **255909-53-6P 255909-66-1P 255909-67-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 9-trimethoxyphenyloxalyl-2-oxo-3,9-diaza[3.3.1]nonanes and analogs as FKBP rotamase inhibitors)

RN 255909-53-6 CAPLUS

CN 3,9-Diazabicyclo[3.3.1]nonan-2-one, 3-[(1R,2R)-1-methyl-2-phenyl-2-(phenylmethoxy)ethyl]-9-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 255909-66-1 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]nonan-2-one, 3-[1-(hydroxymethyl)-2-(phenylmethoxy)ethyl]-9-[oxo(3,4,5-trimethoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)



RN 255909-67-2 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]nonan-2-one, 3-[1-[(acetyloxy)methyl]-2-(phenylmethoxy)ethyl]-9-[oxo(3,4,5-trimethoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 22 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 2000:15184 CAPLUS
DN 132:64256
TI Preparation of non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune and respiratory diseases
IN Duplantier, Allen Jacob; Milici, Anthony John; Chupak, Louis Stanley
PA Pfizer Products Inc., USA
SO PCT Int. Appl., 120 pp.

V. Balasubramanian

CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000000477	A1	20000106	WO 1999-IB973	19990531
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2336625	AA	20000106	CA 1999-2336625	19990531
AU 9938416	A1	20000117	AU 1999-38416	19990531
AU 758939	B2	20030403		
BR 9911701	A	20010320	BR 1999-11701	19990531
EP 1091943	A1	20010418	EP 1999-921046	19990531
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
JP 2002519344	T2	20020702	JP 2000-557238	19990531
NZ 508033	A	20021220	NZ 1999-508033	19990531
ZA 9903777	A	20001204	ZA 1999-3777	19990604
US 6306887	B1	20011023	US 1999-338832	19990623
US 6355662	B1	20020312	US 1999-403846	19991026
NO 2000006600	A	20010221	NO 2000-6600	20001222
BG 105190	A	20011231	BG 2001-105190	20010126
PRAI US 1998-91180P	P	19980630		
WO 1999-IB973	W	19990531		
US 1999-338832	A3	19990623		

OS MARPAT 132:64256
IT **253346-18-8P 253346-22-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune and respiratory diseases)
RN 253346-18-8 CAPLUS
CN 1-Piperazinepropanoic acid, .beta.-methyl-4-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-3-(2-methylpropyl)-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



V. Balasubramanian

RN 253346-22-4 CAPLUS
CN 1-Piperazinepropanoic acid, .beta.-1,3-benzodioxol-5-yl-4-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-3-(2-methylpropyl)-2-oxo- (9CI) (CA INDEX NAME)



IT **253348-65-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune and respiratory diseases)
RN 253348-65-1 CAPLUS
CN 1-Piperazinepropanoic acid, .beta.-methyl-4-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-3-(2-methylpropyl)-2-oxo-, methyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 23 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1999:511143 CAPLUS
DN 131:170361
TI Preparation of sulfonamides as inhibitors of activated blood coagulation factor X
IN Tawada, Hiroyuki; Itoh, Fumio; Banno, Hiroshi; Terashita, Zenichi
PA Takeda Chemical Industries, Ltd., Japan
SO PCT Int. Appl., 187 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

V. Balasubramanian

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9940075	A1	19990812	WO 1999-JP470	19990204
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2317017	AA	19990812	CA 1999-2317017	19990204
	AU 9922988	A1	19990823	AU 1999-22988	19990204
	JP 2000204081	A2	20000725	JP 1999-27053	19990204
	EP 1054005	A1	20001122	EP 1999-902829	19990204
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	US 6403595	B1	20020611	US 2000-601660	20000803
	US 2002193382	A1	20021219	US 2002-128809	20020424
PRAI	JP 1998-24833	A	19980205		
	JP 1998-317205	A	19981109		
	WO 1999-JP470	W	19990204		
	US 2000-601660	A3	20000803		

OS MARPAT 131:170361

IT **239071-71-7P 239071-72-8P 239071-98-8P**
239072-70-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of sulfonamides as inhibitors of activated blood coagulation factor X)

RN 239071-71-7 CAPLUS

CN 1-Piperazineacetonitrile, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-.alpha.-[1-(4-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 239071-72-8 CAPLUS

CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[1-[4-(1H-imidazol-1-yl)phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 239071-98-8 CAPLUS
CN 1-Piperazinepropanoic acid, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-.beta.-[1-(4-pyridinyl)-4-piperidinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 239072-70-9 CAPLUS
CN 1-Piperazineacetic acid, .alpha.-[4-(aminoiminomethyl)phenyl]-4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



IT **239073-30-4P 239073-31-5P 239073-33-7P 239073-60-0P 239073-62-2P 239074-07-8P 239074-08-9P 239074-09-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of sulfonamides as inhibitors of activated blood coagulation factor X)

RN 239073-30-4 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-1-piperazinyl]cyanomethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX

NAME)



RN 239073-31-5 CAPLUS
CN 1-Piperazineacetonitrile, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-.alpha.-4-piperidinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 239073-33-7 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[1-[4-(1H-imidazol-1-yl)phenyl]ethyl]-3-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 239073-60-0 CAPLUS
CN 1-Piperazinepropanoic acid, 4-[(1,1-dimethylethoxy)carbonyl]-2-oxo-.beta.-[1-[(phenylmethoxy)carbonyl]-4-piperidinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 239073-62-2 CAPLUS
CN 1-Piperazinepropanoic acid, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-.beta.-[1-[(phenylmethoxy)carbonyl]-4-piperidinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 239074-07-8 CAPLUS
CN 1-Piperazineacetic acid, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-.alpha.-(4-cyanophenyl)-2-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 239074-08-9 CAPLUS
CN 1-Piperazineacetic acid, .alpha.-(4-bromophenyl)-4-[(1,1-dimethylethoxy)carbonyl]-2-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 239074-09-0 CAPLUS
CN 1-Piperazineacetic acid, .alpha.-(4-cyanophenyl)-4-[(1,1-dimethylethoxy)carbonyl]-2-oxo-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 24 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1999:434172 CAPLUS
DN 131:81017
TI N-tert-butoxycarbonyl-N,N'-ethylene-bridged (S)-tyrosyl-(S)-tyrosine methyl ester
AU Yamato, Kazuhiro; Miyake, Hiroyuki; Hirotsu, Ken; Kojima, Yoshitane
CS Department of Chemistry, Graduate School of Science, Osaka City University, Osaka, 558-585, Japan
SO Acta Crystallographica, Section C: Crystal Structure Communications (1999), C55(6), 1023-1025
CODEN: ACSCEE; ISSN: 0108-2701
PB Munksgaard International Publishers Ltd.
DT Journal
LA English
IT **229024-26-4**
RL: PRP (Properties)
(crystal structure of)
RN 229024-26-4 CAPLUS
CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-.alpha.,3-bis[(4-hydroxyphenyl)methyl]-2-oxo-, methyl ester, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 226890-57-9 CAPLUS
CN 1-Piperazineacetamide, 4-(3-amino-3-methyl-1-oxobutyl)-N-methyl-N-[(1R)-2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl]-.alpha.-(2-naphthalenylmethyl)-2-oxo-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **226890-50-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and biol. activity of piperazinone-contg. peptidomimetics as constrained analogs of the growth hormone secretagogue NN-703)
RN 226890-50-2 CAPLUS
CN D-Phenylalaninamide, 2-methylalanyl-(.alpha.R)-.alpha.-(2-naphthalenylmethyl)-2-oxo-1-piperazineacetyl-N,N.alpha.-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 26 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1998:742814 CAPLUS
DN 130:81880
TI Selective BH3-reduction of amide carbonyl groups of lithium salts of N-tert-butoxycarbonyl-(S)-O-benzyltyrosyl-(S)-proline and N,N'-ethylene-bridged dipeptides
AU Adachi, Kenichi; Tsuru, Eiji; Banjyo, Eri; Doe, Matsumi; Shibata, Kozo; Yamashita, Tetsushi
CS Department Chemistry, Faculty Science, Osaka City University, Osaka, 558, Japan
SO Synthesis (1998), (11), 1623-1626
CODEN: SYNTBF; ISSN: 0039-7881
PB Georg Thieme Verlag
DT Journal
LA English
OS CASREACT 130:81880
IT **172801-42-2 217977-54-3 217977-55-4**
217977-56-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(selective borane-redn. of amide carbonyl groups of dipeptide lithium salts)
RN 172801-42-2 CAPLUS
CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-.alpha.,3-bis[2-(methylthio)ethyl]-2-oxo-, ethyl ester, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 217977-54-3 CAPLUS
CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-.alpha.,3-bis[(4-hydroxyphenyl)methyl]-2-oxo-, ethyl ester, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 217977-55-4 CAPLUS
CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-2-oxo-.alpha.,3-bis(phenylmethyl)-, ethyl ester, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 217977-56-5 CAPLUS
CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-.alpha.,3-bis(2-methylpropyl)-2-oxo-, ethyl ester, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **217977-57-6P 217977-58-7P 218160-81-7P 218162-88-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(selective borane-redn. of amide carbonyl groups of dipeptide lithium salts)

RN 217977-57-6 CAPLUS

CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-2-oxo-.alpha.,3-bis[[4-(phenylmethoxy)phenyl]methyl]-, lithium salt, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 217977-58-7 CAPLUS

CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-.alpha.,3-bis[2-(methylthio)ethyl]-2-oxo-, lithium salt, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Li

RN 218160-81-7 CAPLUS
CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-2-oxo-.alpha.,3-bis(phenylmethyl)-, lithium salt, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● Li

RN 218162-88-0 CAPLUS
CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-.alpha.,3-bis(2-methylpropyl)-2-oxo-, lithium salt, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● Li

V. Balasubramanian

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 27 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1998:689985 CAPLUS
DN 130:81803
TI Efficient synthesis of substituted oxopiperazines from amino acids
AU Mohamed, Nazim; Bhatt, Ulhas; Just, George
CS Dep. of Chemistry, McGill University, Montreal, QC, H3A 2K6, Can.
SO Tetrahedron Letters (1998), 39(45), 8213-8216
CODEN: TELEAY; ISSN: 0040-4039
PB Elsevier Science Ltd.
DT Journal
LA English
IT **218785-69-4P 218785-70-7P 218785-71-8P**
218785-72-9P 218785-73-0P 218785-74-1P
218785-78-5DP, resin-bound **218785-81-0DP**, resin-bound
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(efficient synthesis of substituted oxopiperazines from amino acids as peptide mimics by cyclocondensation of N-(nitrobenzenesulfonyl)dipeptides with ethylene dibromide or bromoethanol)
RN 218785-69-4 CAPLUS
CN 1-Piperazineacetic acid, .alpha.-(2-methylpropyl)-4-[(4-nitrophenyl)sulfonyl]-2-oxo-, methyl ester, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 218785-70-7 CAPLUS
CN 1-Piperazineacetic acid, 3-methyl-4-[(4-nitrophenyl)sulfonyl]-2-oxo-.alpha.-(phenylmethyl)-, methyl ester, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 218785-71-8 CAPLUS
CN 1-Piperazineacetic acid, 3-(1-methylethyl)-.alpha.-(2-methylpropyl)-4-[(4-nitrophenyl)sulfonyl]-2-oxo-, methyl ester, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 218785-72-9 CAPLUS
CN 1-Piperazineacetic acid, 3-methyl-4-[(2-nitrophenyl)sulfonyl]-2-oxo-.alpha.-(phenylmethyl)-, methyl ester, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 218785-73-0 CAPLUS
CN 1-Piperazineacetic acid, 3-(1-methylethyl)-4-[(2-nitrophenyl)sulfonyl]-2-oxo-.alpha.-(phenylmethyl)-, methyl ester, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 218785-74-1 CAPLUS
CN 1H-Indole-3-propanoic acid, .alpha.-[(3S)-4-[(2-nitrophenyl)sulfonyl]-2-oxo-3-(phenylmethyl)-1-piperazinyl]-, methyl ester, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 218785-78-5 CAPLUS
CN 1-Piperazineacetic acid, 3-methyl-4-[(2-nitrophenyl)sulfonyl]-2-oxo-.alpha.-(phenylmethyl)-, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 218785-81-0 CAPLUS
CN 1-Piperazineacetic acid, 4-[(2S)-2-[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]-3-methyl-2-oxo-.alpha.-(phenylmethyl)-, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **218785-54-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(efficient synthesis of substituted oxopiperazines from amino acids as peptide mimics by cyclocondensation of N-(nitrobenzenesulfonyl)dipeptides with ethylene dibromide or bromoethanol)
RN 218785-54-7 CAPLUS
CN 1-Piperazineacetic acid, 4-[(2S)-2-amino-1-oxopropyl]-3-methyl-2-oxo-.alpha.-(phenylmethyl)-, (.alpha.S,3S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 218785-53-6
CMF C17 H23 N3 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 28 OF 82 CAPLUS COPYRIGHT 2003 ACS

V. Balasubramanian

AN 1998:556399 CAPLUS
DN 129:312485
TI Structure of secreted aspartic proteinases from Candida: implications for the design of antifungal agents
AU Abad-Zapatero, Cele; Goldman, Robert; Muchmore, Steven W.; Hutchins, Charles; Oie, Tetsuro; Stewart, Kent; Cutfield, Sue M.; Cutfield, John F.; Foundling, Stephen I.; Ray, Thomas L.
CS Laboratory of Protein Crystallography, Abbott Laboratories, Abbott Park, IL, 60064, USA
SO Advances in Experimental Medicine and Biology (1998), 436(Aspartic Proteinases), 297-313
CODEN: AEMBAP; ISSN: 0065-2598
PB Plenum Publishing Corp.
DT Journal; General Review
LA English
IT **142928-23-2**, A-70450
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(inhibitor binding conformation; structure of secreted aspartic proteinases from Candida and implications for the design of antifungal agents)
RN 142928-23-2 CAPLUS
CN 1-Piperazineacetamide, .alpha.-butyl-N-[(1S,2S,4R)-4-[(butylamino)carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, monohydrochloride, (.alpha.S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 29 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1998:482693 CAPLUS
DN 129:216902
TI Conformational probes for elucidating the nature of substance P binding to the NK1 receptor: initial efforts to map the Phe7-Phe8 region
AU Tong, Yunsong; Fobian, Yvette M.; Wu, Meiye; Boyd, Norman D.; Moeller, Kevin D.
CS The Department of Chemistry, Washington University, St. Louis, MO, 63130,

V. Balasubramanian

USA

SO Bioorganic & Medicinal Chemistry Letters (1998), 8(13), 1679-1682
CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier Science Ltd.

DT Journal

LA English

IT **212612-56-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of piperazinone-based conformational probes for studying the binding of substance P to NK1 receptor)

RN 212612-56-1 CAPLUS

CN L-Methioninamide, L-arginyl-L-prolyl-L-lysyl-L-prolyl-L-glutaminyl-L-glutaminyl-(.alpha.S,3S)-2-oxo-.alpha.,3-bis(phenylmethyl)-1-piperazineacetylglycyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



V. Balasubramanian

IT **193091-13-3P 212612-64-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of piperazinone-based conformational probes for studying the binding of substance P to NK1 receptor)
RN 193091-13-3 CAPLUS
CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-2-oxo-.alpha.,3-bis(phenylmethyl)-, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 212612-64-1 CAPLUS
CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-2-oxo-.alpha.,3-bis(phenylmethyl)-, methyl ester, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 30 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1998:403019 CAPLUS
DN 129:136488
TI New fMLF-OMe analogs containing constrained mimics of phenylalanine residue
AU Torrini, Ines; Mastropietro, Gaia; Pagani Zecchini, Giampiero; Paglialunga Paradisi, Mario; Lucente, Gino; Spisani, Susanna
CS Dipartimento Studi Farmaceutici, Univ. La Sapienza, Rome, I-00185, Italy
SO Archiv der Pharmazie (Weinheim, Germany) (1998), 331(5), 170-176
CODEN: ARPMAS; ISSN: 0365-6233
PB Wiley-VCH Verlag GmbH
DT Journal
LA English
IT **210473-08-8P**

V. Balasubramanian

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and biol. activity of formyl peptide analogs contg. constrained mimics of phenylalanine residue)
RN 210473-08-8 CAPLUS
CN 1-Piperazineacetic acid, 4-(N-formyl-L-methionyl-L-leucyl)-2-oxo-.alpha.,3-bis(phenylmethyl)-, methyl ester, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **210473-24-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and biol. activity of formyl peptide analogs contg. constrained mimics of phenylalanine residue)
RN 210473-24-8 CAPLUS
CN 1-Piperazineacetic acid, 4-[N-[(1,1-dimethylethoxy)carbonyl]-L-methionyl-L-leucyl]-2-oxo-.alpha.,3-bis(phenylmethyl)-, methyl ester, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 31 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1998:270546 CAPLUS
DN 129:16374
TI The use of heterocycles for the conformational restriction of biologically active peptoids
AU Horwell, David C.; Lewthwaite, Russell A.; Pritchard, Martyn C.; Ratcliffe, Giles S.; Rubin, J. Ronald
CS Parke-Davis Neurosci. Research Centre, Cambridge Univ. Forvie Site, Cambridge, CB2 2QB, UK

V. Balasubramanian



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 25 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1999:292485 CAPLUS
DN 131:32160
TI Synthesis of piperazinones and their application in constrained mimetics of the growth hormone secretagogue NN-703
AU Hansen, Thomas K.; Schlienger, Nathalie; Hansen, Birgit S.; Andersen, Peter H.; Bryce, Martin R.
CS Medicinal Chemistry Research, Novo Nordisk A/S, Malov, 2760, Den.
SO Tetrahedron Letters (1999), 40(18), 3651-3654
CODEN: TELEAY; ISSN: 0040-4039
PB Elsevier Science Ltd.
DT Journal
LA English
IT **226890-56-8P 226890-57-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PNU (Preparation, unclassified); BIOL (Biological study); PREP (Preparation)
(synthesis and biol. activity of piperazinone-contg. peptidomimetics as constrained analogs of the growth hormone secretagogue NN-703)
RN 226890-56-8 CAPLUS
CN 1H-Indole-3-propanoic acid, .alpha.-[(3R)-4-[(2E)-5-amino-5-methyl-1-oxo-2-hexenyl]-3-(1H-indol-3-ylmethyl)-2-oxo-1-piperazinyl]-6,7-dihydro-, methyl ester, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

V. Balasubramanian

SO Tetrahedron (1998), 54(18), 4591-4606
CODEN: TETRAB; ISSN: 0040-4020
PB Elsevier Science Ltd.
DT Journal
LA English
IT **207690-72-0**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(use of heterocycles for conformational restriction of biol. active peptoids)
RN 207690-72-0 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[(1S)-1-(hydroxymethyl)-2-phenylethyl]-2-(1H-indol-3-ylmethyl)-3-oxo-, tricyclo[3.3.1.13,7]dec-1-yl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **207690-54-8P 207690-62-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(use of heterocycles for conformational restriction of biol. active peptoids)
RN 207690-54-8 CAPLUS
CN 1-Piperazinecarboxylic acid, 3-oxo-4-[(1S)-1-phenylethyl]-2-(phenylmethyl)-, (1R)-2-methyl-1-phenylpropyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 207690-62-8 CAPLUS
CN 1-Piperazinecarboxylic acid, 2-(1H-indol-3-ylmethyl)-3-oxo-4-[(1S)-1-

phenylethyl]-, 2-benzofuranylmethyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **207690-55-9P 207690-71-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(use of heterocycles for conformational restriction of biol. active peptoids)

RN 207690-55-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 3-oxo-4-[(1S)-1-phenylethyl]-2-(phenylmethyl)-, (1S)-2-methyl-1-phenylpropyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 207690-71-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 2-(1H-indol-3-ylmethyl)-3-oxo-4-[(1S)-1-(phenylmethyl)-2-[[tris(1-methylethyl)silyl]oxy]ethyl]-, tricyclo[3.3.1.13,7]dec-1-yl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

V. Balasubramanian



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 32 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1998:163571 CAPLUS
DN 128:204899
TI Heterocyclic metalloprotease inhibitors
IN Pikul, Stanislaw; McDow-Dunham, Kelly Lynn; De, Biswanath; Taiwo, Yetunde Olabisi; Almstead, Neil Gregory; Bradley, Rimma Sandler; Natchus, Michael George; Cupps, Thomas Lee
PA Procter & Gamble Company, USA
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9808823	A1	19980305	WO 1997-US14553	19970822
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9741530	A1	19980319	AU 1997-41530	19970822
	AU 734834	B2	20010621		
	EP 923561	A1	19990623	EP 1997-939443	19970822
	EP 923561	B1	20021023		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	CN 1228772	A	19990915	CN 1997-197544	19970822
	BR 9712085	A	20001024	BR 1997-12085	19970822
	NZ 334254	A	20001124	NZ 1997-334254	19970822
	JP 2000516953	T2	20001219	JP 1998-511713	19970822
	JP 3347331	B2	20021120		
	AT 226573	E	20021115	AT 1997-939443	19970822
	US 6121258	A	20000919	US 1997-918957	19970826
	ZA 9707696	A	19980223	ZA 1997-7696	19970827
	NO 9900759	A	19990427	NO 1999-759	19990218

V. Balasubramanian

	US 6399598	B1	20020604	US 2000-516726	20000301
PRAI	US 1996-24846P	P	19960828		
	WO 1997-US14553	W	19970822		
	US 1997-918957	A3	19970826		

OS MARPAT 128:204899

IT **203938-93-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heterocyclic metalloprotease inhibitors and their pharmaceutical compns.)

RN 203938-93-6 CAPLUS

CN 2-Piperazinecarboxamide, N-hydroxy-4-[(4-methoxyphenyl)sulfonyl]-1-(1-methylethyl)-6-oxo-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 33 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 1998:93877 CAPLUS

DN 128:226371

TI Biologically active analogs of arginine vasopressin containing conformationally restricted dipeptide fragments

AU Lammek, Bernard; Czaja, Malgorzata; Derdowska, Izabela; Lempicka, Elzbieta; Sikora, Piotr; Szkrobka, Witold; Trzeciak, Henryk I.

CS Faculty of Chemistry, University of Gdansk, Gdansk, 80-952, Pol.

SO Journal of Peptide Research (1998), 51(2), 149-154
CODEN: JPERFA; ISSN: 1397-002X

PB Munksgaard International Publishers Ltd.

DT Journal

LA English

IT **193091-13-3P 204758-26-9P 204758-27-0P**
204758-28-1P 204758-40-7P
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(biol. active analogs of arginine vasopressin contg. conformationally restricted dipeptide fragments)

RN 193091-13-3 CAPLUS

CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-2-oxo-.alpha.,3-bis(phenylmethyl)-, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 204758-26-9 CAPLUS
CN Glycinamide, S-(phenylmethyl)-L-cysteinyl-(.alpha.S,3S)-2-oxo-.alpha.,3-bis(phenylmethyl)-1-piperazineacetyl-L-glutaminyl-L-asparaginyl-S-(phenylmethyl)-L-cysteinyl-L-prolyl-N5-[imino[[(4-methylphenyl)sulfonyl]amino]methyl]-L-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 204758-27-0 CAPLUS
CN Glycinamide, N2-[(2S)-1-oxo-2-[(3S)-2-oxo-4-[1-oxo-3-[(phenylmethyl)thio]propyl]-3-(phenylmethyl)-1-piperazinyl]-3-

V. Balasubramanian

phenylpropyl]-L-glutaminyl-L-asparaginyl-S-(phenylmethyl)-L-cysteinyl-L-prolyl-N5-[imino[[(4-methylphenyl)sulfonyl]amino]methyl]-L-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 204758-28-1 CAPLUS

CN Glycinamide, N-[(2S)-1-oxo-2-[(3S)-2-oxo-3-(phenylmethyl)-4-[[1-[(phenylmethyl)thio]cyclohexyl]acetyl]-1-piperazinyl]-3-phenylpropyl]-L-glutaminyl-L-asparaginyl-S-(phenylmethyl)-L-cysteinyl-L-prolyl-N5-[imino[[(4-methylphenyl)sulfonyl]amino]methyl]-L-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 204758-40-7 CAPLUS
CN Glycinamide, N-[(2S)-1-oxo-2-[(3S)-2-oxo-3-(phenylmethyl)-4-[[1-[(phenylmethyl)thio]cyclohexyl]acetyl]-1-piperazinyl]-3-phenylpropyl]-L-valyl-L-asparaginyl-S-(phenylmethyl)-L-cysteinyl-L-prolyl-N5-[imino[[(4-methylphenyl)sulfonyl]amino]methyl]-L-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 34 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1998:93872 CAPLUS
DN 128:192910
TI Synthesis and conformational analysis of two 2-oxopiperazine-containing tetrapeptide analogs
AU Pohlmann, Adriana; Guillaume, Dominique; Quirion, Jean-Charles; Husson, Henri-Philippe
CS Laboratoire de Chimie Therapeutique, Faculte des Sciences Pharmaceutiques et Biologiques, Paris, Fr.
SO Journal of Peptide Research (1998), 51(2), 116-120
CODEN: JPERFA; ISSN: 1397-002X
PB Munksgaard International Publishers Ltd.
DT Journal

V. Balasubramanian

LA English
IT **186821-29-4**
RL: PRP (Properties)
(synthesis and conformational anal. of oxopiperazine-contg. tetrapeptide analogs)
RN 186821-29-4 CAPLUS
CN 1-Piperazineacetic acid, .alpha.-(2-methylpropyl)-2-oxo-4-[1-oxo-2-[[(phenylmethoxy)carbonyl]amino]propyl]-, methyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **186821-31-8**
RL: PRP (Properties); RCT (Reactant); RACT (Reactant or reagent)
(synthesis and conformational anal. of oxopiperazine-contg. tetrapeptide analogs)
RN 186821-31-8 CAPLUS
CN 1-Piperazineacetic acid, 3-methyl-.alpha.-(2-methylpropyl)-2-oxo-4-[1-oxo-2-[[(phenylmethoxy)carbonyl]amino]propyl]-, methyl ester, [3S-[1(R*),3R*,4(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **203575-40-0P 203575-41-1P**
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and conformational anal. of oxopiperazine-contg. tetrapeptide analogs)
RN 203575-40-0 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[1-[[[1-(methoxycarbonyl)-3-methylbutyl]amino]carbonyl]-3-methylbutyl]-3-oxo-, 1,1-dimethylethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 203575-41-1 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[1-[[[1-(methoxycarbonyl)-3-methylbutyl]amino]carbonyl]-3-methylbutyl]-2-methyl-3-oxo-, 1,1-dimethylethyl ester, [2S-[2R*,4[R*(R*)]]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **203575-42-2P 203575-43-3P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(synthesis and conformational anal. of oxopiperazine-contg. tetrapeptide analogs)
RN 203575-42-2 CAPLUS
CN L-Leucine, N-[(phenylmethoxy)carbonyl]-L-alanyl-(.alpha.S)-.alpha.-(2-methylpropyl)-2-oxo-1-piperazineacetyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 203575-43-3 CAPLUS
CN L-Leucine, N-[(phenylmethoxy)carbonyl]-L-alanyl-(.alpha.S,3S)-3-methyl-.alpha.-(2-methylpropyl)-2-oxo-1-piperazineacetyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **186821-11-4 203575-44-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(synthesis and conformational anal. of oxopiperazine-contg. tetrapeptide analogs)
RN 186821-11-4 CAPLUS
CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-.alpha.-(2-methylpropyl)-2-oxo-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 203575-44-4 CAPLUS

V. Balasubramanian

CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-3-methyl-.alpha.-(2-methylpropyl)-2-oxo-, methyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 35 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1998:87706 CAPLUS
DN 128:154388
TI Preparation of peptide analogs with growth hormone releasing properties
IN Peschke, Bernd; Ankersen, Michael; Hansen, Thomas Kruse; Thogersen, Henning
PA Novo Nordisk A/S, Den.; Peschke, Bernd; Ankersen, Michael; Hansen, Thomas Kruse; Thogersen, Henning
SO PCT Int. Appl., 178 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9803473	A1	19980129	WO 1997-DK314	19970717
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9734346	A1	19980210	AU 1997-34346	19970717
	EP 923539	A1	19990623	EP 1997-930368	19970717
	EP 923539	B1	20020605		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	US 5922770	A	19990713	US 1997-896550	19970717
	JP 2000515517	T2	20001121	JP 1998-506465	19970717
	EP 1184370	A2	20020306	EP 2001-123155	19970717
	EP 1184370	A3	20020327		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	AT 218537	E	20020615	AT 1997-930368	19970717
	US 6127354	A	20001003	US 1999-270862	19990317
	US 6274584	B1	20010814	US 2000-619227	20000719

V. Balasubramanian

PRAI DK 1996-803 A 19960722
EP 1997-930368 A3 19970717
US 1997-896550 A3 19970717
WO 1997-DK314 W 19970717
US 1999-270862 A3 19990317
OS MARPAT 128:154388
IT **202810-14-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of peptide analogs with growth hormone releasing properties)
RN 202810-14-8 CAPLUS
CN 1-Piperazineacetamide, 4-(5-amino-5-methyl-1-oxo-2-hexenyl)-N-methyl-5-(2-naphthalenylmethyl)-2-oxo-.alpha.-(phenylmethyl)-, [R-[R*,R*-(E)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT **202810-94-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of peptide analogs with growth hormone releasing properties)
RN 202810-94-4 CAPLUS
CN Carbamic acid, [1,1-dimethyl-5-[4-[2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl]-2-(2-naphthalenylmethyl)-5-oxo-1-piperazinyl]-5-oxo-3-pentenyl]-, 1,1-dimethylethyl ester, [R-[R*,R*-(E)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 36 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1998:66709 CAPLUS
DN 128:149206
TI Novel Non-Peptide Fibrinogen Receptor Antagonists. 1. Synthesis and Glycoprotein IIb-IIIa Antagonistic Activities of 1,3,4-Trisubstituted 2-Oxopiperazine Derivatives Incorporating Side-Chain Functions of the RGDF Peptide
AU Sugihara, Hirosada; Fukushi, Hideto; Miyawaki, Toshio; Imai, Yumi; Terashita, Zen-ichi; Kawamura, Masaki; Fujisawa, Yukio; Kita, Shunbun
CS Pharmaceutical Research Division, Takeda Chemical Industries Ltd., Osaka, 532, Japan
SO Journal of Medicinal Chemistry (1998), 41(4), 489-502
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
IT **148126-81-2P 148126-89-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and glycoprotein IIb-IIIa antagonistic activities of trisubstituted oxopiperazine derivs. incorporating RGDF side chain functions)
RN 148126-81-2 CAPLUS
CN 1,3-Piperazinediacetic acid, 4-[[[4-(aminoiminomethyl)benzoyl]amino]acetyl]-2-oxo-.alpha.1-(phenylmethyl)-, monohydrochloride, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

V. Balasubramanian



● HCl

RN 148126-89-0 CAPLUS
CN 1,3-Piperazinediacetic acid, 4-[[[4-[(aminoiminomethyl)amino]benzoyl]amino]acetyl]-.alpha.1-methyl-2-oxo-, monohydrochloride, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L5 ANSWER 37 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1998:5383 CAPLUS
DN 128:102361
TI Synthesis and opiate activity of pseudo-tetrapeptides containing chiral piperazin-2-one and piperazine derivatives
AU Yamashita, Tetsushi; Tsuru, Eiji; Banjyo, Eri; Doe, Matsumi; Shibata, Kozo; Yasuda, Masahide; Gemba, Munekazu
CS Department of Chemistry, Faculty of Science, Osaka City University, Osaka, 558, Japan
SO Chemical & Pharmaceutical Bulletin (1997), 45(12), 1940-1944 CODEN: CPBTAL; ISSN: 0009-2363
PB Pharmaceutical Society of Japan
DT Journal

V. Balasubramanian

LA English

IT **201293-48-3P 201293-55-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and opiate activity of pseudotetrapeptides contg. chiral piperazinone and piperazine derivs.)

RN 201293-48-3 CAPLUS

CN Glycine, L-tyrosyl-(.alpha.S,3S)-3-methyl-2-oxo-.alpha.-(phenylmethyl)-1-piperazineacetyl-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 201293-55-2 CAPLUS

CN Glycine, D-tyrosyl-(.alpha.R,3R)-3-methyl-2-oxo-.alpha.-(phenylmethyl)-1-piperazineacetyl-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

IT **201293-41-6P 201293-42-7P 201293-45-0P**
201293-47-2P 201293-50-7P 201293-51-8P
201414-33-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and opiate activity of pseudotetrapeptides contg. chiral piperazinone and piperazine derivs.)

RN 201293-41-6 CAPLUS
CN 1-Piperazineacetic acid, 3-methyl-2-oxo-4-[(phenylmethoxy)carbonyl]-.alpha.-(phenylmethyl)-, ethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 201293-42-7 CAPLUS
CN 1-Piperazineacetic acid, 3-methyl-2-oxo-4-[(phenylmethoxy)carbonyl]-.alpha.-(phenylmethyl)-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 201293-45-0 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[(2-ethoxy-2-oxoethyl)amino]-2-oxo-1-(phenylmethyl)ethyl]-2-methyl-3-oxo-, phenylmethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 201293-47-2 CAPLUS
CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl-(.alpha.S,3S)-3-methyl-2-oxo-.alpha.-(phenylmethyl)-1-piperazineacetyl-, ethyl ester (9CI) (CA INDEX NAME)

V. Balasubramanian

Absolute stereochemistry.



RN 201293-50-7 CAPLUS
CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-.alpha.,3-bis[(4-hydroxyphenyl)methyl]-2-oxo-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 201293-51-8 CAPLUS
CN Glycine, N-[(2S)-2-[(3S)-4-[(1,1-dimethylethoxy)carbonyl]-3-[(4-hydroxyphenyl)methyl]-2-oxo-1-piperazinyl]-3-(4-hydroxyphenyl)-1-oxopropyl]-L-phenylalanyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

V. Balasubramanian



RN 201414-33-7 CAPLUS
CN 1-Piperazineacetic acid, 3-methyl-2-oxo-4-[(phenylmethoxy)carbonyl]-.alpha.-(phenylmethyl)-, lithium salt, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● Li

RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 38 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1997:425268 CAPLUS
DN 127:34247
TI Preparation of bicyclic heteroaryl-alkylene-(homo)piperazinones and -thiones as selective agonists of 5-HT1-like receptors
IN Chambers, Mark Stuart; Hobbs, Sarah Christine; Street, Leslie Joseph
PA Merck Sharp & Dohme Limited, UK; Chambers, Mark Stuart; Hobbs, Sarah Christine; Street, Leslie Joseph
SO PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9716446	A1	19970509	WO 1996-GB2624	19961028

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG

	AU 9673190	A1	19970522	AU 1996-73190	19961028
	US 5998415	A	19991207	US 1998-65020	19980417
PRAI	GB 1995-22473		19951102		
	GB 1995-23907		19951122		
	WO 1996-GB2624		19961028		

OS MARPAT 127:34247

IT **190953-84-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of bicyclic heteroaryl-alkylene-(homo)piperazinones and -thiones as selective agonists of 5-HT1-like receptors)

RN 190953-84-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 3-oxo-4-(1-phenylethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 39 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 1997:421503 CAPLUS

DN 127:136058

TI Antagonists of bradykinin modified with conformationally restricted dipeptide fragment

AU Prahl, A.; Wierzba, T.; Winklewski, P.; Musial, P.; Juzwa, W.; Lammek, B.

CS Department Chemistry, University Gdansk, Gdansk, 80-952, Pol.

SO Polish Journal of Chemistry (1997), 71(7), 929-935
CODEN: PJCHDQ; ISSN: 0137-5083

PB Polish Chemical Society

DT Journal

LA English

IT **193091-08-6P 193091-09-7P 193091-10-0P**
193091-11-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and structure-activity of conformationally restricted bradykinin antagonists)

RN 193091-08-6 CAPLUS

CN L-Arginine, D-arginyl-L-arginyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-L-phenylalanyl-L-seryl-(.alpha.S,3S)-2-oxo-.alpha.,3-bis(phenylmethyl)-1-piperazineacetyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

PAGE 1-A



PAGE 1-B



RN 193091-09-7 CAPLUS

CN L-Arginine, N2-(tricyclo[3.3.1.13,7]dec-1-ylacetyl)-D-arginyl-L-arginyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-L-phenylalanyl-L-seryl-(.alpha.S,3S)-2-oxo-.alpha.,3-bis(phenylmethyl)-1-piperazineacetyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

PAGE 1-A



PAGE 1-B



RN 193091-10-0 CAPLUS
CN L-Arginine, D-arginyl-L-arginyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-(.alpha.S,3S)-2-oxo-.alpha.,3-bis(phenylmethyl)-1-piperazineacetyl-3-(2-thienyl)-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

PAGE 1-A



PAGE 1-B



RN 193091-11-1 CAPLUS
CN L-Arginine, N2-(tricyclo[3.3.1.13,7]dec-1-ylacetyl)-D-arginyl-L-arginyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-(.alpha.S,3S)-2-oxo-.alpha.,3-bis(phenylmethyl)-1-piperazineacetyl-3-(2-thienyl)-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

PAGE 1-A



PAGE 2-A



IT **193091-13-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and structure-activity of conformationally restricted bradykinin antagonists)

RN 193091-13-3 CAPLUS

CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-2-oxo-.alpha.,3-bis(phenylmethyl)-, (.alpha.S,3S)- (9CI) (CA INDEX NAME)



L5 ANSWER 41 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1997:88714 CAPLUS
DN 126:157788
TI Efficient Synthesis of Conformationally Constrained Peptidomimetics Containing 2-Oxopiperazines
AU Pohlmann, Adriana; Schanen, Vincent; Guillaume, Dominique; Quirion, Jean-Charles; Husson, Henri-Philippe
CS Laboratoire de Chimie Therapeutique Faculte des Sciences Pharmaceutiques et Biologiques, Universite Rene Descartes, Paris, 75270, Fr.
SO Journal of Organic Chemistry (1997), 62(4), 1016-1022
CODEN: JOCEAH; ISSN: 0022-3263
PB American Chemical Society
DT Journal
LA English
OS CASREACT 126:157788
IT **174585-12-7P 186820-89-3P 186820-92-8P 186820-93-9P 186820-95-1P 186820-96-2P 186820-97-3P 186820-99-5P 186821-01-2P 186821-11-4P 186821-12-5P 186821-13-6P 186821-17-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(efficient prepn. of conformationally constrained oxopiperazine-contg. peptide mimics)
RN 174585-12-7 CAPLUS
CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-.alpha.,3-bis(2-methylpropyl)-2-oxo-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 186820-89-3 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[1-(hydroxymethyl)-3-methylbutyl]-3-oxo-, 1,1-dimethylethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L5 ANSWER 40 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1997:348294 CAPLUS
DN 127:66135
TI Derivatized oxopiperazine rings from amino acids
AU Bhatt, Ulhas; Mohamed, Nazim; Just. George; Roberts, Edward
CS Dep. Chem., McGill Univ., Montreal, QC, H3A 2K6, Can.
SO Tetrahedron Letters (1997), 38(21), 3679-3682
CODEN: TELEAY; ISSN: 0040-4039
PB Elsevier
DT Journal
LA English
OS CASREACT 127:66135
IT **191337-32-3P 191337-35-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(derivatized oxopiperazine rings from amino acids)
RN 191337-32-3 CAPLUS
CN 1-Piperazineacetic acid, 5-hydroxy-.alpha.-(1-methylethyl)-2-oxo-4-[(phenylmethoxy)carbonyl]-3-(phenylmethyl)-, methyl ester, [1(S),3S]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 191337-35-6 CAPLUS
CN 1,3-Piperazinediacetic acid, 5-hydroxy-2-oxo-4-[(phenylmethoxy)carbonyl]-.alpha.1-(phenylmethyl)-, .alpha.1-methyl .alpha.3-(phenylmethyl) ester, [1(S),3S]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186820-96-2 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[1-(hydroxymethyl)-3-methylbutyl]-3-oxo-2-(phenylmethyl)-, 1,1-dimethylethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 186820-97-3 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[1-(hydroxymethyl)-3-methylbutyl]-2-(2-methylpropyl)-3-oxo-, 1,1-dimethylethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 186820-99-5 CAPLUS
CN 1-Piperazinecarboxylic acid, 2-[(2-bromophenyl)methyl]-4-[1-(hydroxymethyl)-3-methylbutyl]-3-oxo-, 1,1-dimethylethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

Absolute stereochemistry. Rotation (-).



RN 186820-92-8 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[1-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-3-methylbutyl]-3-oxo-, 1,1-dimethylethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 186820-93-9 CAPLUS
CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-.alpha.-(2-methylpropyl)-2-oxo-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 186820-95-1 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[1-(hydroxymethyl)-3-methylbutyl]-2-methyl-3-oxo-, 1,1-dimethylethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 186821-01-2 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[1-(hydroxymethyl)-3-methylbutyl]-3-oxo-2-(2-propenyl)-, 1,1-dimethylethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 186821-11-4 CAPLUS
CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-.alpha.-(2-methylpropyl)-2-oxo-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 186821-12-5 CAPLUS
CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-3-methyl-.alpha.-(2-methylpropyl)-2-oxo-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 186821-13-6 CAPLUS
CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-.alpha.-(2-methylpropyl)-2-oxo-3-(phenylmethyl)-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 186821-17-0 CAPLUS
CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-.alpha.-(2-methylpropyl)-2-oxo-3-(2-propenyl)-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **186821-04-5P 186821-05-6P 186821-07-8P**
186821-09-0P 186821-16-9P 186821-29-4P
186821-31-8P 186821-33-0P 186821-35-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(efficient prepn. of conformationally constrained oxopiperazine-contg. peptide mimics)
RN 186821-04-5 CAPLUS
CN 2-Piperazineacetic acid, 1-[(1,1-dimethylethoxy)carbonyl]-4-[1-(hydroxymethyl)-3-methylbutyl]-3-oxo-, 1,1-dimethylethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

V. Balasubramanian



RN 186821-05-6 CAPLUS
CN 2-Piperazineacetic acid, 1-[(1,1-dimethylethoxy)carbonyl]-4-[1-(hydroxymethyl)-3-methylbutyl]-3-oxo-, ethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186821-07-8 CAPLUS
CN 1-Piperazinecarboxylic acid, 2-[2-(acetyloxy)ethyl]-4-[1-(hydroxymethyl)-3-methylbutyl]-3-oxo-, 1,1-dimethylethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186821-09-0 CAPLUS
CN 1-Piperazinecarboxylic acid, 2-(2-hydroxyethyl)-4-[1-(hydroxymethyl)-3-methylbutyl]-3-oxo-, 1,1-dimethylethyl ester, [4(S)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177980-76-6 CAPLUS
CN Glycine, N-[2-[4-[[[(1,1-dimethylethoxy)carbonyl]methylamino]acetyl]-3-(2-methylpropyl)-2-oxo-1-piperazinyl]-4-methyl-1-oxopentyl]-, ethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177980-77-7 CAPLUS
CN Glycine, N-[N-[2-[4-[[[(1,1-dimethylethoxy)carbonyl]methylamino]acetyl]-3-(2-methylpropyl)-2-oxo-1-piperazinyl]-4-methyl-1-oxopentyl]glycyl]-N-methyl-, ethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177980-78-8 CAPLUS
CN Carbamic acid, [2-[4-[1-[[[2-[[2-[(2,5-dioxo-1-pyrrolidinyl)oxy]-2-oxoethyl]methylamino]-2-oxoethyl]amino]carbonyl]-3-methylbutyl]-2-(2-

methylpropyl)-3-oxo-1-piperazinyl]-2-oxoethyl]methyl-, 1,1-dimethylethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 44 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1996:295914 CAPLUS
DN 125:47488
TI Synthesis and structure of chiral dinuclear copper(II) complex of novel structurally reinforced hexaazamacrocyclic ligand
AU Seki, Yoshio; Miyake, Hiroyuki; Kojima, Yoshitane; Doi, Mayumi; Yano, Shigenobu
CS Dep. Chem., Osaka City Univ., Osaka, 558, Japan
SO Molecular Crystals and Liquid Crystals Science and Technology, Section A: Molecular Crystals and Liquid Crystals (1996), 276, 79-84
CODEN: MCLCE9; ISSN: 1058-725X
PB Gordon & Breach
DT Journal
LA English
IT **174585-12-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(for prepn. of tricyclohexaazamacrocyclic deriv. and its reduced tetraisobutylhexaazatricyclodocosane)
RN 174585-12-7 CAPLUS
CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-.alpha.,3-bis(2-methylpropyl)-2-oxo-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L5 ANSWER 45 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1996:210303 CAPLUS
DN 124:311048
TI Structure of a secreted aspartic protease from Candida albicans complexed



RN 186821-16-9 CAPLUS
CN 1-Piperazineacetic acid, 3-[(2-bromophenyl)methyl]-4-[(1,1-dimethylethoxy)carbonyl]-.alpha.-(2-methylpropyl)-2-oxo-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 186821-29-4 CAPLUS
CN 1-Piperazineacetic acid, .alpha.-(2-methylpropyl)-2-oxo-4-[1-oxo-2-[[(phenylmethoxy)carbonyl]amino]propyl]-, methyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 186821-31-8 CAPLUS
CN 1-Piperazineacetic acid, 3-methyl-.alpha.-(2-methylpropyl)-2-oxo-4-[1-oxo-2-[[(phenylmethoxy)carbonyl]amino]propyl]-, methyl ester, [3S-[1(R*),3R*,4(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

with a potent inhibitor: implications for the design of antifungal agents
AU Abad-Zapatero, Cele; Goldman, Robert; Muchmore, Steven W.; Hutchins, Charles; Stewart, Kent; Navaza, Jorge; Payne, Candia D.; Ray, Thomas L.
CS Laboratory Protein Crystallography, Abbott Laboratories, Abbott Park, IL, 60064-3500, USA
SO Protein Science (1996), 5(4), 640-52
CODEN: PRCIEI; ISSN: 0961-8368
PB Cambridge University Press
DT Journal
LA English
IT **142928-23-2 176047-03-3 176047-04-4 176047-05-5 176200-46-7 176200-47-8 176200-48-9 176200-49-0**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(structure of secreted aspartic protease from Candida albicans complexed with potent inhibitor and implications for design of antifungal agents)
RN 142928-23-2 CAPLUS
CN 1-Piperazineacetamide, .alpha.-butyl-N-[(1S,2S,4R)-4-[(butylamino)carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, monohydrochloride, (.alpha.S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 176047-03-3 CAPLUS
CN 1-Piperazineacetamide, .alpha.-butyl-N-[4-[(butylamino)methyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, [3R-[1[S*(1S*,2S*,4S*)],3R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 176047-04-4 CAPLUS
CN 1-Piperazineacetamide, .alpha.-butyl-N-[1-(cyclohexylmethyl)-4-[[[2-(dimethylamino)ethyl]amino]carbonyl]-2-hydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, [3R-[1[S*(1S*,2S*,4S*)],3R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 176047-05-5 CAPLUS
CN 1-Piperazineacetamide, .alpha.-butyl-N-[1-(cyclohexylmethyl)-4-[[[3-(dimethylamino)propyl]amino]carbonyl]-2-hydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, [3R-[1[S*(1S*,2S*,4S*)],3R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 176200-46-7 CAPLUS

V. Balasubramanian

CN 1-Piperazineacetamide, .alpha.-butyl-N-[4-[(butylamino)carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, [3R-[1[R*(1S*,2S*,4S*)],3R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 176200-47-8 CAPLUS
CN 1-Piperazineacetamide, .alpha.-butyl-N-[4-[(butylamino)carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, [3S-[1[R*(1R*,2R*,4R*)],3R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 176200-48-9 CAPLUS
CN 1-Piperazineacetamide, .alpha.-butyl-N-[4-[(butylamino)carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)sulfonyl]-2-oxo-3-(phenylmethyl)-, [3R-[1[S*(1S*,2S*,4S*)],3R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 176200-49-0 CAPLUS
CN 1-Piperazineacetamide, .alpha.-butyl-N-[1-(cyclohexylmethyl)-2-hydroxy-5-methyl-4-[[[3-(4-morpholinyl)propyl]amino]carbonyl]hexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, [3R-[1[S*(1S*,2S*,4S*)],3R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L5 ANSWER 46 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1996:98979 CAPLUS
DN 124:276741
TI Syntheses and structures of novel optically active dinuclear copper(II) complexes of structurally reinforced macrocyclic polyamines
AU Seki, Yoshio; Miyake, Hiroyuki; Kojima, Yoshitane

V. Balasubramanian

CS Dep. Chem., Osaka City Univ., Sumiyoshi, 558, Japan
SO Chemistry Letters (1996), (2), 153-4
CODEN: CMLTAG; ISSN: 0366-7022
PB Nippon Kagakkai
DT Journal
LA English
IT **174585-12-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(for prepn. of hexaazamacrocycle)
RN 174585-12-7 CAPLUS
CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-.alpha.,3-bis(2-methylpropyl)-2-oxo-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L5 ANSWER 47 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1995:984449 CAPLUS
DN 124:104652
TI Syntheses of silver(I) complexes with N,N'-ethylene-bridged-(S)-histidyl-(S)-histidine and -(S)-methionyl-(S)-methionine derivatives
AU Kojima, Yoshitane; Watanabe, Masaaki; Miyake, Hiroyuki
CS Fac. Sci., Osaka City Univ., Osaka, 558, Japan
SO Chemistry Letters (1995), (12), 1097-8
CODEN: CMLTAG; ISSN: 0366-7022
PB Nippon Kagakkai
DT Journal
LA English
IT **171731-29-6 172801-42-2**
RL: RCT (Reactant); RACT (Reactant or reagent)
(for prepn. of silver complexes)
RN 171731-29-6 CAPLUS
CN 1-Piperazineacetic acid, 4-formyl-.alpha.,3-bis(1H-imidazol-4-ylmethyl)-2-oxo-, methyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



V. Balasubramanian

RN 172801-42-2 CAPLUS
CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-.alpha.,3-bis[2-(methylthio)ethyl]-2-oxo-, ethyl ester, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **171731-29-6D**, dimeric silver complexes **172801-42-2D**, dimeric silver complexes
RL: FMU (Formation, unclassified); FORM (Formation, nonpreparative)
(formation in dissocn. of monomeric silver complexes)
RN 171731-29-6 CAPLUS
CN 1-Piperazineacetic acid, 4-formyl-.alpha.,3-bis(1H-imidazol-4-ylmethyl)-2-oxo-, methyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 172801-42-2 CAPLUS
CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-.alpha.,3-bis[2-(methylthio)ethyl]-2-oxo-, ethyl ester, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 48 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1995:966510 CAPLUS
DN 124:3950
TI The crystal structure of a major secreted aspartic proteinase from Candida albicans in complexes with two inhibitors
AU Cutfield, S. M.; Dodson, E. J.; Anderson, B. F.; Moody, P. C. E.; Marshall, C. J.; Sullivan, P. A.; Cutfield, J. F.
CS Biochemistry Department, University Otago, Dunedin, N. Z.
SO Structure (London) (1995), 3(11), 1261-71
CODEN: STRUE6; ISSN: 0969-2126
PB Current Biology
DT Journal
LA English
IT **142928-23-2D**, A70450, complexes with secreted aspartic proteinase
RL: PRP (Properties)
(crystal structure of Candida albicans secreted aspartic proteinase SAP2 complexes with synthetic hexapeptide analog inhibitor and pepstatin A)
RN 142928-23-2 CAPLUS
CN 1-Piperazineacetamide, .alpha.-butyl-N-[(1S,2S,4R)-4-[(butylamino)carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, monohydrochloride, (.alpha.S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 49 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1995:794797 CAPLUS
DN 124:30346
TI Syntheses of novel structurally constrained (S)-histidyl-(S)-histidine derivatives and their copper(II) complexes
AU Kojima, Yoshitane; Watanabe, Masaaki; Seki, Yoshio; Yamato, Kazuhiro; Miyake, Hiroyuki
CS Fac. Sci., Osaka City univ., Osaka, 558, Japan
SO Chemistry Letters (1995), (9), 797-8
CODEN: CMLTAG; ISSN: 0366-7022
PB Nippon Kagakkai
DT Journal

V. Balasubramanian

LA English
OS CASREACT 124:30346
IT **171731-29-6P 171731-30-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and properties of ethylene-bridged histidylhistidine copper(II) complexes)
RN 171731-29-6 CAPLUS
CN 1-Piperazineacetic acid, 4-formyl-.alpha.,3-bis(1H-imidazol-4-ylmethyl)-2-oxo-, methyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 171731-30-9 CAPLUS
CN 1-Piperazineacetic acid, 4-[[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]-.alpha.,3-bis(1H-imidazol-4-ylmethyl)-2-oxo-, methyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L5 ANSWER 50 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1995:427460 CAPLUS
DN 123:83982
TI Structure of cyclic hexa-pseudopeptide constructed from N,N'-ethylene-bridged-(S)-alanyl-(S)-alanine and glycine
AU Kojima, Yoshitane; Yamashita, Tetsushi; Miyake, Hiroyuki
CS Fac. Sci., Osaka City Univ., Osaka, 558, Japan
SO Chemistry Letters (1995), (3), 201-2
CODEN: CMLTAG; ISSN: 0366-7022
PB Nippon Kagakkai
DT Journal
LA English
IT **164857-03-8**

V. Balasubramanian

RL: RCT (Reactant); RACT (Reactant or reagent)
(structure of cyclic hexapseudopeptide constructed from ethylene-bridged alanylalanine and glycine)

RN 164857-03-8 CAPLUS

CN Piperazinone, 4-(aminoacetyl)-1-[2-[(2,5-dioxo-1-pyrrolidinyl)oxy]-1-methyl-2-oxoethyl]-3-methyl-, monohydrochloride, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L5 ANSWER 51 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 1995:384242 CAPLUS

DN 122:265988

TI Conformation constraints emerging in the N,N'-ethylene- and N,N'-propylene-bridged dipeptide units

AU Czaplewski, C.; Lammek, B.; Ciarkowski, J.

CS Fac. Chem., Univ. Gdansk, Gdansk, 80-952, Pol.

SO Polish Journal of Chemistry (1994), 68(12), 2589-98
CODEN: PJCHDQ; ISSN: 0137-5083

PB Polish Chemical Society

DT Journal

LA English

IT **162611-47-4**
RL: PRP (Properties)
(conformation of N,N'-ethylene- and N,N'-propylene-bridged dipeptides)

RN 162611-47-4 CAPLUS

CN 1-Piperazineacetamide, 4-acetyl-N-methyl-2-oxo-.alpha.,3-bis(phenylmethyl)-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

V. Balasubramanian



L5 ANSWER 52 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1994:681106 CAPLUS
DN 121:281106
TI Conformations of 24-membered ring pseudopeptides containing N,N'-ethylene-bridged dipeptides constructed from (S)-alanine, -leucine, -isoleucine, and -phenylalanine
AU Kojima, Yoshitane; Goto, Hisayo; Miyake, Hiroyuki; Yamashita, Tetsushi
CS Fac. Sci., Osaka City Univ., Osaka, 558, Japan
SO Polymer Journal (Tokyo, Japan) (1994), 26(3), 257-65
CODEN: POLJB8; ISSN: 0032-3896
DT Journal
LA English
IT **158861-92-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and peptide coupling reactions of, in prepn. of ethylene-bridged cyclooctapeptide)
RN 158861-92-8 CAPLUS
CN 1-Piperazineacetic acid, 4-[[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]-.alpha.,3-bis(1-methylpropyl)-2-oxo-, [3S-[1[R*(R*)],3R*(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



V. Balasubramanian

L5 ANSWER 53 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1994:591121 CAPLUS
DN 121:191121
TI silver halide color photographic material
IN Saito, Naoki; Nakagawa, Hajime
PA Fuji Photo Film Co Ltd, Japan
SO Jpn. Kokai Tokkyo Koho, 48 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 05341461	A2	19931224	JP 1992-170039	19920605
PRAI JP 1992-170039		19920605		

IT **157683-21-1**
RL: USES (Uses)
(yellow photog. coupler)
RN 157683-21-1 CAPLUS
CN Benzoic acid, 3-[[3-(5-bromo-2,3-dihydro-1H-indol-1-yl)-2-[4-[(dimethylamino)sulfonyl]-2,6-dioxo-1-piperazinyl]-1,3-dioxopropyl]amino]-4-(4-carboxyphenoxy)-5-chloro-, 1-dodecyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 54 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1994:457461 CAPLUS
DN 121:57461
TI Asymmetric synthesis. XXXI. Synthesis of 2-substituted piperazines from chiral non-racemic lactams
AU Schanen, Vincent; Riche, Claude; Chiaroni, Angele; Quirion, Jean-Charles; Husson, Henri-Philippe
CS Fac. Sci. Pharm. Biol., Univ. R. Descartes, Paris, 75270/06, Fr.
SO Tetrahedron Letters (1994), 35(16), 2533-6
CODEN: TELEAY; ISSN: 0040-4039
DT Journal
LA English

V. Balasubramanian

OS CASREACT 121:57461
IT **156022-76-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and benzylation of)
RN 156022-76-3 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-(2-hydroxy-1-phenylethyl)-2-methyl-3-oxo-, 1,1-dimethylethyl ester, [R-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **156022-75-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and diastereoselective alkylation of)
RN 156022-75-2 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-(2-hydroxy-1-phenylethyl)-3-oxo-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **156022-79-6P 156022-80-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 156022-79-6 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-(2-hydroxy-1-phenylethyl)-3-oxo-2-(phenylmethyl)-, 1,1-dimethylethyl ester, [R-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

V. Balasubramanian



RN 156022-80-9 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-(2-hydroxy-1-phenylethyl)-3-oxo-2-(2-propenyl)-, 1,1-dimethylethyl ester, [R-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 55 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1994:211394 CAPLUS
DN 120:211394
TI Crystallization of inhibited aspartic proteinase from Candida albicans
AU Cutfield, Sue; Marshall, Craig; Moody, Peter; Sullivan, Patrick; Cutfield, John
CS Biochem. Dep., Univ. Otago, Dunedin, N. Z.
SO Journal of Molecular Biology (1993), 234(4), 1266-9
CODEN: JMOBAK; ISSN: 0022-2836
DT Journal
LA English
IT **142928-23-2**, A70450
RL: BIOL (Biological study)
(aspartic proteinase of Candida albicans treated with, crystn. and structure of)
RN 142928-23-2 CAPLUS
CN 1-Piperazineacetamide, .alpha.-butyl-N-[(1S,2S,4R)-4-[(butylamino)carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, monohydrochloride, (.alpha.S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L5 ANSWER 56 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1994:135148 CAPLUS
DN 120:135148
TI N,N'-ethylene-bridged dipeptide composed of different optically active (.alpha.)-amino acids and production thereof
IN Kojima, Yoshitane; Yamashita, Tetsushi; Adachi, Hidenari
PA Sanyo Fine Co., Ltd., Japan
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9318013	A1	19930916	WO 1993-JP292	19930310
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	JP 3265378	B2	20020311	JP 1993-515534	19930310
PRAI	JP 1992-51241	A	19920310		
	WO 1993-JP292	W	19930310		

OS CASREACT 120:135148; MARPAT 120:135148
IT **153052-92-7P 153052-93-8P 153052-94-9P**
153052-95-0P 153052-98-3P 153092-45-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as intermediate for physiolog. active peptides, process for)
RN 153052-92-7 CAPLUS
CN 1-Piperazineacetic acid, 4-(2,4-dinitrobenzoyl)-3-[3-[[imino[[(4-methylphenyl)sulfonyl]amino]methyl]amino]propyl]-2-oxo-.alpha.-[(phenylmethoxy)methyl]-, ethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 153052-93-8 CAPLUS
CN 1-Piperazineacetic acid, 4-(2,4-dinitrobenzoyl)-.alpha.-[3-[[imino[[(4-methylphenyl)sulfonyl]amino]methyl]amino]propyl]-2-oxo-3-[(phenylmethoxy)methyl]-, ethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 153052-94-9 CAPLUS
CN 1-Piperazineacetic acid, 4-(2,4-dinitrobenzoyl)-.alpha.-(1-hydroxyethyl)-3-[3-[[imino[[(4-methylphenyl)sulfonyl]amino]methyl]amino]propyl]-2-oxo-, ethyl ester, [3S-[1[R*(S*)]]]- (9CI) (CA INDEX NAME)



RN 153052-95-0 CAPLUS
CN 1-Piperazineacetic acid, 4-(2,4-dinitrobenzoyl)-3-methyl-2-oxo-.alpha.-(phenylmethyl)-, ethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 153052-98-3 CAPLUS
CN 1-Piperazineacetic acid, 4-(2,4-dinitrobenzoyl)-.alpha.-methyl-2-oxo-3-[(phenylmethoxy)methyl]-, ethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



V. Balasubramanian

RN 153092-45-6 CAPLUS
CN 1-Piperazineacetic acid, 4-(2,4-dinitrobenzoyl)-.alpha.-[3-[[[(2,4-dinitrobenzoyl)amino][[(4-methylphenyl)sulfonyl]amino]methylene]amino]propyl]-3-(1-hydroxyethyl)-2-oxo-, ethyl ester, [3S-[1(R*),3R*(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



L5 ANSWER 57 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1993:671678 CAPLUS
DN 119:271678
TI Preparations of N,N'-ethylene-bridged dipeptides (eXX) constructed from (S)-methionine, -tryptophan, -tyrosine and -N(.epsilon.)-benzyloxycarbonyllysine through acid-catalyzed cyclization
AU Yamashita, T.; Takenaka, H.; Kojima, Y.
CS Fac. Sci., Osaka City Univ., Osaka, Japan
SO Amino Acids (1993), 4(1-2), 187-92
CODEN: AACIE6; ISSN: 0939-4451
DT Journal
LA English
OS CASREACT 119:271678
IT **150763-75-0P 150763-76-1P 150763-78-3P 150763-79-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 150763-75-0 CAPLUS
CN 1-Piperazineacetic acid, 4-(3,5-dinitrobenzoyl)-.alpha.,3-bis[2-(methylthio)ethyl]-2-oxo-, ethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 150763-76-1 CAPLUS
CN 1H-Indole-2-propanoic acid, .alpha.-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]-3-(1H-indol-2-ylmethyl)-2-oxo-1-piperazinyl]-, ethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 150763-78-3 CAPLUS
CN 1-Piperazineacetic acid, 4-(3,5-dinitrobenzoyl)-2-oxo-.alpha.,3-bis[4-[[(phenylmethoxy)carbonyl]amino]butyl]-, ethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 150763-79-4 CAPLUS
CN 1-Piperazineacetic acid, 4-(3,5-dinitrobenzoyl)-.alpha.,3-bis[2-(methylthio)ethyl]-2-oxo-, methyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 58 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1993:650442 CAPLUS
DN 119:250442
TI Synthesis of Met- and Leu-enkephalin analogs containing chiral N,N'-ethylene-bridged phenylalanyl-methionine and -leucine
AU Takenaka, Hiroshi; Miyake, Hiroyuki; Kojima, Yoshitane; Yasuda, Masahide; Gemba, Munekazu; Yamashita, Tetsushi
CS Fac. Sci., Osaka City Univ., Osaka, 558, Japan
SO Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1993), (8), 933-7
CODEN: JCPRB4; ISSN: 0300-922X
DT Journal
LA English
OS CASREACT 119:250442
IT **151141-70-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and deblocking of)
RN 151141-70-7 CAPLUS
CN L-Tyrosine, N-[N-[N-[2-[4-[(1,1-dimethylethoxy)carbonyl]-3-[2-(methylthio)ethyl]-2-oxo-1-piperazinyl]-1-oxo-3-phenylpropyl]glycyl]-D-alanyl]-, ethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



IT **151141-60-5P 151141-61-6P 151215-18-8P**
151215-19-9P 151215-20-2P 151215-21-3P
151215-22-4P 151215-23-5P 151215-24-6P
151215-25-7P 151282-41-6P 151282-42-7P
151282-43-8P 151282-44-9P 151282-45-0P
151282-46-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and opiate activity of)

RN 151141-60-5 CAPLUS

CN D-Alaninamide, N-[(1,1-dimethylethoxy)carbonyl]-O-(phenylmethyl)-L-tyrosyl-N-[2-[4-[1-(ethoxycarbonyl)-3-(methylthio)propyl]-3-oxo-2-(phenylmethyl)-1-piperazinyl]-2-oxoethyl]-, monohydrochloride, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

PAGE 1-A



● HCl

PAGE 1-B



RN 151141-61-6 CAPLUS

CN D-Alaninamide, N-[(1,1-dimethylethoxy)carbonyl]-O-(phenylmethyl)-L-tyrosyl-N-[2-[4-[1-(ethoxycarbonyl)-3-methylbutyl]-3-oxo-2-(phenylmethyl)-1-piperazinyl]-2-oxoethyl]-, monohydrochloride, [S-(R*,R*)]- (9CI) (CA

INDEX NAME)

PAGE 1-A



● HCl

PAGE 1-B

— Ph

RN 151215-18-8 CAPLUS
CN D-Alaninamide, N-[(1,1-dimethylethoxy)carbonyl]-O-(phenylmethyl)-L-tyrosyl-N-[2-[4-[1-(ethoxycarbonyl)-3-(methylthio)propyl]-3-oxo-2-(phenylmethyl)-1-piperazinyl]-2-oxoethyl]-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

RN 151215-19-9 CAPLUS
CN D-Alaninamide, N-[(1,1-dimethylethoxy)carbonyl]-O-(phenylmethyl)-L-tyrosyl-N-[2-[4-[1-(ethoxycarbonyl)-3-(methylthio)propyl]-3-oxo-2-(phenylmethyl)-1-piperazinyl]-2-oxoethyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

RN 151215-20-2 CAPLUS
CN D-Alaninamide, N-[(1,1-dimethylethoxy)carbonyl]-O-(phenylmethyl)-L-tyrosyl-N-[2-[4-[1-(ethoxycarbonyl)-3-(methylthio)propyl]-3-oxo-2-(phenylmethyl)-1-piperazinyl]-2-oxoethyl]-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 151215-21-3 CAPLUS
CN D-Alaninamide, N-[(1,1-dimethylethoxy)carbonyl]-O-(phenylmethyl)-L-tyrosyl-N-[2-[4-[1-(ethoxycarbonyl)-3-(methylthio)propyl]-3-oxo-2-(phenylmethyl)-1-piperazinyl]-2-oxoethyl]-, [R-(R*,R*)]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 151215-22-4 CAPLUS
CN D-Alaninamide, N-[(1,1-dimethylethoxy)carbonyl]-O-(phenylmethyl)-L-tyrosyl-N-[2-[4-[1-(ethoxycarbonyl)-3-methylbutyl]-3-oxo-2-(phenylmethyl)-1-piperazinyl]-2-oxoethyl]-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

PAGE 1-A

PAGE 1-B



RN 151215-23-5 CAPLUS
CN D-Alaninamide, N-[(1,1-dimethylethoxy)carbonyl]-O-(phenylmethyl)-L-tyrosyl-N-[2-[4-[1-(ethoxycarbonyl)-3-methylbutyl]-3-oxo-2-(phenylmethyl)-1-piperazinyl]-2-oxoethyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— Ph

RN 151215-24-6 CAPLUS
CN D-Alaninamide, N-[(1,1-dimethylethoxy)carbonyl]-O-(phenylmethyl)-L-tyrosyl-N-[2-[4-[1-(ethoxycarbonyl)-3-methylbutyl]-3-oxo-2-(phenylmethyl)-1-piperazinyl]-2-oxoethyl]-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— Ph

RN 151215-25-7 CAPLUS
CN D-Alaninamide, N-[(1,1-dimethylethoxy)carbonyl]-O-(phenylmethyl)-L-tyrosyl-N-[2-[4-[1-(ethoxycarbonyl)-3-methylbutyl]-3-oxo-2-(phenylmethyl)-1-piperazinyl]-2-oxoethyl]-, [R-(R*,R*)]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— Ph

RN 151282-41-6 CAPLUS
CN D-Alaninamide, N-[(1,1-dimethylethoxy)carbonyl]-O-(phenylmethyl)-L-tyrosyl-N-[2-[4-[1-(ethoxycarbonyl)-3-(methylthio)propyl]-3-oxo-2-(phenylmethyl)-1-piperazinyl]-2-oxoethyl]-, monohydrochloride, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

PAGE 1-A



● HCl

PAGE 1-B



RN 151282-42-7 CAPLUS
CN D-Alaninamide, N-[(1,1-dimethylethoxy)carbonyl]-O-(phenylmethyl)-L-tyrosyl-N-[2-[4-[1-(ethoxycarbonyl)-3-(methylthio)propyl]-3-oxo-2-(phenylmethyl)-1-piperazinyl]-2-oxoethyl]-, monohydrochloride, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

PAGE 1-A



● HCl

PAGE 1-B

RN 151282-43-8 CAPLUS
CN D-Alaninamide, N-[(1,1-dimethylethoxy)carbonyl]-O-(phenylmethyl)-L-tyrosyl-N-[2-[4-[1-(ethoxycarbonyl)-3-(methylthio)propyl]-3-oxo-2-(phenylmethyl)-1-piperazinyl]-2-oxoethyl]-, monohydrochloride, [R-(R*,R*)]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 151282-44-9 CAPLUS
CN D-Alaninamide, N-[(1,1-dimethylethoxy)carbonyl]-O-(phenylmethyl)-L-tyrosyl-N-[2-[4-[1-(ethoxycarbonyl)-3-methylbutyl]-3-oxo-2-(phenylmethyl)-1-piperazinyl]-2-oxoethyl]-, monohydrochloride, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

PAGE 1-A



● HCl

PAGE 1-B

— Ph

RN 151282-45-0 CAPLUS
CN D-Alaninamide, N-[(1,1-dimethylethoxy)carbonyl]-O-(phenylmethyl)-L-tyrosyl-N-[2-[4-[1-(ethoxycarbonyl)-3-methylbutyl]-3-oxo-2-(phenylmethyl)-1-piperazinyl]-2-oxoethyl]-, monohydrochloride, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

PAGE 1-A



● HCl

PAGE 1-B

— Ph

RN 151282-46-1 CAPLUS
CN D-Alaninamide, N-[(1,1-dimethylethoxy)carbonyl]-O-(phenylmethyl)-L-tyrosyl-N-[2-[4-[1-(ethoxycarbonyl)-3-methylbutyl]-3-oxo-2-(phenylmethyl)-1-piperazinyl]-2-oxoethyl]-, monohydrochloride, [R-(R*,R*)]- (9CI) (CA INDEX NAME)

PAGE 1-A



● HCl

PAGE 1-B

— Ph

IT **151141-65-0P 151141-66-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and peptide coupling of, with peptide ester)
RN 151141-65-0 CAPLUS
CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-3-[2-(methylthio)ethyl]-2-oxo-.alpha.-(phenylmethyl)-, ethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 151141-66-1 CAPLUS
CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-3-(2-methylpropyl)-2-oxo-.alpha.-(phenylmethyl)-, ethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **151141-48-9P 151141-49-0P 151141-50-3P**
151141-51-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 151141-48-9 CAPLUS
CN 1-Piperazineacetic acid, 4-(aminoacetyl)-.alpha.-[2-(methylthio)ethyl]-2-oxo-3-(phenylmethyl)-, ethyl ester, monohydrochloride, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 151141-49-0 CAPLUS
CN 1-Piperazineacetic acid, 4-(aminoacetyl)-3-[2-(methylthio)ethyl]-2-oxo-.alpha.-(phenylmethyl)-, ethyl ester, monohydrochloride, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 151141-50-3 CAPLUS
CN 1-Piperazineacetic acid, 4-(aminoacetyl)-.alpha.-[2-(methylthio)ethyl]-2-oxo-3-(phenylmethyl)-, ethyl ester, monohydrochloride, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

V. Balasubramanian



● HCl

RN 151141-51-4 CAPLUS
CN 1-Piperazineacetic acid, 4-(aminoacetyl)-3-[2-(methylthio)ethyl]-2-oxo-.alpha.-(phenylmethyl)-, ethyl ester, monohydrochloride, [S-(R*,S*)]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L5 ANSWER 59 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1993:472626 CAPLUS
DN 119:72626
TI Preparation and formulation of 4-[(.alpha.-acylamino)acyl]-2-oxopiperazine-1-acetates and analogs as cell adhesion inhibitors
IN Sugihara, Hirosada; Terashita, Zenichi
PA Takeda Chemical Industries, Ltd., Japan
SO Eur. Pat. Appl., 49 pp.
CODEN: EPXXDW
DT Patent
LA English

V. Balasubramanian

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 529858	A1	19930303	EP 1992-307292	19920810
	EP 529858	B1	19971015		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	AU 9220908	A1	19930225	AU 1992-20908	19920807
	AU 646966	B2	19940310		
	US 5294713	A	19940315	US 1992-926171	19920807
	AT 159249	E	19971115	AT 1992-307292	19920810
	JP 06025285	A2	19940201	JP 1992-217778	19920817
	JP 2879280	B2	19990405		
	NO 9203253	A	19930224	NO 1992-3253	19920819
	HU 63154	A2	19930728	HU 1992-2686	19920819
	CA 2076619	AA	19930224	CA 1992-2076619	19920821
	CN 1069730	A	19930310	CN 1992-109703	19920822
	JP 09169742	A2	19970630	JP 1996-346409	19961226
	JP 3125212	B2	20010115		
PRAI	JP 1991-212397	A	19910823		
	JP 1992-123146	A	19920515		
	JP 1992-217778	A3	19920817		

OS MARPAT 119:72626

IT **148126-81-2P 148126-89-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as cell adhesion inhibitor)

RN 148126-81-2 CAPLUS

CN 1,3-Piperazinediacetic acid, 4-[[[4-(aminoiminomethyl)benzoyl]amino]acetyl]-2-oxo-.alpha.1-(phenylmethyl)-, monohydrochloride, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RN 148126-89-0 CAPLUS

CN 1,3-Piperazinediacetic acid, 4-[[[4-[(aminoiminomethyl)amino]benzoyl]amino]acetyl]-.alpha.1-methyl-2-oxo-, monohydrochloride, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L5 ANSWER 60 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1993:409168 CAPLUS
DN 119:9168
TI Preparation of oxiranyl and oxetanyl renin inhibiting compounds
IN Rosenberg, Saul H.
PA Abbott Laboratories, USA
SO PCT Int. Appl., 168 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9222313	A1	19921223	WO 1992-US4423	19920526
	W: AU, CA, JP, KR				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
	US 5258362	A	19931102	US 1992-880250	19920513
	AU 9221593	A1	19930112	AU 1992-21593	19920526
PRAI	US 1991-713475		19910611		
	US 1992-880250		19920513		
	WO 1992-US4423		19920526		

OS MARPAT 119:9168
IT **147933-38-8**
RL: RCT (Reactant); RACT (Reactant or reagent)
(peptide coupling reactions of, in prepn. of renin inhibitors)
RN 147933-38-8 CAPLUS
CN 1-Piperazineacetic acid, 4-[(4-methylphenyl)sulfonyl]-2-oxo-3-(phenylmethyl)-.alpha.-(4-thiazolylmethyl)- (9CI) (CA INDEX NAME)



V. Balasubramanian

IT **147896-50-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of, as renin inhibitor)
RN 147896-50-2 CAPLUS
CN L-Altritol, 4,6-anhydro-1-cyclohexyl-1,2,5-trideoxy-5-ethyl-2-[[2-[4-[(4-methylphenyl)sulfonyl]-2-oxo-3-(phenylmethyl)-1-piperazinyl]-1-oxo-3-(4-thiazolyl)propyl]amino]- (9CI) (CA INDEX NAME)



L5 ANSWER 61 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1993:408830 CAPLUS
DN 119:8830
TI Compounds with renin-inhibiting properties, process for their preparation and their use
IN Heitsch, Holger; Henning, Rainer; Urbach, Hansjoerg; Ruppert, Dieter; Linz, Wolfgang
PA Hoechst A.-G., Germany
SO Eur. Pat. Appl., 18 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 519433	A1	19921223	EP 1992-110244	19920617
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, PT, SE				
NO 9202426	A	19921222	NO 1992-2426	19920619
CA 2071744	AA	19921222	CA 1992-2071744	19920619
BR 9202325	A	19930119	BR 1992-2325	19920619
ZA 9204522	A	19930224	ZA 1992-4522	19920619
HU 61744	A2	19930301	HU 1992-2062	19920619
JP 05186461	A2	19930727	JP 1992-160476	19920619
CN 1068112	A	19930120	CN 1992-104887	19920620
PRAI DE 1991-4120510		19910621		

OS CASREACT 119:8830; MARPAT 119:8830
IT **147937-63-1P 147937-64-2P 147937-67-5P**
147937-68-6P 147937-69-7P 147961-52-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as antihypertensive (renin inhibitor))
RN 147937-63-1 CAPLUS

V. Balasubramanian

CN 1-Piperazinecarboxylic acid, 4-[1-[[[1-(cyclohexylmethyl)-2,3-dihydroxy-5-(2-pyridinyl)pentyl]amino]carbonyl]pentyl]-3-oxo-2-(phenylmethyl)-, 1,1-dimethylethyl ester, [2R-[2R*,4[S*(1S*,2R*,3S*)]]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 147937-64-2 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[[1-(cyclohexylmethyl)-2,3-dihydroxy-5-(2-pyridinyl)pentyl]amino]-1-(1H-imidazol-4-ylmethyl)-2-oxoethyl]-3-oxo-2-(phenylmethyl)-, 1,1-dimethylethyl ester, [2R-[2R*,4[S*(1S*,2R*,3S*)]]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 147937-67-5 CAPLUS
CN 1-Piperazineacetamide, N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-(2-pyridinyl)pentyl]-4-[(4-methylphenyl)sulfonyl]-2-oxo-3-(phenylmethyl)-.alpha.-(4-thiazolylmethyl)- (9CI) (CA INDEX NAME)



RN 147937-68-6 CAPLUS
CN 1-Piperazineacetamide, N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-(2-pyridinyl)pentyl]-4-[(4-methyl-1-piperazinyl)sulfonyl]-2-oxo-3-(phenylmethyl)-.alpha.-(4-thiazolylmethyl)- (9CI) (CA INDEX NAME)



RN 147937-69-7 CAPLUS
CN 1-Piperazineacetamide, N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-(2-pyridinyl)pentyl]-.alpha.-(1H-imidazol-4-ylmethyl)-4-[(4-methyl-1-piperazinyl)sulfonyl]-2-oxo-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 147961-52-2 CAPLUS
CN 1-Piperazineacetamide, N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-(2-pyridinyl)pentyl]-4-(4-morpholinylcarbonyl)-2-oxo-3-(phenylmethyl)-.alpha.-(4-thiazolylmethyl)- (9CI) (CA INDEX NAME)





IT **131288-18-1 147937-73-3**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant for N-[[(benzyl)piperazinyl]alkanoyl]cyclohexyldihydroxy(pyridyl)hexylamine deriv. (antihypertensive))
RN 131288-18-1 CAPLUS
CN 1-Piperazineacetic acid, .alpha.-butyl-4-[(1,1-dimethylethoxy)carbonyl]-2-oxo-3-(phenylmethyl)-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 147937-73-3 CAPLUS
CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-.alpha.-(1H-imidazol-4-ylmethyl)-2-oxo-3-(phenylmethyl)-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **147933-38-8 147937-75-5 147937-76-6**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant for N-[[(benzyl)piperazinyl]alkanoyl]cyclohexyldihydroxy(pyridyl)hexylamine deriv. deriv. (antihypertensive))

RN 147933-38-8 CAPLUS
CN 1-Piperazineacetic acid, 4-[(4-methylphenyl)sulfonyl]-2-oxo-3-(phenylmethyl)-.alpha.-(4-thiazolylmethyl)- (9CI) (CA INDEX NAME)



RN 147937-75-5 CAPLUS
CN 1-Piperazineacetic acid, 4-(4-morpholinylcarbonyl)-2-oxo-3-(phenylmethyl)-.alpha.-(4-thiazolylmethyl)- (9CI) (CA INDEX NAME)



RN 147937-76-6 CAPLUS
CN 1-Piperazineacetic acid, 4-[(4-methyl-1-piperazinyl)sulfonyl]-2-oxo-3-(phenylmethyl)-.alpha.-(4-thiazolylmethyl)- (9CI) (CA INDEX NAME)



IT **147937-77-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant for N-[[(benzyl)piperidinyl]alkanoyl]cyclohexyldihydroxy(pyridyl)hexylamine deriv. (antihypertensive))
RN 147937-77-7 CAPLUS
CN 1-Piperazineacetic acid, .alpha.-[[1-[(1,1-dimethylethoxy)carbonyl]-1H-imidazol-4-yl]methyl]-4-[(4-methyl-1-piperazinyl)sulfonyl]-2-oxo-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 62 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1992:571470 CAPLUS
DN 117:171470
TI Candida acid protease inhibiting compounds
IN Goldman, Robert C.; Baker, William R.; Jae, Hwan Soo; De, Biswanath; Zydowsky, Thomas M.; De Lara, Edwin
PA Abbott Laboratories, USA
SO U.S., 14 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5120718	A	19920609	US 1991-714820	19910613
PRAI US 1991-714820		19910613		

OS MARPAT 117:171470
IT **143487-50-7P 143692-59-5P 143692-61-9P**
143692-70-0P 143692-82-4P 143692-87-9P
143692-89-1P 143692-95-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and amidation of)
RN 143487-50-7 CAPLUS
CN 1-Piperazineacetic acid, .alpha.-butyl-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, [R-(R*,S*)]- (9CI) (CA

INDEX NAME)

Absolute stereochemistry.



RN 143692-59-5 CAPLUS
CN 1-Piperazineacetic acid, .alpha.-butyl-4-[(4-methylphenyl)sulfonyl]-2-oxo-5-(phenylmethyl)-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 143692-61-9 CAPLUS
CN 1-Piperazineacetic acid, .alpha.-butyl-4-[(4-methylphenyl)sulfonyl]-2-oxo-3-(phenylmethyl)-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 143692-70-0 CAPLUS
CN L-Norleucine, N-[2-[4-[(4-methylphenyl)sulfonyl]-2-oxo-5-(phenylmethyl)-1-piperazinyl]-1-oxohexyl]-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)



RN 143692-82-4 CAPLUS
CN 1-Piperazineacetic acid, .alpha.-butyl-4-[(4-methyl-1-piperazinyl)sulfonyl]-2-oxo-3-(phenylmethyl)-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 143692-87-9 CAPLUS
CN 1-Piperazineacetic acid, .alpha.-butyl-4-[[4-(methoxymethoxy)-1-piperazinyl]carbonyl]-2-oxo-3-(phenylmethyl)-, lithium salt, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



INDEX NAME)

Absolute stereochemistry.



RN 143692-95-9 CAPLUS
CN 1-Piperazineacetic acid, .alpha.-butyl-4-[(4-methoxyphenyl)sulfonyl]-2-oxo-3-(phenylmethyl)-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **143692-86-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and conversion of, to lithium salt)
RN 143692-86-8 CAPLUS
CN 1-Piperazineacetic acid, .alpha.-butyl-4-[[4-(methoxymethoxy)-1-piperazinyl]carbonyl]-2-oxo-3-(phenylmethyl)-, methyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **143692-76-6P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and coupling of, with phenylalanine Me ester)

RN 143692-76-6 CAPLUS
CN 1-Piperazineacetic acid, .alpha.-butyl-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **131288-17-0P 143487-49-4P 143692-58-4P 143692-68-6P 143692-69-7P 143692-78-8P 143692-81-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and hydrolysis of)

RN 131288-17-0 CAPLUS
CN 1-Piperazineacetic acid, .alpha.-butyl-4-[(1,1-dimethylethoxy)carbonyl]-2-oxo-3-(phenylmethyl)-, methyl ester, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 143487-49-4 CAPLUS
CN 1-Piperazineacetic acid, .alpha.-butyl-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, methyl ester, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 143692-58-4 CAPLUS
CN 1-Piperazineacetic acid, .alpha.-butyl-4-[(4-methylphenyl)sulfonyl]-2-oxo-5-(phenylmethyl)-, methyl ester, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 143692-68-6 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[1-[[[1-(methoxycarbonyl)pentyl]amino]carbonyl]pentyl]-5-oxo-2-(phenylmethyl)-, 1,1-dimethylethyl ester, [2S-[2R*,4[R*(R*)]]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 143692-69-7 CAPLUS
CN L-Norleucine, N-[2-[4-[(4-methylphenyl)sulfonyl]-2-oxo-5-(phenylmethyl)-1-

piperazinyl]-1-oxohexyl]-, methyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)



RN 143692-78-8 CAPLUS
CN 1-Piperazineacetic acid, .alpha.-butyl-4-[[4-(methylamino)phenyl]sulfonyl]-2-oxo-3-(phenylmethyl)-, methyl ester, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 143692-81-3 CAPLUS
CN 1-Piperazineacetic acid, .alpha.-butyl-4-[(4-methyl-1-piperazinyl)sulfonyl]-2-oxo-3-(phenylmethyl)-, methyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **131288-18-1P**

V. Balasubramanian

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of, with phosgene in presence of methylpiperazine)

RN 131288-18-1 CAPLUS

CN 1-Piperazineacetic acid, .alpha.-butyl-4-[(1,1-dimethylethoxy)carbonyl]-2-oxo-3-(phenylmethyl)-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **143788-47-0P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and toluenesulfonylation of)

RN 143788-47-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-[[[1-(methoxycarbonyl)pentyl]amino]carbonyl]pentyl]-5-oxo-2-(phenylmethyl)-, 1,1-dimethylethyl ester, monohydrochloride, [2S-[2R*,4[R*(R*)]]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT **131287-78-0P 143692-55-1P 143692-60-8P**
143692-62-0P 143692-63-1P 143692-71-1P
143692-75-5P 143692-79-9P 143692-80-2P
143692-83-5P 143692-88-0P 143692-90-4P
143692-92-6P 143692-94-8P 143715-51-9P
143731-22-0P 143731-24-2P 143731-25-3P

143788-48-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as Candida acid protease inhibitor)
RN 131287-78-0 CAPLUS
CN 1-Piperazineacetamide, .alpha.-butyl-N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, [3R-[1[S*(1S*,2R*,3S*)],3R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 143692-55-1 CAPLUS
RN 143692-60-8 CAPLUS
CN 1-Piperazineacetamide, .alpha.-butyl-N-[4-[(butylamino)carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-methylphenyl)sulfonyl]-2-oxo-5-(phenylmethyl)-, [5R-[1[S*(1S*,2S*,4R*)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 143692-62-0 CAPLUS
CN 1-Piperazineacetamide, .alpha.-butyl-N-[4-[(butylamino)carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-methylphenyl)sulfonyl]-2-oxo-3-(phenylmethyl)-, [3R-[1[S*(1S*,2S*,4R*)],3R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 143692-63-1 CAPLUS

CN 1-Piperazineacetamide, .alpha.-butyl-N-[4-[(butylamino)carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-methoxyphenyl)sulfonyl]-2-oxo-3-(phenylmethyl)-, [3R-[1[S*(1S*,2S*,4R*)],3R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 143692-71-1 CAPLUS

CN 1-Piperazineacetamide, .alpha.-butyl-N-[1-[[[4-[(butylamino)carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]amino]carbonyl]pentyl]-4-[(4-methylphenyl)sulfonyl]-2-oxo-5-(phenylmethyl)-, [5S-[1[R*[R*(1R*,2R*,4S*)]],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 143692-75-5 CAPLUS

V. Balasubramanian

CN 1-Piperazineacetamide, N-[4-[(butylamino)carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-methylphenyl)sulfonyl]-2-oxo-3-(phenylmethyl)-.alpha.-4-thiazolyl-, [3R-[1[S*(1S*,2S*,4R*)],3R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 143692-79-9 CAPLUS
CN 1-Piperazineacetamide, .alpha.-butyl-N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-4-[[4-(methylamino)phenyl]sulfonyl]-2-oxo-3-(phenylmethyl)-, [3R-[1[S*(1S*,2R*,3S*)],3R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 143692-80-2 CAPLUS
CN 1-Piperazineacetamide, .alpha.-butyl-N-[1-(cyclohexylmethyl)-2-hydroxy-5-methyl-4-[[[3-(4-morpholinyl)propyl]amino]carbonyl]hexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, [3S-[1[R*(1R*,2R*,4S*)],3R*]]- (9CI) (CA INDEX NAME)

V. Balasubramanian

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 143692-83-5 CAPLUS
CN 1-Piperazineacetamide, .alpha.-butyl-N-[4-[(butylamino)carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)sulfonyl]-2-oxo-3-(phenylmethyl)-, [3S-[1[R*(1R*,2R*,4S*)],3R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 143692-88-0 CAPLUS
CN 1-Piperazineacetamide, .alpha.-butyl-N-[1-(cyclohexylmethyl)-2-hydroxy-5-methyl-4-[[[3-(4-morpholinyl)propyl]amino]carbonyl]hexyl]-4-[(4-methyl-1-piperazinyl)sulfonyl]-2-oxo-3-(phenylmethyl)-, [3S-[1[R*(1R*,2R*,4S*)],3R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 143692-90-4 CAPLUS
CN 1-Piperazineacetamide, .alpha.-butyl-N-[1-(cyclohexylmethyl)-2-hydroxy-5-methyl-4-[[[3-(4-morpholinyl)propyl]amino]carbonyl]hexyl]-4-[[4-(methoxymethoxy)-1-piperazinyl]carbonyl]-2-oxo-3-(phenylmethyl)-, [3S-[1[R*(1R*,2R*,4S*)],3R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 143692-92-6 CAPLUS
CN 1-Piperazineacetamide, .alpha.-butyl-N-[1-(cyclohexylmethyl)-4-[[2-(dimethylamino)ethyl]amino]-2-hydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, [3R-[1[S*(1S*,2S*,4R*)],3R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 143692-94-8 CAPLUS
CN 1-Piperazineacetamide, .alpha.-butyl-N-[1-(cyclohexylmethyl)-4-[[3-(dimethylamino)propyl]amino]-2-hydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, [3R-[1[S*(1S*,2S*,4R*)],3R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 143715-51-9 CAPLUS
CN 1-Piperazineacetamide, .alpha.-butyl-N-[4-[(butylamino)carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[[4-(methoxymethoxy)-1-piperazinyl]carbonyl]-2-oxo-3-(phenylmethyl)-, [3S-[1[R*(1R*,2R*,4S*)],3R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 143731-22-0 CAPLUS
CN 1-Piperazineacetamide, .alpha.-butyl-N-[(1S,2S,4R)-4-[(butylamino)carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, (.alpha.S,3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 143731-24-2 CAPLUS

V. Balasubramanian

CN 1-Piperazineacetamide, .alpha.-butyl-N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, monohydrochloride, [3S-[1[R*(1R*,2S*,3R*)],3R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 143731-25-3 CAPLUS

CN 1-Piperazineacetamide, .alpha.-butyl-N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, monohydrochloride, [3R-[1[S*(1S*,2R*,3S*)],3R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 143788-48-1 CAPLUS

V. Balasubramanian

CN 1-Piperazineacetamide, .alpha.-butyl-N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, [3S-[1[R*(1R*,2S*,3R*)],3R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **143692-84-6**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with methoxymethoxypiperidine)
RN 143692-84-6 CAPLUS
CN 1-Piperazineacetic acid, .alpha.-butyl-4-(chlorocarbonyl)-2-oxo-3-(phenylmethyl)-, methyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 63 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1992:506860 CAPLUS
DN 117:106860
TI Application of a fluorogenic substrate in the assay of proteolytic activity and in the discovery of a potent inhibitor of Candida albicans

V. Balasubramanian

aspartic proteinase
AU Capobianco, John O.; Lerner, Claude G.; Goldman, Robert C.
CS Dep. 47M, Abbott Lab., Abbott Park, IL, 60064-3500, USA
SO Analytical Biochemistry (1992), 204(1), 96-102
CODEN: ANBCA2; ISSN: 0003-2697
DT Journal
LA English
IT **142928-23-2**, A 70450
RL: ANST (Analytical study)
(aspartic proteinase of Candida albicans inhibition by)
RN 142928-23-2 CAPLUS
CN 1-Piperazineacetamide, .alpha.-butyl-N-[(1S,2S,4R)-4-[(butylamino)carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, monohydrochloride, (.alpha.S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L5 ANSWER 64 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1992:59994 CAPLUS
DN 116:59994
TI Preparation of p-chlorophenylacetyl-containing peptides as tachykinin agonists and/or antagonists
IN Weber, Wolf Dietrich; Hoelzemann, Guenter; Jonczyk, Alfred; Lues, Ingeborg; Bartoszyk, Gerd; Greiner, Hartmut
PA Merck Patent G.m.b.H., Germany
SO Eur. Pat. Appl., 15 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 446706	A2	19910918	EP 1991-102903	19910228
EP 446706	A3	19920930		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
DE 4007869	A1	19910919	DE 1990-4007869	19900313
AU 9172760	A1	19910919	AU 1991-72760	19910308
CA 2037990	AA	19910914	CA 1991-2037990	19910311

V. Balasubramanian

	HU 56580	A2	19910930	HU 1991-802	19910312
	ZA 9101849	A	19911224	ZA 1991-1849	19910313
	JP 05078390	A2	19930330	JP 1991-154150	19910313
PRAI	DE 1990-4007869		19900313		

OS MARPAT 116:59994

IT **138564-51-9 138564-52-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(peptide coupling of, in prepn. of tachykinin agonists and/or antagonists)

RN 138564-51-9 CAPLUS

CN 1H-Indole-3-propanamide, .alpha.-amino-N-[1-[[4-[1-[[[2-amino-2-oxo-1-(phenylmethyl)ethyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]carbonyl]-2-methylbutyl]-, stereoisomer (9CI) (CA INDEX NAME)



RN 138564-52-0 CAPLUS

CN 1-Piperazineacetamide, N-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-4-(2-amino-1-oxo-3-phenylpropyl)-.alpha.-(2-methylpropyl)-2-oxo-3-(phenylmethyl)-(9CI) (CA INDEX NAME)



IT **138564-29-1P 138564-30-4P 138564-31-5P**
138564-32-6P 138564-33-7P 138564-34-8P
138564-35-9P 138564-36-0P 138564-37-1P
138564-38-2P 138564-39-3P 138564-40-6P
138564-41-7P 138564-42-8P 138564-47-3P
138564-48-4P 138564-49-5P 138564-50-8P

138581-63-2P 138662-47-2P 138662-48-3P
138662-49-4P 138662-50-7P 138662-51-8P
138662-52-9P 138662-53-0P 138662-54-1P
138662-55-2P 138662-56-3P 138662-57-4P
138663-55-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as tachykinin agonist and/or antagonist)

RN 138564-29-1 CAPLUS
CN 1H-Indole-3-propanamide, N-[1-[[4-[1-[[[2-amino-2-oxo-1-(phenylmethyl)ethyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]carbonyl]-2-methylbutyl]-.alpha.-[[(4-chlorophenyl)acetyl]amino]-, stereoisomer (9CI) (CA INDEX NAME)



RN 138564-30-4 CAPLUS
CN 1-Piperazineacetamide, N-[1-(aminocarbonyl)-3-(methylthio)propyl]-4-[N-[N-[(4-chlorophenyl)acetyl]-L-phenylalanyl]-L-valyl]-.alpha.-(2-methylpropyl)-2-oxo-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

PAGE 1-A





RN 138564-31-5 CAPLUS
CN 1-Piperazineacetic acid, 4-[2-[[[2-[(4-chlorophenyl)acetyl]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-yl]carbonyl]amino]-1-oxo-3-phenylpropyl]-.alpha.-(2-methylpropyl)-2-oxo-, methyl ester, [3R-[3R*[S*(S*)]]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 138564-32-6 CAPLUS
CN 1H-Indole-3-propanamide, N-[2-[4-[1-[[[1-(aminocarbonyl)-3-methylbutyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-.alpha.-[[(4-chlorophenyl)acetyl]amino]-, [.alpha.S-[N[R*[R*(R*)]],.alpha.R*]]- (9CI) (CA INDEX NAME)



RN 138564-33-7 CAPLUS
CN 1-Piperazineacetic acid, 4-[N-[N-[(4-chlorophenyl)acetyl]-D-tryptophyl]-L-phenylalanyl]-.alpha.-(2-methylpropyl)-2-oxo-, methyl ester, (S)- (9CI) (CA INDEX NAME)



RN 138564-34-8 CAPLUS
CN 1H-Indole-3-propanamide, N-[2-[4-[1-[[[1-(aminocarbonyl)-2-methylbutyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-.alpha.-[[(4-chlorophenyl)acetyl]amino]-, [1S-[1R*[R*[R*(S*)]],2R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 138564-35-9 CAPLUS
CN 1H-Indole-3-propanamide, N-[2-[4-[1-[[[1-(aminocarbonyl)-3-(methylsulfonyl)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-.alpha.-[[(4-chlorophenyl)acetyl]amino]-, [.alpha.R-[N[S*[S*(S*)]],.alpha.R*]]- (9CI) (CA INDEX NAME)

PAGE 1-A



—Me

RN 138564-36-0 CAPLUS
CN 1H-Indole-3-propanamide, N-[2-[4-[1-[[[1-(aminocarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-.alpha.-[[(4-chlorophenyl)acetyl]amino]-, [.alpha.R-[N[S*[S*(R*)]],.alpha.R*]]- (9CI) (CA INDEX NAME)



RN 138564-37-1 CAPLUS
CN 1H-Indole-3-propanamide, N-[2-[4-[1-[[[2-amino-2-oxo-1-(phenylmethyl)ethyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-.alpha.-[[(4-chlorophenyl)acetyl]amino]-, [.alpha.R-[N[S*[S*(S*)]],.alpha.R*]]- (9CI) (CA INDEX NAME)



RN 138564-38-2 CAPLUS
CN L-Phenylalanine, N-[2-[4-[N-[N-[(4-chlorophenyl)acetyl]-D-tryptophyl]-L-phenylalanyl]-2-oxo-1-piperazinyl]-4-methyl-1-oxopentyl]-, methyl ester, (S)- (9CI) (CA INDEX NAME)



RN 138564-39-3 CAPLUS
CN 1H-Indole-3-propanamide, N-[2-[4-[1-[[[2-amino-2-oxo-1-(phenylmethyl)ethyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-1-[(4-hydroxyphenyl)methyl]-2-oxoethyl]-.alpha.-[[(4-chlorophenyl)acetyl]amino]-, [.alpha.R-[N[S*[S*(S*)]],.alpha.R*]]- (9CI) (CA INDEX NAME)



RN 138564-40-6 CAPLUS
CN 1H-Indole-3-propanamide, N-[2-[4-[1-[[[1-(aminocarbonyl)-3-methylbutyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-.alpha.-[[(4-chlorophenyl)acetyl]methylamino]-, [.alpha.S-[N[R*[R*(R*)]],.alpha.R*]]- (9CI) (CA INDEX NAME)



RN 138564-41-7 CAPLUS
CN 1-Piperazineacetic acid, 4-[N-[N-[(4-chlorophenyl)acetyl]-N-methyltryptophyl]-L-isoleucyl]-.alpha.-(2-methylpropyl)-2-oxo-, methyl ester, (S)- (9CI) (CA INDEX NAME)



RN 138564-42-8 CAPLUS
CN 1H-Indole-3-propanamide, N-[2-[4-[1-[[[2-amino-2-oxo-1-(phenylmethyl)ethyl]amino]carbonyl]-3-methylbutyl]-3-oxo-2-(phenylmethyl)-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-.alpha.-[[(4-chlorophenyl)acetyl]amino]- (9CI) (CA INDEX NAME)



RN 138564-47-3 CAPLUS
CN 1-Piperazineacetic acid, 4-[N-[N-[(4-chlorophenyl)acetyl]-D-tryptophyl]-L-phenylalanyl]-.alpha.-(2-methylpropyl)-2-oxo-, (S)- (9CI) (CA INDEX NAME)



RN 138564-48-4 CAPLUS
CN 1-Piperazineacetic acid, 4-[2-[[[2-[(4-chlorophenyl)acetyl]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-yl]carbonyl]amino]-1-oxo-3-phenylpropyl]-.alpha.-(2-methylpropyl)-2-oxo-, [3R-[3R*[S*(S*)]]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 138564-49-5 CAPLUS
CN 1-Piperazineacetic acid, 4-[N-[N-[(4-chlorophenyl)acetyl]-N-methyl-D-phenylalanyl]-L-phenylalanyl]-.alpha.-(2-methylpropyl)-2-oxo-, (S)- (9CI) (CA INDEX NAME)



RN 138564-50-8 CAPLUS
CN 1-Piperazineacetamide, N-[1-(aminocarbonyl)-3-(methylsulfinyl)propyl]-4-[N-[N-[(4-chlorophenyl)acetyl]-L-phenylalanyl]-L-valyl]-.alpha.-(2-methylpropyl)-2-oxo-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 138581-63-2 CAPLUS
CN 1H-Pyrido[3,4-b]indole-3-carboxamide, N-[2-[4-[1-[[[2-amino-2-oxo-1-(phenylmethyl)ethyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-2-[(4-chlorophenyl)acetyl]-2,3,4,9-tetrahydro-, [3R-[3R*[S*[S*(S*)]]]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 138662-47-2 CAPLUS
CN 1H-Indole-3-propanamide, N-[2-[4-[1-[[[1-(aminocarbonyl)-3-methylbutyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-.alpha.-[[(4-chlorophenyl)acetyl]amino]-, stereoisomer (9CI) (CA INDEX NAME)



RN 138662-48-3 CAPLUS
CN 1H-Indole-3-propanamide, N-[1-[[4-[1-[[[2-amino-2-oxo-1-(phenylmethyl)ethyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]carbonyl]-2-methylbutyl]-.alpha.-[[(4-chlorophenyl)acetyl]amino]-, stereoisomer (9CI) (CA INDEX NAME)



RN 138662-49-4 CAPLUS
CN 1H-Indole-3-propanamide, N-[2-[4-[1-[[[1-(aminocarbonyl)-2-methylbutyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-.alpha.-[[(4-chlorophenyl)acetyl]amino]-, stereoisomer (9CI) (CA INDEX NAME)



RN 138662-50-7 CAPLUS
CN 1H-Indole-3-propanamide, N-[2-[4-[1-[[[1-(aminocarbonyl)-3-methylbutyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-.alpha.-[[(4-chlorophenyl)acetyl]amino]-, stereoisomer (9CI) (CA INDEX NAME)



RN 138662-51-8 CAPLUS
CN 1H-Indole-3-propanamide, N-[2-[4-[1-[[[1-(aminocarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-.alpha.-[[(4-chlorophenyl)acetyl]amino]-, stereoisomer (9CI) (CA INDEX NAME)



RN 138662-52-9 CAPLUS
CN L-Phenylalanine, N-[2-[4-[N-[N-[(4-chlorophenyl)acetyl]-D-tryptophyl]-L-phenylalanyl]-2-oxo-1-piperazinyl]-4-methyl-1-oxopentyl]-, methyl ester, (R)- (9CI) (CA INDEX NAME)



RN 138662-53-0 CAPLUS
CN 1H-Indole-3-propanamide, N-[2-[4-[1-[[[2-amino-2-oxo-1-(phenylmethyl)ethyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-.alpha.-[[(4-chlorophenyl)acetyl]amino]-, stereoisomer (9CI) (CA INDEX NAME)



RN 138662-54-1 CAPLUS
CN 1H-Indole-3-propanamide, N-[2-[4-[1-[[[2-amino-2-oxo-1-(phenylmethyl)ethyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-1-[(4-hydroxyphenyl)methyl]-2-oxoethyl]-.alpha.-[[(4-chlorophenyl)acetyl]amino]-, stereoisomer (9CI) (CA INDEX NAME)



RN 138662-55-2 CAPLUS
CN 1H-Indole-3-propanamide, N-[2-[4-[1-[[[1-(aminocarbonyl)-3-methylbutyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-.alpha.-[[(4-chlorophenyl)acetyl]methylamino]-, stereoisomer (9CI) (CA INDEX NAME)



RN 138662-56-3 CAPLUS
CN 1H-Indole-3-propanamide, N-[2-[4-[1-[[[1-(aminocarbonyl)-3-methylbutyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-.alpha.-[[(4-chlorophenyl)acetyl]methylamino]-, stereoisomer (9CI) (CA INDEX NAME)



RN 138662-57-4 CAPLUS
CN 1H-Indole-3-propanamide, N-[2-[4-[1-[[[1-(aminocarbonyl)-3-methylbutyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-.alpha.-[[(4-chlorophenyl)acetyl]methylamino]-, stereoisomer (9CI) (CA INDEX NAME)



RN 138663-55-5 CAPLUS
CN 1H-Pyrido[3,4-b]indole-3-carboxamide, N-[2-[4-[1-[[[2-amino-2-oxo-1-(phenylmethyl)ethyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-2-[(4-chlorophenyl)acetyl]-2,3,4,9-tetrahydro-, [3R-[3R*[R*[S*(S*)]]]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 65 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1991:536730 CAPLUS
DN 115:136730
TI Preparations, solution conformations and molecular structures of N,N-ethylene-bridged dipeptides and their derivatives
AU Kojima, Yoshitane; Ikeda, Youko; Kumata, Etsuko; Maruo, Joji; Okamoto, Akihiro; Hirotsu, ken; Shibata, Kozo; Ohsuka, Akio
CS Fac. Sci., Osaka City Univ., Osaka, 558, Japan
SO International Journal of Peptide & Protein Research (1991), 37(6), 468-75
CODEN: IJPPC3; ISSN: 0367-8377
DT Journal
LA English
IT **135928-49-3**
RL: PRP (Properties)
(crystal structure of and conformation of, by NMR and mol. mechanics calcns.)
RN 135928-49-3 CAPLUS
CN 1-Piperazineacetic acid, 4-[[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]-2-oxo-.alpha.,3-bis(phenylmethyl)-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **135884-97-8P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and conformation of, by NMR and mol. mechanics calcns.)
RN 135884-97-8 CAPLUS
CN Glycine, N-[2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]-3-(1-methylethyl)-2-oxo-1-piperazinyl]-3-methyl-1-oxobutyl]-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **135884-99-0P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and crystal structure of)
RN 135884-99-0 CAPLUS
CN 1-Piperazineacetic acid, 4-[[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]-.alpha.,3-bis(1-methylethyl)-2-oxo-, hydrate (2:1), [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●1/2 H_2O

IT **135884-96-7P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and mol. structure of)
RN 135884-96-7 CAPLUS
CN 1-Piperazineacetic acid, 4-[[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]-.alpha.,3-bis(1-methylethyl)-2-oxo-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 66 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1991:229392 CAPLUS
DN 114:229392
TI Preparation of peptides as renin inhibitors for treating vascular diseases
IN Kleinert, Hollis D.
PA Abbott Laboratories, USA
SO PCT Int. Appl., 189 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

V. Balasubramanian

PI WO 9005531 A1 19900531 WO 1989-US5248 19891120
W: JP, US
RW: BE, CH, DE, ES, FR, GB, IT, NL, SE
CA 2003382 AA 19900521 CA 1989-2003382 19891120
EP 444156 A1 19910904 EP 1990-901238 19891120
R: BE, CH, DE, ES, FR, GB, IT, LI, NL, SE
JP 04503802 T2 19920709 JP 1990-501551 19891120
PRAI US 1988-275151 19881121
WO 1989-US5248 19891120
OS MARPAT 114:229392
IT **131385-71-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of, in renin inhibitor prepn. for vascular disease treatment)
RN 131385-71-2 CAPLUS
CN 1-Piperazineacetic acid, 4-[(4-methyl-1-piperazinyl)sulfonyl]-2-oxo-3-(phenylmethyl)-.alpha.-(4-thiazolylmethyl)-, methyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 67 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1991:82497 CAPLUS
DN 114:82497
TI Macrocyclic peptides. 5. Chiral recognition of (R)- and (S)-trimethyl-1-phenethylammonium bromides by 24-, 27- and 36-membered ring peptides containing glycine and N,N'-ethylene-bridged (S)-leucyl-(S)-leucine
AU Miyake, Hiroyuki; Shibata, Kozo; Kojima, Yoshitane; Yamashita, Tetsushi; Ohsuka, Akio
CS Fac. Sci., Osaka City Univ., Osaka, 558, Japan
SO Makromolekulare Chemie, Rapid Communications (1990), 11(12), 667-71
CODEN: MCRCD4; ISSN: 0173-2803
DT Journal
LA English
IT **131919-88-5**
RL: RCT (Reactant); RACT (Reactant or reagent)
(complexation of, with trimethylphenethylammonium bromide stereoisomers)
RN 131919-88-5 CAPLUS
CN 1-Piperazineacetic acid, 4-[[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]-.alpha.,3-bis(2-methylpropyl)-2-oxo-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

V. Balasubramanian

Absolute stereochemistry.



L5 ANSWER 68 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1991:43580 CAPLUS
DN 114:43580
TI Preparation of heterocyclic peptides as renin and retroviral protease inhibitors
IN De, Biswanath; Dellaria, Joseph F.; Baker, William R.; Zydowsky, Thomas M.; Rosenberg, Saul H.; Jae, Hwan Soo
PA Abbott Laboratories, USA
SO Eur. Pat. Appl., 150 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 365992	A1	19900502	EP 1989-119329	19891018
	R: ES, GR				
	CA 2000929	AA	19900419	CA 1989-2000929	19891018
	WO 9004917	A1	19900517	WO 1989-US4649	19891018
	W: AU, DK, JP, KR, US				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	AU 9048493	A1	19900528	AU 1990-48493	19891018
	EP 439556	A1	19910807	EP 1990-901957	19891018
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	JP 04501566	T2	19920319	JP 1990-502077	19891018
	DK 9100704	A	19910617	DK 1991-704	19910418
	US 5164388	A	19921117	US 1991-678266	19910418
PRAI	US 1988-259959		19881019		
	US 1989-390571		19890807		
	WO 1989-US4649		19891018		

OS MARPAT 114:43580
IT **131288-17-0P 131288-18-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as intermediate for heterocyclylpeptide renin inhibitor and antiretroviral)
RN 131288-17-0 CAPLUS
CN 1-Piperazineacetic acid, .alpha.-butyl-4-[(1,1-dimethylethoxy)carbonyl]-2-oxo-3-(phenylmethyl)-, methyl ester, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 131288-18-1 CAPLUS
CN 1-Piperazineacetic acid, .alpha.-butyl-4-[(1,1-dimethylethoxy)carbonyl]-2-oxo-3-(phenylmethyl)-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **131287-76-8P 131287-77-9P 131287-78-0P**
131287-79-1P 131287-80-4P 131287-81-5P
131287-82-6P 131287-92-8P 131287-93-9P
131287-95-1P 131287-96-2P 131287-97-3P
131287-98-4P 131287-99-5P 131288-00-1P
131288-01-2P 131316-82-0P 131316-83-1P
131316-84-2P 131349-10-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as renin inhibitor and antiretroviral)
RN 131287-76-8 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[1-[[[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]amino]carbonyl]pentyl]-3-oxo-2-(phenylmethyl)-, 1,1-dimethylethyl ester, [2R-[2R*,4[S*(1S*,2R*,3S*)]]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 131287-77-9 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]amino]-1-(1H-imidazol-4-ylmethyl)-2-oxoethyl]-3-oxo-2-(phenylmethyl)-, 1,1-dimethylethyl ester, [2R-[2R*,4[R*(1S*,2R*,3S*)]]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 131287-78-0 CAPLUS
CN 1-Piperazineacetamide, .alpha.-butyl-N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, [3R-[1[S*(1S*,2R*,3S*)],3R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 131287-79-1 CAPLUS
CN 1-Piperazineacetamide, .alpha.-butyl-N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-4-[[[2-(methoxymethoxy)ethyl]methylamino]carbonyl]-2-oxo-3-(phenylmethyl)-, [3R-[1[S*(1S*,2R*,3S*)],3R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 131287-80-4 CAPLUS
CN 1-Piperazineacetamide, N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-4-(4-morpholinylcarbonyl)-2-oxo-3-(phenylmethyl)-.alpha.-(4-thiazolylmethyl)-, [3R-[1[R*(1S*,2R*,3S*)],3R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 131287-81-5 CAPLUS
CN 1-Piperazineacetamide, .alpha.-butyl-N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-4-(4-morpholinylcarbonyl)-2-oxo-3-(phenylmethyl)-, [3R-[1[S*(1S*,2R*,3S*)],3R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 131287-82-6 CAPLUS
CN 1-Piperazineacetamide, N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-.alpha.-(1H-imidazol-4-ylmethyl)-4-(4-morpholinylcarbonyl)-2-oxo-3-(phenylmethyl)-, [3R-[1[S*(1S*,2R*,3S*)],3R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 131287-92-8 CAPLUS
CN 1-Piperazineacetamide, N-[5-(butylamino)-1-(cyclohexylmethyl)-2-hydroxy-4-(1-methylethyl)-5-oxopentyl]-4-(4-morpholinylcarbonyl)-2-oxo-3-(phenylmethyl)-.alpha.-(4-thiazolylmethyl)- (9CI) (CA INDEX NAME)



RN 131287-93-9 CAPLUS
CN 1-Piperazineacetamide, N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-4-[(4-methylphenyl)sulfonyl]-2-oxo-3-(phenylmethyl)-.alpha.-(4-thiazolylmethyl)- (9CI) (CA INDEX NAME)



V. Balasubramanian

RN 131287-95-1 CAPLUS
CN 1-Piperazineacetamide, N-[1-(cyclohexylmethyl)-2-hydroxy-2-(tetrahydro-4-methyl-2-furanyl)ethyl]-4-[(4-methylphenyl)sulfonyl]-2-oxo-3-(phenylmethyl)-.alpha.-(4-thiazolylmethyl)- (9CI) (CA INDEX NAME)



RN 131287-96-2 CAPLUS
CN 1-Piperazineacetamide, N-[4-[(butylamino)carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)sulfonyl]-2-oxo-3-(phenylmethyl)-.alpha.-(4-thiazolylmethyl)- (9CI) (CA INDEX NAME)



RN 131287-97-3 CAPLUS
CN 1H-Imidazole-1-carboxylic acid, 2-[3-[[1-(cyclohexylmethyl)-2-(3-ethyl-2-oxo-5-oxazolidinyl)-2-hydroxyethyl]amino]-2-[4-[(4-methyl-1-piperazinyl)sulfonyl]-2-oxo-3-(phenylmethyl)-1-piperazinyl]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 131287-98-4 CAPLUS
CN 1-Piperazineacetamide, N-[1-(cyclohexylmethyl)-2-(3-ethyl-2-oxo-5-oxazolidinyl)-2-hydroxyethyl]-.alpha.-(1H-imidazol-2-ylmethyl)-4-[(4-methyl-1-piperazinyl)sulfonyl]-2-oxo-3-(phenylmethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





RN 131287-99-5 CAPLUS
CN 1H-Imidazole-1-carboxylic acid, 2-[3-[[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]amino]-2-[4-[(4-methyl-1-piperazinyl)sulfonyl]-2-oxo-3-(phenylmethyl)-1-piperazinyl]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 131288-00-1 CAPLUS
CN 1H-Imidazole-1-carboxylic acid, 2-[3-[[1-(cyclohexylmethyl)-2-hydroxy-2-(tetrahydro-4-methyl-2-furanyl)ethyl]amino]-2-[4-[(4-methyl-1-piperazinyl)sulfonyl]-2-oxo-3-(phenylmethyl)-1-piperazinyl]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 131288-01-2 CAPLUS
CN 1-Piperazineacetamide, N-[1-(cyclohexylmethyl)-2-hydroxy-2-(tetrahydro-4-methyl-2-furanyl)ethyl]-.alpha.-(1H-imidazol-2-ylmethyl)-4-[(4-methyl-1-piperazinyl)sulfonyl]-2-oxo-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 131316-82-0 CAPLUS
CN 1-Piperazineacetamide, N-[4-[(butylamino)carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-methylphenyl)sulfonyl]-2-oxo-3-(phenylmethyl)-.alpha.-(4-thiazolylmethyl)- (9CI) (CA INDEX NAME)



RN 131316-83-1 CAPLUS
CN 1-Piperazineacetamide, N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-.alpha.-(1H-imidazol-2-ylmethyl)-4-[(4-methyl-1-piperazinyl)sulfonyl]-2-oxo-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 131316-84-2 CAPLUS
CN 1-Piperazineacetamide, N-[1-(cyclohexylmethyl)-2-hydroxy-4-methyl-5-[(1-methylethyl)sulfonyl]pentyl]-4-[(4-methyl-1-piperazinyl)sulfonyl]-2-oxo-3-(phenylmethyl)-.alpha.-(4-thiazolylmethyl)- (9CI) (CA INDEX NAME)



RN 131349-10-5 CAPLUS
CN 1-Piperazineacetamide, N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-4-(4-morpholinylcarbonyl)-2-oxo-3-(phenylmethyl)-.alpha.-(4-thiazolylmethyl)-, [3R-[1[S*(1S*,2R*,3S*)],3R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



V. Balasubramanian

L5 ANSWER 69 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1990:7904 CAPLUS
DN 112:7904
TI Macrocyclic peptides. II. Synthesis and structure of a novel dipeptide, (2S,3'S)-2-(2'-oxo-3'-methylpiperazin-1'-yl)-propanoic acid, and its use as the unit of cyclic peptides
AU Yamashita, Tetsushi; Kojima, Yoshitane; Hirotsu, Ken; Ohsuka, Akio
CS Fac. Sci., Osaka City Univ., Osaka, 558, Japan
SO International Journal of Peptide & Protein Research (1989), 33(2), 110-14
CODEN: IJPPC3; ISSN: 0367-8377
DT Journal
LA English
OS CASREACT 112:7904
IT **124194-13-4P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and crystal structure of)
RN 124194-13-4 CAPLUS
CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-.alpha.,3-dimethyl-2-oxo-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **124194-21-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and cyclization of)
RN 124194-21-4 CAPLUS
CN 1-Piperazineacetamide, N-[2-[[2-[4-[2-[[2-[4-[2-[[2-[(2,5-dioxo-1-pyrrolidinyl)oxy]-2-oxoethyl]methylamino]-1-methyl-2-oxoethyl]-2-methyl-3-oxo-1-piperazinyl]-2-oxoethyl]methylamino]-1-methyl-2-oxoethyl]-2-methyl-3-oxo-1-piperazinyl]-2-oxoethyl]methylamino]-2-oxoethyl]-N,.alpha.,3-trimethyl-4-[[methyl[2-[3-methyl-4-[(methylamino)acetyl]-2-oxo-1-piperazinyl]-1-oxopropyl]amino]acetyl]-2-oxo-, stereoisomer, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 124194-20-3
CMF C54 H83 N15 O17

PAGE 1-A



PAGE 1-B



PAGE 1-C



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT **124194-14-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and deblocking of, with trifluoroacetic acid)

RN 124194-14-5 CAPLUS
CN Glycine, N-[2-[4-[[[(1,1-dimethylethoxy)carbonyl]methylamino]acetyl]-3-methyl-2-oxo-1-piperazinyl]-1-oxopropyl]-N-methyl-, ethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **124194-15-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and peptide coupling of, with [oxo(methyl)piperazinyl]propanoic acid dipeptide)
RN 124194-15-6 CAPLUS
CN Glycine, N-methyl-N-[2-[3-methyl-4-[(methylamino)acetyl]-2-oxo-1-piperazinyl]-1-oxopropyl]-, ethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **124194-18-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and peptide coupling of, with pentapeptide deriv.)
RN 124194-18-9 CAPLUS
CN Glycine, N-methyl-N-[2-[3-methyl-4-[[methyl[2-[3-methyl-4-[(methylamino)acetyl]-2-oxo-1-piperazinyl]-1-oxopropyl]amino]acetyl]-2-oxo-

1-piperazinyl]-1-oxopropyl]-, ethyl ester, [3S-[1(R*),3R*,4[R*(R*)]]]-
(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—NHMe

IT **124194-17-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and peptide coupling of, with pentapeptide ester)

RN 124194-17-8 CAPLUS

CN Glycine, N-[2-[4-[[[2-[4-[[[(1,1-dimethylethoxy)carbonyl]methylamino]acetyl]-3-methyl-2-oxo-1-piperazinyl]-1-oxopropyl]methylamino]acetyl]-3-methyl-2-oxo-1-piperazinyl]-1-oxopropyl]-N-methyl-, [3S-[1(R*),3R*,4[R*(R*)]]]-
(9CI) (CA INDEX NAME)

PAGE 1-A



—CH_2—CO_2H

IT **114967-01-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and peptide coupling of, with sarcosine Et ester)
RN 114967-01-0 CAPLUS
CN 1-Piperazineacetic acid, 4-[[[(1,1-dimethylethoxy)carbonyl]methylamino]acetyl]-.alpha.,3-dimethyl-2-oxo-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **114967-00-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and sapon. of)
RN 114967-00-9 CAPLUS
CN 1-Piperazineacetic acid, 4-[[[(1,1-dimethylethoxy)carbonyl]methylamino]acetyl]-.alpha.,3-dimethyl-2-oxo-, methyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **124194-16-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and sapon. or deblocking of)
RN 124194-16-7 CAPLUS
CN Glycine, N-[2-[4-[[[2-[4-[[[(1,1-dimethylethoxy)carbonyl]methylamino]acetyl]-3-methyl-2-oxo-1-piperazinyl]-1-oxopropyl]methylamino]acetyl]-3-methyl-2-oxo-1-piperazinyl]-1-oxopropyl]-N-methyl-, ethyl ester, [3S-[1(R*),3R*,4[R*(R*)]]]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



IT **124194-19-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and sequential sapon., esterification of, with hydroxysuccinimide, and deblocking of)
RN 124194-19-0 CAPLUS
CN Glycine, N-[2-[4-[[[2-[4-[N-[N-[2-[4-[[[2-[4-[[[(1,1-dimethylethoxy)carbonyl]methylamino]acetyl]-3-methyl-2-oxo-1-piperazinyl]-

1-oxopropyl]methylamino]acetyl]-3-methyl-2-oxo-1-piperazinyl]-1-oxopropyl]-N-methylglycyl]-N-methylglycyl]-3-methyl-2-oxo-1-piperazinyl]-1-oxopropyl]methylamino]acetyl]-3-methyl-2-oxo-1-piperazinyl]-1-oxopropyl]-N-methyl-, ethyl ester, stereoisomer (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C



L5 ANSWER 70 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1989:478575 CAPLUS
DN 111:78575
TI Macrocyclic peptides. 3. Enantioface-differentiating abilities of 24-membered ring peptides containing N,N'-ethylene-bridged dipeptides, glycine and sarcosine
AU Kojima, Yoshitane; Yamashita, Tetsushi; Washizawa, Megumi; Ohsuka, Akio
CS Fac. Sci., Osaka City Univ., Sugimoto, 558, Japan
SO Makromolekulare Chemie, Rapid Communications (1989), 10(3), 121-5
CODEN: MCRCD4; ISSN: 0173-2803
DT Journal
LA English
OS CASREACT 111:78575
IT **121925-95-9P**

V. Balasubramanian

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and cyclization of)

RN 121925-95-9 CAPLUS

CN 1-Piperazineacetamide, 4-(aminoacetyl)-N-[2-[[2-[4-[1-[[[2-[(2,5-dioxo-1-pyrrolidinyl)oxy]-2-oxoethyl]amino]carbonyl]-3-methylbutyl]-2-(2-methylpropyl)-3-oxo-1-piperazinyl]-2-oxoethyl]amino]-2-oxoethyl]-.alpha.,3-bis(2-methylpropyl)-2-oxo-, monohydrochloride, [2S-[1[R*(R*)],2R*,4(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



● HCl

PAGE 1-B



IT **121925-91-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and deblocking of)
RN 121925-91-5 CAPLUS
CN Glycine, N-[2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]-3-(2-methylpropyl)-2-oxo-1-piperazinyl]-4-methyl-1-oxopentyl]-, methyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **121925-92-6P 121925-93-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and peptide coupling of)
RN 121925-92-6 CAPLUS
CN Glycine, N-[2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]-3-(2-methylpropyl)-2-oxo-1-piperazinyl]-4-methyl-1-oxopentyl]-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 121925-93-7 CAPLUS

V. Balasubramanian

CN Glycine, N-[2-[4-(aminoacetyl)-3-(2-methylpropyl)-2-oxo-1-piperazinyl]-4-methyl-1-oxopentyl]-, methyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **121925-90-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and sapon.-peptide coupling of)
RN 121925-90-4 CAPLUS
CN 1-Piperazineacetic acid, 4-[[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]-.alpha.,3-bis(2-methylpropyl)-2-oxo-, methyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **121925-94-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and sequential sapon. and esterification with hydroxysuccinimide)
RN 121925-94-8 CAPLUS
CN Glycine, N-[2-[4-[[[[[2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]-3-(2-methylpropyl)-2-oxo-1-piperazinyl]-4-methyl-1-oxopentyl]amino]acetyl]amino]acetyl]-3-(2-methylpropyl)-2-oxo-1-piperazinyl]-4-methyl-1-oxopentyl]-, methyl ester, [3S-[1(R*),3R*,4[R*(R*)]]]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L5 ANSWER 71 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1989:115348 CAPLUS
DN 110:115348
TI Preparation of tachykinin agonists and antagonists as drugs
IN Weber, Wolf Dietrich; Hoelzemann, Guenter; Jonczyk, Alfred; Wild, Albrecht; Lues, Ingeborg; Wienrich, Marion; Greiner, Hartmut
PA Merck Patent G.m.b.H., Fed. Rep. Ger.
SO Eur. Pat. Appl., 21 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 284942	A2	19881005	EP 1988-104483	19880321
	EP 284942	A3	19900905		
	R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
	DE 3711335	A1	19881020	DE 1987-3711335	19870403
	AU 8814134	A1	19881006	AU 1988-14134	19880331
	ZA 8802347	A	19881130	ZA 1988-2347	19880331
	JP 63258894	A2	19881026	JP 1988-78334	19880401
	HU 49149	A2	19890828	HU 1988-1623	19880401
PRAI	DE 1987-3711335		19870403		

OS CASREACT 110:115348; MARPAT 110:115348
IT **119156-28-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(acylation of, in prepn. of drug)
RN 119156-28-4 CAPLUS
CN L-Phenylalaninamide, L-phenylalanyl-N-[1-[[4-[1-[[[1-(aminocarbonyl)-3-

(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]carbonyl]-2-methylpropyl]-, monohydrochloride, stereoisomer (9CI) (CA INDEX NAME)



IT **119156-41-1P 119156-42-2P 119156-43-3P**
119156-44-4P 119156-45-5P 119156-46-6P
119156-47-7P 119156-48-8P 119156-49-9P
119156-50-2P 119156-51-3P 119156-52-4P
119156-53-5P 119156-54-6P 119156-55-7P
119156-56-8P 119156-57-9P 119156-68-2P
119156-69-3P 119156-91-1P 119156-92-2P
119157-38-9P 119157-39-0P 119157-40-3P
119157-41-4P 119157-45-8P 119188-54-4P
119240-51-6P 119240-60-7P 119240-61-8P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as drug)

RN 119156-41-1 CAPLUS

CN D-Tryptophanamide, N2-[(1,1-dimethylethoxy)carbonyl]-L-lysyl-N-[2-[4-[1-[[[1-(aminocarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-, stereoisomer (9CI) (CA INDEX NAME)



RN 119156-42-2 CAPLUS
CN L-Phenylalaninamide, N-(3-carboxy-1-oxopropyl)-L-phenylalanyl-N-[1-[[4-[1-[[[1-(aminocarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]carbonyl]-2-methylpropyl]-, stereoisomer (9CI) (CA INDEX NAME)



RN 119156-43-3 CAPLUS
CN D-Tryptophanamide, N2-[(1,1-dimethylethoxy)carbonyl]-N6-[(phenylmethoxy)carbonyl]-L-lysyl-N-[2-[4-[1-[[[1-(methoxycarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-, stereoisomer (9CI) (CA INDEX NAME)



RN 119156-44-4 CAPLUS
CN D-Tryptophanamide, N2-[(1,1-dimethylethoxy)carbonyl]-N6-[(phenylmethoxy)carbonyl]-L-lysyl-N-[2-[4-[1-[[[1-carboxy-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-, stereoisomer (9CI) (CA INDEX NAME)



RN 119156-45-5 CAPLUS
CN D-Tryptophanamide, N2-[(1,1-dimethylethoxy)carbonyl]-N6-[(phenylmethoxy)carbonyl]-L-lysyl-N-[2-[4-[1-[[[1-(aminocarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-, stereoisomer (9CI) (CA INDEX NAME)



RN 119156-46-6 CAPLUS
CN Carbamic acid, [2-[[1-[[4-[1-[[[1-(aminocarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]carbonyl]-2-methylpropyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-, phenylmethyl ester, stereoisomer (9CI) (CA INDEX NAME)



RN 119156-47-7 CAPLUS
CN Carbamic acid, [2-[[2-[4-[1-[[[2-amino-2-oxo-1-(phenylmethyl)ethyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]amino]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-, 1,1-dimethylethyl ester, stereoisomer (9CI) (CA INDEX NAME)



RN 119156-48-8 CAPLUS
CN D-Tryptophanamide, D-prolyl-N-[2-[4-[1-[[[2-amino-2-oxo-1-(phenylmethyl)ethyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-, stereoisomer (9CI) (CA INDEX NAME)



RN 119156-49-9 CAPLUS
CN 1H-Indole-3-propanamide, .alpha.-amino-N-[2-[4-[1-[[[1-(aminocarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-, [.alpha.R-[N[S*[S*(S*)]],.alpha.R*]]- (9CI) (CA INDEX NAME)



RN 119156-50-2 CAPLUS
CN Butanoic acid, 4-[[2-[[1-[[4-[1-[[[1-(aminocarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]carbonyl]-2-methylpropyl]amino]-2-oxo-1-

(phenylmethyl)ethyl]amino]-4-oxo-, stereoisomer (9CI) (CA INDEX NAME)



RN 119156-51-3 CAPLUS
CN 1-Piperazineacetamide, N-[1-(aminocarbonyl)-3-(methylthio)propyl]-.alpha.-(2-methylpropyl)-2-oxo-4-[N-[N-(phenylacetyl)-L-phenylalanyl]-L-valyl]-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)



RN 119156-52-4 CAPLUS
CN 1-Piperazineacetamide, N-[1-(aminocarbonyl)-3-(methylthio)propyl]-4-[N-(N-benzoyl-L-phenylalanyl)-L-valyl]-.alpha.-(2-methylpropyl)-2-oxo-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)



RN 119156-53-5 CAPLUS
CN 1-Piperazineacetamide, N-[1-(aminocarbonyl)-3-(methylthio)propyl]-4-[N-[N-[(4-aminophenyl)acetyl]-L-phenylalanyl]-L-valyl]-.alpha.-(2-methylpropyl)-2-oxo-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 119156-54-6 CAPLUS
CN L-Phenylalaninamide, 5-oxo-L-prolyl-N-[1-[[4-[1-[[[1-(aminocarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]carbonyl]-2-methylbutyl]-, [1S-[1R*[R*(R*)],2R*]]- (9CI) (CA

INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 119156-55-7 CAPLUS
CN L-Phenylalaninamide, 1-[(1,1-dimethylethoxy)carbonyl]-L-prolyl-N-[2-[4-[1-[[[1-(aminocarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-N,N.alpha.-dimethyl-, stereoisomer (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 119156-56-8 CAPLUS
CN 1-Piperazineacetamide, 4-[N-(N-acetyl-L-phenylalanyl)-L-valyl]-N-[1-(aminocarbonyl)-3-(methylthio)propyl]-.alpha.-(2-methylpropyl)-2-oxo-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)



RN 119156-57-9 CAPLUS
CN Carbamic acid, [2-[[2-[4-[1-[[[1-(aminocarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-, phenylmethyl ester, stereoisomer (9CI) (CA INDEX NAME)



RN 119156-68-2 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[1-[[[1-(aminocarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-, 1,1-dimethylethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 119156-69-3 CAPLUS
CN L-Phenylalaninamide, N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-[1-[[4-[1-[[[1-(aminocarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]carbonyl]-2-methylpropyl]-, stereoisomer (9CI) (CA INDEX NAME)



RN 119156-91-1 CAPLUS
CN D-Tryptophanamide, N6-[(phenylmethoxy)carbonyl]-L-lysyl-N-[2-[4-[1-[[[1-(aminocarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-, stereoisomer (9CI) (CA INDEX NAME)



RN 119156-92-2 CAPLUS
CN D-Tryptophanamide, N6-[(phenylmethoxy)carbonyl]-L-lysyl-N-[2-[4-[1-[[[1-(methoxycarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-, stereoisomer (9CI) (CA INDEX NAME)



RN 119157-38-9 CAPLUS
CN L-Phenylalaninamide, 5-oxo-L-prolyl-N-[2-[4-[1-[[[1-(aminocarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-, stereoisomer (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 119157-39-0 CAPLUS
CN L-Phenylalaninamide, 5-oxo-L-prolyl-N-[2-[4-[1-[[[1-(methoxycarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-, stereoisomer (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 119157-40-3 CAPLUS
CN L-Phenylalaninamide, N-[(phenylmethoxy)carbonyl]-L-.alpha.-aspartyl-L-phenylalanyl-N-[1-[[4-[1-[[[1-(aminocarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester, stereoisomer (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 119157-41-4 CAPLUS
CN L-Phenylalaninamide, N-[(phenylmethoxy)carbonyl]-L-.alpha.-aspartyl-L-phenylalanyl-N-[1-[[4-[1-[[[1-(methoxycarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester, stereoisomer (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 119157-45-8 CAPLUS

CN L-Phenylalaninamide, N-[(phenylmethoxy)carbonyl]-L-.alpha.-aspartyl-L-phenylalanyl-N-[1-[[4-[1-[[[1-(aminocarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]carbonyl]-2-methylpropyl]-, stereoisomer (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 119188-54-4 CAPLUS
CN L-Phenylalaninamide, L-.alpha.-aspartyl-L-phenylalanyl-N-[1-[[4-[1-[[[1-(aminocarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]carbonyl]-2-methylpropyl]-, stereoisomer (9CI) (CA INDEX NAME)



RN 119240-51-6 CAPLUS
CN L-Phenylalaninamide, L-phenylalanyl-N-[1-[[4-[1-[[[1-(aminocarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]carbonyl]-2-methylpropyl]-, stereoisomer (9CI) (CA INDEX NAME)



RN 119240-60-7 CAPLUS
CN L-Phenylalaninamide, 5-oxo-L-prolyl-N-[2-[4-[1-[[[1-(aminocarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-, stereoisomer (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 119240-61-8 CAPLUS
CN L-Phenylalaninamide, 5-oxo-L-prolyl-N-[2-[4-[1-[[[1-(methoxycarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-, stereoisomer (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT **119156-39-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in prepn. of drug)
RN 119156-39-7 CAPLUS
CN L-Phenylalaninamide, N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-[1-[[4-(1-carboxy-3-methylbutyl)-3-oxo-1-piperazinyl]carbonyl]-2-methylpropyl]-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)



L5 ANSWER 72 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1988:423356 CAPLUS
DN 109:23356
TI Interactions of organic substrates with 30- and 36-membered ring peptides containing (2S,3'S)-2-(2'-oxo-3'-methylpiperazin-1'-yl)propanoic acid and sarcosine
AU Kojima, Yoshitane; Yamashita, Tetsushi; Shibata, Kozo; Ohsuka, Akio
CS Fac. Sci., Osaka City Univ., Osaka, 558, Japan
SO Polymer Journal (Tokyo, Japan) (1987), 19(10), 1221-3
CODEN: POLJB8; ISSN: 0032-3896
DT Journal
LA English
IT **114967-10-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and cyclization of)
RN 114967-10-1 CAPLUS
CN 1-Piperazineacetamide, N-[2-[4-[2-[[2-[4-[2-[(2,5-dioxo-1-pyrrolidinyl)oxy]-1-methyl-2-oxoethyl]-2-methyl-3-oxo-1-piperazinyl]-2-oxoethyl]methylamino]-1-methyl-2-oxoethyl]-2-methyl-3-oxo-1-piperazinyl]-2-oxoethyl]-N,.alpha.,3-trimethyl-4-[[methyl[2-[3-methyl-4-[(methylamino)acetyl]-2-oxo-1-piperazinyl]-1-oxopropyl]amino]acetyl]-2-oxo-, [3S-[1[R*[R*[R*[R*(R*)]]]],3R*,4[R*(R*)]]]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 114967-09-8
CMF C48 H73 N13 O15

PAGE 1-A



PAGE 1-B



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT **114967-00-9P 114967-04-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and hydrolysis of)
RN 114967-00-9 CAPLUS
CN 1-Piperazineacetic acid, 4-[[[(1,1-dimethylethoxy)carbonyl]methylamino]acetyl]-.alpha.,3-dimethyl-2-oxo-, methyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 114967-04-3 CAPLUS
CN 1-Piperazineacetic acid, 4-[[[2-[4-[[[(1,1-dimethylethoxy)carbonyl]methylamino]acetyl]-3-methyl-2-oxo-1-piperazinyl]-1-oxopropyl]methylamino]acetyl]-.alpha.,3-dimethyl-2-oxo-, methyl ester, [3S-[1(R*),3R*,4[2R*(3R*)]]]- (9CI) (CA INDEX NAME)



IT **114967-01-0P 114967-03-2P 114967-05-4P 114967-07-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and peptide coupling of)
RN 114967-01-0 CAPLUS
CN 1-Piperazineacetic acid, 4-[[[(1,1-dimethylethoxy)carbonyl]methylamino]acetyl]-.alpha.,3-dimethyl-2-oxo-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 114967-03-2 CAPLUS
CN 1-Piperazineacetic acid, .alpha.,3-dimethyl-4-[(methylamino)acetyl]-2-oxo-, methyl ester, [S-(R*,R*)]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 114967-02-1
CMF C12 H21 N3 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 114967-05-4 CAPLUS

CN 1-Piperazineacetic acid, 4-[[[2-[4-[[[(1,1-dimethylethoxy)carbonyl]methylamino]acetyl]-3-methyl-2-oxo-1-piperazinyl]-1-oxopropyl]methylamino]acetyl]-.alpha.,3-dimethyl-2-oxo-, [3S-[1(R*),3R*,4[R*(R*)]]]- (9CI) (CA INDEX NAME)



RN 114967-07-6 CAPLUS
CN 1-Piperazineacetic acid, .alpha.,3-dimethyl-4-[[methyl[2-[3-methyl-4-[(methylamino)acetyl]-2-oxo-1-piperazinyl]-1-oxopropyl]amino]acetyl]-2-oxo-, methyl ester, [3S-[1(R*),3R*,4[R*(R*)]]]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 114967-06-5
CMF C23 H38 N6 O7



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT **114967-08-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn., sapon., and esterification of, with hydroxysuccinimide)
RN 114967-08-7 CAPLUS
CN 1-Piperazineacetic acid, 4-[[[2-[4-[[[2-[4-[[[2-[4-[[[(1,1-

dimethylethoxy)carbonyl]methylamino]acetyl]-3-methyl-2-oxo-1-piperazinyl]-1-oxopropyl]methylamino]acetyl]-3-methyl-2-oxo-1-piperazinyl]-1-oxopropyl]methylamino]acetyl]-3-methyl-2-oxo-1-piperazinyl]-1-oxopropyl]methylamino]acetyl]-.alpha.,3-dimethyl-2-oxo-, methyl ester, [3S-[1(R*),3R*,4[R*[R*[R*[R*[R*(R*)]]]]]]]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L5 ANSWER 73 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1987:28107 CAPLUS
DN 106:28107
TI Analgesic activities of spinal cord substance P antagonists implicate substance P as a neurotransmitter of pain sensation
AU Piercey, M. F.; Moon, M. W.; Blinn, J. R.; Dobry-Schreur, P. J. K.
CS Upjohn Co., Kalamazoo, MI, 49001, USA
SO Brain Research (1986), 385(1), 74-85
CODEN: BRREAP; ISSN: 0006-8993
DT Journal
LA English
IT **105655-58-1 105655-59-2 105680-08-8**
105761-69-1 106121-83-9
RL: BIOL (Biological study)
(as analgesic)
RN 105655-58-1 CAPLUS
CN L-Methioninamide, 5-oxo-L-prolyl-(.alpha.S,3R)-2-oxo-.alpha.,3-bis(phenylmethyl)-1-piperazineacetylglycyl-L-leucyl- (9CI) (CA INDEX NAME)



RN 105655-59-2 CAPLUS
CN L-Methioninamide, 5-oxo-L-prolyl-(.alpha.S,3R)-2-oxo-.alpha.,3-bis(phenylmethyl)-1-piperazineacetyl-D-prolyl-L-leucyl- (9CI) (CA INDEX NAME)



RN 105680-08-8 CAPLUS
CN L-Methioninamide, 5-oxo-L-prolyl-(.alpha.S,3R)-2-oxo-.alpha.,3-bis(phenylmethyl)-1-piperazineacetyl-(.alpha.S,3R)-3-amino-.alpha.-(2-methylpropyl)-2-oxo-1-pyrrolidineacetyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 105761-69-1 CAPLUS
CN L-Methioninamide, 5-oxo-L-prolyl-(.alpha.S,3S)-2-oxo-.alpha.,3-bis(phenylmethyl)-1-piperazineacetyl-D-prolyl-L-leucyl- (9CI) (CA INDEX NAME)



RN 106121-83-9 CAPLUS
CN 1-Piperazineacetamide, N-[(3R)-1-[(3R)-1-[[[(1S)-1-(aminocarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-2-oxo-3-pyrrolidinyl]-2-oxo-4-[[(4S)-2-oxo-4-imidazolidinyl]carbonyl]-.alpha.,3-bis(phenylmethyl)-, (.alpha.S)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L5 ANSWER 74 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1986:110169 CAPLUS
DN 104:110169
TI (Phenylalanyl)-2-piperazinones and -1,4-diazepin-2-ones
IN Moon, Malcolm W.
PA Upjohn Co., USA
SO U.S., 25 pp. Division of U.S. Ser. No. 153,435.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4534897	A	19850813	US 1984-598608	19840410
	US 4593098	A	19860603	US 1980-153435	19800527
PRAI	US 1980-153435		19800527		
	US 1979-48330		19790614		

OS CASREACT 104:110169
IT **78551-78-7P 78551-79-8P 78551-80-1P**
78551-81-2P 78551-82-3P 78551-83-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of)
RN 78551-78-7 CAPLUS
CN 1-Piperazineacetic acid, .alpha.-(2-methylpropyl)-2-oxo-4-[(phenylmethoxy)carbonyl]-3-(phenylmethyl)-, methyl ester, [S-(R*,R*)]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 78551-79-8 CAPLUS
CN 1-Piperazineacetic acid, .alpha.-(2-methylpropyl)-2-oxo-4-[(phenylmethoxy)carbonyl]-3-(phenylmethyl)-, methyl ester, [R-(R*,R*)]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 78551-80-1 CAPLUS
CN 1-Piperazineacetic acid, .alpha.-(2-methylpropyl)-2-oxo-4-[(phenylmethoxy)carbonyl]-3-(phenylmethyl)-, methyl ester, [R-(R*,S*)]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 78551-81-2 CAPLUS
CN 1-Piperazineacetic acid, .alpha.-(2-methylpropyl)-2-oxo-4-[(phenylmethoxy)carbonyl]-3-(phenylmethyl)-, methyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 78551-82-3 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[1-(aminocarbonyl)-3-methylbutyl]-3-oxo-2-(phenylmethyl)-, phenylmethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 78551-83-4 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[1-(aminocarbonyl)-3-methylbutyl]-3-oxo-2-(phenylmethyl)-, phenylmethyl ester, [R-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **100459-94-7P 100471-85-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 100459-94-7 CAPLUS
CN 1-Piperazineacetic acid, .alpha.-(2-methylpropyl)-2-oxo-4-[(phenylmethoxy)carbonyl]-3-(phenylmethyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 100471-85-0 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[1-(aminocarbonyl)-3-methylbutyl]-3-oxo-2-(phenylmethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 75 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1985:79151 CAPLUS
DN 102:79151
TI Organic phosphorous quinoxalinones and their use
IN Kondo, Michitada; Sato, Ryo; Matsumoto, Hiroshi; Okabe, Takayuki
PA Sumitomo Chemical Co., Ltd. , Japan
SO Eur. Pat. Appl., 31 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 118982	A1	19840919	EP 1984-300532	19840127
	R: CH, DE, FR, GB, IT, LI				
	JP 59141592	A2	19840814	JP 1983-15838	19830201
	JP 60081195	A2	19850509	JP 1983-190545	19831012
PRAI	JP 1983-15838		19830201		
	JP 1983-190545		19831012		

IT **94562-18-2P 94562-19-3P 94562-20-6P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and herbicidal activity of)
RN 94562-18-2 CAPLUS
CN Phosphorodithioic acid, S-[2-[3,4-dihydro-4-(1-methylethyl)-3-oxo-1(2H)-quinoxalinyl]-2-oxoethyl] O,O-diethyl ester (9CI) (CA INDEX NAME)



RN 94562-19-3 CAPLUS
CN Phosphorothioic acid, S-[2-[3,4-dihydro-4-(1-methylethyl)-3-oxo-1(2H)-quinoxalinyl]-2-oxoethyl] O,O-diethyl ester (9CI) (CA INDEX NAME)



RN 94562-20-6 CAPLUS
CN Phosphorodithioic acid, S-[2-[3,4-dihydro-4-(1-methylethyl)-3-oxo-1(2H)-quinoxalinyl]-2-oxoethyl] O,O-dipropyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 76 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1985:62424 CAPLUS
DN 102:62424
TI 1,2,3,4-Tetrahydro-2-quinoxalone derivatives
PA Sumitomo Chemical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 59141592	A2	19840814	JP 1983-15838	19830201
	EP 118982	A1	19840919	EP 1984-300532	19840127
	R: CH, DE, FR, GB, IT, LI				
PRAI	JP 1983-15838		19830201		
	JP 1983-190545		19831012		

IT **94562-18-2P 94562-19-3P 94562-20-6P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and herbicidal activity of)

RN 94562-18-2 CAPLUS
CN Phosphorodithioic acid, S-[2-[3,4-dihydro-4-(1-methylethyl)-3-oxo-1(2H)-quinoxalinyl]-2-oxoethyl] O,O-diethyl ester (9CI) (CA INDEX NAME)



RN 94562-19-3 CAPLUS
CN Phosphorothioic acid, S-[2-[3,4-dihydro-4-(1-methylethyl)-3-oxo-1(2H)-quinoxalinyl]-2-oxoethyl] O,O-diethyl ester (9CI) (CA INDEX NAME)



RN 94562-20-6 CAPLUS
CN Phosphorodithioic acid, S-[2-[3,4-dihydro-4-(1-methylethyl)-3-oxo-1(2H)-quinoxalinyl]-2-oxoethyl] O,O-dipropyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 77 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1983:71807 CAPLUS
DN 98:71807
TI Penicillins.
PA Toyama Chemical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 36 pp.

V. Balasubramanian

CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 57118587	A2	19820723	JP 1981-188407	19811126
PRAI JP 1981-188407		19811126		

OS CASREACT 98:71807
IT **59702-78-2 59702-94-2**
RL: RCT (Reactant); RACT (Reactant or reagent)
(acylation by, of glycinamidopenam deriv.)
RN 59702-78-2 CAPLUS
CN 1-Piperazinecarbonyl chloride, 4-(1-methylethyl)-3-oxo- (9CI) (CA INDEX NAME)



RN 59702-94-2 CAPLUS
CN 1-Piperazinecarbonyl chloride, 4-(1-methyl-2-propenyl)-3-oxo- (9CI) (CA INDEX NAME)



IT **59703-50-3P 59703-66-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and bactericidal activity of)
RN 59703-50-3 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-[[[[[4-(1-methylethyl)-3-oxo-1-piperazinyl]carbonyl]amino]phenylacetyl]amino]-7-oxo-, monosodium salt, [2S-[2.alpha.,5.alpha.,6.beta.(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

RN 59703-66-1 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-[[[[[4-(1-methyl-2-propenyl)-3-oxo-1-piperazinyl]carbonyl]amino]phenylacetyl]amino]-7-oxo-, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 78 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1982:211131 CAPLUS
DN 96:211131
TI Piperazinone enkephalin analogs
AU Moon, M. W.; Lahti, R. A.; Vonvoigtlander, P. F.; Samanen, J.
CS Upjohn Co., Kalamazoo, MI, 49001, USA
SO Pept.: Synth., Struct., Funct., Proc. Am. Pept. Symp., 7th (1981), 641-4. Editor(s): Rich, Daniel H.; Gross, Erhard. Publisher: Pierce Chem. Co., Rockford, Ill.
CODEN: 47LMAO
DT Conference
LA English
IT **81851-85-6 81851-86-7 81939-19-7**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(analgesic activity of, structure in relation to)
RN 81851-85-6 CAPLUS
CN D-Alaninamide, L-tyrosyl-N-[2-[4-[1-(aminocarbonyl)-3-methylbutyl]-3-oxo-2-(phenylmethyl)-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)



RN 81851-86-7 CAPLUS
CN 1-Piperazineacetamide, N-[1-(aminocarbonyl)-3-methylbutyl]-2-oxo-.alpha.-(phenylmethyl)-4-(N-L-tyrosyl-D-alanyl)-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)



RN 81939-19-7 CAPLUS
CN 1-Piperazineacetamide, N-[1-(aminocarbonyl)-3-methylbutyl]-2-oxo-.alpha.-(phenylmethyl)-4-(N-L-tyrosyl-D-alanyl)-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)



L5 ANSWER 79 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1982:7084 CAPLUS
DN 96:7084
TI Piperazinone and piperazine polypeptides
IN Moos, Malcolm W.
PA Upjohn Co., USA
SO U.S., 23 pp.
CODEN: USXXAM
DT Patent

V. Balasubramanian

LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4251438	A	19810217	US 1979-48330	19790614
	US 4593098	A	19860603	US 1980-153435	19800527
PRAI	US 1979-48330		19790614		

IT **78551-78-7P 78551-79-8P 78551-80-1P**
78551-81-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and amidation)
RN 78551-78-7 CAPLUS
CN 1-Piperazineacetic acid, .alpha.-(2-methylpropyl)-2-oxo-4-[(phenylmethoxy)carbonyl]-3-(phenylmethyl)-, methyl ester, [S-(R*,R*)]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 78551-79-8 CAPLUS
CN 1-Piperazineacetic acid, .alpha.-(2-methylpropyl)-2-oxo-4-[(phenylmethoxy)carbonyl]-3-(phenylmethyl)-, methyl ester, [R-(R*,R*)]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 78551-80-1 CAPLUS
CN 1-Piperazineacetic acid, .alpha.-(2-methylpropyl)-2-oxo-4-[(phenylmethoxy)carbonyl]-3-(phenylmethyl)-, methyl ester, [R-(R*,S*)]-

(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 78551-81-2 CAPLUS
CN 1-Piperazineacetic acid, .alpha.-(2-methylpropyl)-2-oxo-4-[(phenylmethoxy)carbonyl]-3-(phenylmethyl)-, methyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **78551-82-3P 78551-83-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 78551-82-3 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[1-(aminocarbonyl)-3-methylbutyl]-3-oxo-2-(phenylmethyl)-, phenylmethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 78551-83-4 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[1-(aminocarbonyl)-3-methylbutyl]-3-oxo-2-(phenylmethyl)-, phenylmethyl ester, [R-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 80 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1978:62362 CAPLUS
DN 88:62362
TI Studies on .beta.-lactam antibiotics for medicinal purposes. I. Synthesis of D(-)-.alpha.-[(monooxo)-1-piperazinecarboxamido]benzylpenicillins and structure-antibacterial activity
AU Saikawa, Isamu; Takano, Shuntaro; Yoshida, Chosaku; Takashima, Okuta; Momonoi, Kaishu; Yasuda, Takashi; Kasuya, Kyoko
CS Res. Lab., Toyama Chem. Co., Ltd., Toyama, Japan
SO Yakugaku Zasshi (1977), 97(8), 883-9
CODEN: YKKZAJ; ISSN: 0031-6903
DT Journal
LA Japanese
IT **60122-99-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and bactericidal activity of)
RN 60122-99-8 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-[[[[[4-

(1-methylethyl)-3-oxo-1-piperazinyl]carbonyl]amino]phenylacetyl]amino]-7-oxo-, [2S-[2.alpha.,5.alpha.,6.beta.(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **59702-78-2**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with aminobenzylpenicillin)
RN 59702-78-2 CAPLUS
CN 1-Piperazinecarbonyl chloride, 4-(1-methylethyl)-3-oxo- (9CI) (CA INDEX NAME)



L5 ANSWER 81 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 1976:494355 CAPLUS
DN 85:94355
TI Penicillins
IN Saikawa, Isamu; Takano, Shuntaro; Yoshida, Chosaku; Takashima, Okuta; Kuroda, Seietsu; Komatsu, Miwako; Momonoi, Kaishu; Yasuda, Takashi; Kodama, Yutaka
PA Toyama Chemical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 45 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 50148380	A2	19751127	JP 1974-52254	19740513
	AU 7580431	A1	19761028	AU 1975-80431	19750423
	US 4087424	A	19780502	US 1975-571479	19750424
	IL 47168	A1	19790725	IL 1975-47168	19750424
	IL 53485	A1	19790930	IL 1975-53485	19750424
	IN 141981	A	19770514	IN 1975-CA852	19750428
	GB 1508062	A	19780419	GB 1975-17557	19750428
	GB 1508064	A	19780419	GB 1977-15360	19750428

	GB 1508063	A	19780419	GB 1977-15363	19750428
	DE 2519400	A1	19760304	DE 1975-2519400	19750430
	DE 2519400	B2	19810521		
	DE 2519400	C3	19820211		
	DE 2559932	C2	19830421	DE 1975-2559932	19750430
	DE 2560239	C2	19841011	DE 1975-2560239	19750430
	CA 1061331	A1	19790828	CA 1975-226043	19750501
	FR 2269937	A1	19751205	FR 1975-14159	19750506
	FR 2269937	B1	19790615		
	CH 605995	A	19781013	CH 1975-5847	19750506
	FI 7501340	A	19751110	FI 1975-1340	19750507
	FI 63760	B	19830429		
	FI 63760	C	19830810		
	DK 7502019	A	19751110	DK 1975-2019	19750507
	DK 151338	B	19871123		
	DK 151338	C	19880718		
	NL 7505375	A	19751111	NL 1975-5375	19750507
	NL 162386	B	19791217		
	NL 162386	C	19800516		
	AT 7503511	A	19770315	AT 1975-3511	19750507
	AT 340046	B	19771125		
	DD 117882	C	19760205	DD 1975-185922	19750508
	HU 169633	P	19761228	HU 1975-TO1002	19750508
	SE 7505392	A	19751223	SE 1975-5392	19750509
	SE 431457	B	19840206		
	SE 431457	C	19840517		
	GB 1508071	A	19780419	GB 1976-2002	19760119
	US 4112090	A	19780905	US 1976-654060	19760130
	US 4110327	A	19780829	US 1976-732860	19761015
	FR 2320295	A1	19770304	FR 1976-31895	19761022
	FR 2320295	B1	19801107		
	IN 145443	A	19781014	IN 1976-CA2121	19761127
	IN 145444	A	19781014	IN 1976-CA2122	19761127
	US 4410522	A	19831018	US 1977-841608	19771012
	CH 616939	A	19800430	CH 1977-16075	19771227
	FI 62833	B	19821130	FI 1978-330	19780201
	FI 62833	C	19830310		
	US 4219554	A	19800826	US 1978-915873	19780615
	CA 1078384	A1	19800527	CA 1978-308161	19780726
	SE 7808204	A	19780727	SE 1978-8204	19780727
	SE 435062	B	19840903		
	SE 435062	C	19841213		
	DK 7901049	A	19790314	DK 1979-1049	19790314
	DK 149950	B	19861103		
	DK 149950	C	19870928		
	US 4379152	A	19830405	US 1979-39904	19790517
	US 4327097	A	19820427	US 1979-47818	19790612
	DK 8000958	A	19800306	DK 1980-958	19800306
	DK 151958	B	19880118		
	DK 151958	C	19880718		
	FI 8100165	A	19810121	FI 1981-165	19810121
	FI 65780	B	19840330		
	FI 65780	C	19840710		
	FI 8100468	A	19810216	FI 1981-468	19810216
	FI 62834	B	19821130		
	FI 62834	C	19830310		
PRAI	JP 1974-50663		19740509		
	JP 1974-52254		19740513		

JP 1974-60787	19740531
JP 1974-91996	19740813
JP 1974-109954	19740926
JP 1974-142499	19741213
JP 1975-142499	19750327
JP 1975-37027	19750327
JP 1975-37207	19750327
IL 1975-47168	19750424
US 1975-571479	19750424
GB 1975-17557	19750428
IN 1975-CA852	19750428
CH 1975-5847	19750506
DK 1975-2019	19750507
FI 1975-1340	19750507
US 1976-654060	19760130
FI 1978-330	19780201
US 1978-915873	19780615

IT **59703-66-1P 60122-99-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and bactericidal activity of)

RN 59703-66-1 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-[[[[[4-(1-methyl-2-propenyl)-3-oxo-1-piperazinyl]carbonyl]amino]phenylacetyl]amino]-7-oxo-, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 60122-99-8 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-[[[[[4-(1-methylethyl)-3-oxo-1-piperazinyl]carbonyl]amino]phenylacetyl]amino]-7-oxo-, [2S-[2.alpha.,5.alpha.,6.beta.(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 82 OF 82 CAPLUS COPYRIGHT 2003 ACS

V. Balasubramanian

AN 1976:433052 CAPLUS
DN 85:33052
TI Penicillin and cephalosporin derivatives
IN Saikawa, Isamu; Takano, Shuntaro; Yoshida, Chosaku; Takashima, Okuta; Momonoi, Kaishu; Kuroda, Seietsu; Komatsu, Miwako; Yasuda, Takashi; Kodama, Yutaka
PA Toyama Chemical Co., Ltd., Japan
SO Ger. Offen., 237 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2519400	A1	19760304	DE 1975-2519400	19750430
	DE 2519400	B2	19810521		
	DE 2519400	C3	19820211		
	JP 50148378	A2	19751127	JP 1974-50663	19740509
	JP 50148380	A2	19751127	JP 1974-52254	19740513
	JP 50151891	A2	19751206	JP 1974-60787	19740531
	JP 51023284	A2	19760224	JP 1974-91996	19740813
	JP 51039687	A2	19760402	JP 1974-109954	19740926
	JP 51070788	A2	19760618	JP 1974-142499	19741213
	JP 51113890	A2	19761007	JP 1975-37207	19750327
	AT 7608289	A	19771215	AT 1976-8289	19761108
	ES 454266	A1	19771216	ES 1976-454266	19761215
	ES 454267	A1	19771216	ES 1976-454267	19761215
	US 4379152	A	19830405	US 1979-39904	19790517
PRAI	JP 1974-50663		19740509		
	JP 1974-52254		19740513		
	JP 1974-60787		19740531		
	JP 1974-91996		19740813		
	JP 1974-109954		19740926		
	JP 1974-142499		19741213		
	JP 1975-37207		19750327		
	AT 1975-3511		19750507		
	US 1976-654060		19760130		
	US 1978-915873		19780615		

IT **59702-78-2P 59702-94-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and acylation of aminobenzylpenams and aminobenzylcephems by)
RN 59702-78-2 CAPLUS
CN 1-Piperazinecarbonyl chloride, 4-(1-methylethyl)-3-oxo- (9CI) (CA INDEX NAME)



RN 59702-94-2 CAPLUS
CN 1-Piperazinecarbonyl chloride, 4-(1-methyl-2-propenyl)-3-oxo- (9CI) (CA INDEX NAME)



IT **59703-50-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and bactericidal activity of)
RN 59703-50-3 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-[[[[[4-(1-methylethyl)-3-oxo-1-piperazinyl]carbonyl]amino]phenylacetyl]amino]-7-oxo-, monosodium salt, [2S-[2.alpha.,5.alpha.,6.beta.(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

IT **59703-66-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and bactericidal of)
RN 59703-66-1 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-[[[[[4-(1-methyl-2-propenyl)-3-oxo-1-piperazinyl]carbonyl]amino]phenylacetyl]amino]-7-oxo-, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	257.41	406.17

STN INTERNATIONAL LOGOFF AT 11:09:28 ON 14 JUN 2003

V. Balasubramanian

RELATED SEQUENCES AVAILABLE WITH SEQLINK



ALL ANSWERS HAVE BEEN SCANNED

=> s l1 sss ful
FULL SEARCH INITIATED 11:07:53 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 5089 TO ITERATE

100.0% PROCESSED 5089 ITERATIONS 445 ANSWERS
SEARCH TIME: 00.00.01

L4 445 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	148.55	148.76

FILE 'CAPLUS' ENTERED AT 11:07:59 ON 14 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 14 Jun 2003 VOL 138 ISS 25
FILE LAST UPDATED: 13 Jun 2003 (20030613/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l4
L5 82 L4

V. Balasubramanian

=> d l5 1-82 bib hitstr

L5 ANSWER 1 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 2003:173381 CAPLUS
DN 138:221847
TI Preparation of piperazinone compounds as antitumor and anticancer agents
IN Hamilton, Andrew D.; Sebti, Said; Peng, Hairuo
PA Yale University, USA
SO PCT Int. Appl., 90 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003017939	A2	20030306	WO 2002-US26881	20020823

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2001-314795P P 20010824
OS MARPAT 138:221847
IT **501009-95-6P**, GGTI 2376
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of piperazinone compds. as antitumor and anticancer agents)
RN 501009-95-6 CAPLUS
CN 1-Piperazineacetic acid, 4-[3-(1H-imidazol-4-yl)-1-oxopropyl]-2-oxo-.alpha.,3-bis(phenylmethyl)-, ethyl ester, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **501009-96-7P**, GGTI 2377
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of piperazinone compds. as antitumor and anticancer agents)
RN 501009-96-7 CAPLUS

V. Balasubramanian

CN 1-Piperazineacetic acid, 4-[3-(1H-imidazol-4-yl)-1-oxopropyl]-2-oxo-.alpha.,3-bis(phenylmethyl)-, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **500783-09-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of piperazinone compds. as antitumor and anticancer agents)
RN 500783-09-5 CAPLUS
CN 1-Piperazineacetic acid, 2-oxo-4-[1-oxo-3-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-.alpha.,3-bis(phenylmethyl)-, ethyl ester, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 2 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 2002:869496 CAPLUS
DN 137:363033
TI Peptidomimetic modulators of cell adhesion
IN Gour, Barbara J.; Blaschuk, Orest W.; Ali, Anmar; Ni, Feng; Chen, Zhigang; Michaud, Stephanie D.; Wang, Shoameng; Hu, Zenjian
PA Can.
SO U.S. Pat. Appl. Publ., 309 pp., Cont.-in-part of U.S. Ser. No. 491,078.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2002168761	A1	20021114	US 2001-769145	20010124
PRAI US 2000-491078	A2	20000124		

OS MARPAT 137:363033
IT **351857-32-4**, 1-Piperazineacetamide, 4-[(2S)-2-(acetylamino)-3-(1H-

imidazol-4-yl)-1-oxopropyl]-3-methyl-.alpha.-(1-methylethyl)-2-oxo-, (.alpha.S,3S)- **351857-33-5**, 1-Piperazineacetamide, 4-[(2S)-2-(acetylamino)-3-(1H-imidazol-4-yl)-1-oxopropyl]-.alpha.-[(4-hydroxyphenyl)methyl]-3-methyl-2-oxo-, (.alpha.S,3S)- **351857-34-6**, L-Tyrosinamide, N-acetyl-L-histidyl-(.alpha.S,3S)-3-methyl-.alpha.-(1-methylethyl)-2-oxo-1-piperazineacetyl-
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

RN 351857-32-4 CAPLUS
CN 1-Piperazineacetamide, 4-[(2S)-2-(acetylamino)-3-(1H-imidazol-4-yl)-1-oxopropyl]-3-methyl-.alpha.-(1-methylethyl)-2-oxo-, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 351857-33-5 CAPLUS
CN 1-Piperazineacetamide, 4-[(2S)-2-(acetylamino)-3-(1H-imidazol-4-yl)-1-oxopropyl]-.alpha.-[(4-hydroxyphenyl)methyl]-3-methyl-2-oxo-, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 351857-34-6 CAPLUS
CN L-Tyrosinamide, N-acetyl-L-histidyl-(.alpha.S,3S)-3-methyl-.alpha.-(1-methylethyl)-2-oxo-1-piperazineacetyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

V. Balasubramanian



L5 ANSWER 3 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 2002:868740 CAPLUS
DN 137:370075
TI Preparation of diazabicyclo[3.3.1]nonane derivatives as FKBP-ligands
IN Guo, Chuangxing; Augelli-Szafran, Corinne E.; Barta, Nancy Sue; Bender, Steven Lee; Bigge, Christopher Franklin; Caprathe, Bradley William; Chatterjee, Arindam; Deal, Judith; Dong, Liming; Fay, Lorraine Kathleen; Hou, Xinjun; Hudack, Raymond Andrew, Jr.
PA Agouron Pharmaceuticals, Inc., USA; Warner-Lambert Company
SO PCT Int. Appl., 177 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002089806	A1	20021114	WO 2002-US14966	20020510

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2001-289828P P 20010510
OS MARPAT 137:370075
IT **475301-55-4P 475301-58-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of diazabicyclo[3.3.1]nonane derivs. as inhibitors of rotamase)
RN 475301-55-4 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]nonane-9-carboxylic acid, 3-[(1S)-1-methyl-2-phenylethyl]-2,4-dioxo-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

V. Balasubramanian



RN 475301-58-7 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]nonane-9-carboxylic acid, 3-[(1R)-1-methyl-2-phenylethyl]-2,4-dioxo-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 82 CAPLUS COPYRIGHT 2003 ACS
AN 2002:849621 CAPLUS
DN 137:353056
TI Preparation of benzenesulfonylpiperazines as matrix metalloproteinase inhibitors.
IN Chung, Yong-Jun; Lee, Keyong-Ho; Kim, Youn-Chul; Park, Ho-Jin
PA Kolon Ind. Inc., S. Korea
SO PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002088115	A1	20021107	WO 2002-KR759	20020424
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	KR 2001-22767	A	20010426		
	KR 2001-77522	A	20011207		
	KR 2002-14481	A	20020318		

OS MARPAT 137:353056
IT **474410-58-7P**

V. Balasubramanian

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of benzenesulfonylpiperazines as matrix metalloproteinase inhibitors)

RN 474410-58-7 CAPLUS

CN 2-Piperazinecarboxylic acid, 1-[(4'-bromo[1,1'-biphenyl]-4-yl)sulfonyl]-4-(1-octyldecyl)-5-oxo-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 2002:832817 CAPLUS

DN 137:338139

TI Preparation of pyrrolidine, piperidine, or piperazine amino acid derivatives as melanocortin receptor ligands

IN Mazur, Adam Wieslaw; Tian, Xinrong; Hu, Xiufeng Eric; Ebetino, Frank Hallock

PA The Procter & Gamble Company, USA

SO PCT Int. Appl., 143 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002085925	A2	20021031	WO 2002-US13340	20020424
	W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003109556	A1	20030612	US 2002-121874	20020412
PRAI	US 2001-286610P	P	20010425		
	US 2002-386620P	P	20020605		

OS MARPAT 137:338139

IT **474094-72-9P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of pyrrolidine, piperidine, or piperazine amino acid derivs. as melanocortin receptor ligands)

RN 474094-72-9 CAPLUS

CN 1-Piperazineacetic acid, 4-(N-acetyl-L-tyrosyl-4-fluorophenylalanyl)-3-(3-aminopropyl)-.alpha.-(2-naphthalenylmethyl)-2-oxo-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **474094-74-1P 474094-76-3P 474094-78-5P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of pyrrolidine, piperidine, or piperazine amino acid derivs. as melanocortin receptor ligands)

RN 474094-74-1 CAPLUS

CN 1-Piperazineacetic acid, 4-(N-acetyl-L-tyrosyl-4-fluorophenylalanyl)-3-[3-[(aminoiminomethyl)amino]propyl]-.alpha.-(2-naphthalenylmethyl)-2-oxo-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474094-76-3 CAPLUS
CN 1-Piperazineacetamide, 4-(N-acetyl-L-tyrosyl-4-fluorophenylalanyl)-3-(3-aminopropyl)-N-methyl-.alpha.-(2-naphthalenylmethyl)-2-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474094-78-5 CAPLUS
CN 1-Piperazineacetamide, 4-(N-acetyl-L-tyrosyl-4-fluorophenylalanyl)-3-(2-hydroxyethyl)-N-methyl-.alpha.-(2-naphthalenylmethyl)-2-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **474024-25-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of pyrrolidine, piperidine, or piperazine amino acid derivs. as melanocortin receptor ligands)
RN 474024-25-4 CAPLUS
CN 1-Piperazineacetic acid, 4-[2-[[(1,1-dimethylethoxy)carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]-.alpha.-(2-naphthalenylmethyl)-2-oxo-3-[3-[[(phenylmethoxy)carbonyl]amino]propyl]-, methyl ester (9CI) (CA INDEX NAME)



IT **474023-92-2P 474023-94-4P 474023-95-5P**
474023-96-6P 474024-00-5P 474024-01-6P
474024-02-7P 474024-04-9P 474024-05-0P
474024-06-1P 474024-08-3P 474024-09-4P
474094-71-8P 474094-73-0P 474094-75-2P
474094-77-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of pyrrolidine, piperidine, or piperazine amino acid derivs. as melanocortin receptor ligands)
RN 474023-92-2 CAPLUS
CN 1-Piperazineacetic acid, .alpha.-(2-naphthalenylmethyl)-4-[(2-nitrophenyl)sulfonyl]-2-oxo-3-[3-[[(phenylmethoxy)carbonyl]amino]propyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 474023-94-4 CAPLUS
CN 1-Piperazineacetic acid, 4-[2-[[(1,1-dimethylethoxy)carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]-.alpha.-(2-naphthalenylmethyl)-2-oxo-3-[3-[[(phenylmethoxy)carbonyl]amino]propyl]- (9CI) (CA INDEX NAME)



RN 474023-95-5 CAPLUS
CN Carbamic acid, [3-[1-[2-[[(1,1-dimethylethoxy)carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]-4-[2-(methylamino)-1-(2-naphthalenylmethyl)-2-oxoethyl]-3-oxo-2-piperazinyl]propyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 474023-96-6 CAPLUS
CN Carbamic acid, [3-[1-[2-amino-3-(4-fluorophenyl)-1-oxopropyl]-4-[2-(methylamino)-1-(2-naphthalenylmethyl)-2-oxoethyl]-3-oxo-2-piperazinyl]propyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 474024-00-5 CAPLUS
CN 1-Piperazineacetic acid, 3-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-.alpha.-(2-naphthalenylmethyl)-4-[(2-nitrophenyl)sulfonyl]-2-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 474024-01-6 CAPLUS
CN 1-Piperazineacetic acid, 3-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-.alpha.-(2-naphthalenylmethyl)-4-[(2-nitrophenyl)sulfonyl]-2-oxo- (9CI) (CA INDEX NAME)



RN 474024-02-7 CAPLUS
CN 1-Piperazineacetamide, 3-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-N-methyl-.alpha.-(2-naphthalenylmethyl)-4-[(2-nitrophenyl)sulfonyl]-2-oxo- (9CI) (CA INDEX NAME)



RN 474024-04-9 CAPLUS
CN 1-Piperazinecarboxylic acid, 2-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-4-[2-(methylamino)-1-(2-naphthalenylmethyl)-2-oxoethyl]-3-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 474024-05-0 CAPLUS
CN 1-Piperazinecarboxylic acid, 2-(2-hydroxyethyl)-4-[2-(methylamino)-1-(2-naphthalenylmethyl)-2-oxoethyl]-3-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 474024-06-1 CAPLUS
CN 1-Piperazinecarboxylic acid, 2-[2-(acetyloxy)ethyl]-4-[2-(methylamino)-1-(2-naphthalenylmethyl)-2-oxoethyl]-3-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 474024-08-3 CAPLUS
CN Carbamic acid, [2-[2-[2-(acetyloxy)ethyl]-4-[2-(methylamino)-1-(2-naphthalenylmethyl)-2-oxoethyl]-3-oxo-1-piperazinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 474024-09-4 CAPLUS
CN 1-Piperazineacetamide, 3-[2-(acetyloxy)ethyl]-4-[2-amino-3-(4-fluorophenyl)-1-oxopropyl]-N-methyl-.alpha.-(2-naphthalenylmethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 474094-71-8 CAPLUS
CN 1-Piperazineacetic acid, 4-(N-acetyl-L-tyrosyl-4-fluorophenylalanyl)-.alpha.-(2-naphthalenylmethyl)-2-oxo-3-[3-[[(phenylmethoxy)carbonyl]amino]propyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474094-73-0 CAPLUS
CN 1-Piperazineacetic acid, 4-(N-acetyl-L-tyrosyl-4-fluorophenylalanyl)-3-[3-[[bis[[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]propyl]-.alpha.-(2-naphthalenylmethyl)-2-oxo-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474094-75-2 CAPLUS
CN Carbamic acid, [3-[1-(N-acetyl-L-tyrosyl-4-fluorophenylalanyl)-4-[2-(methylamino)-1-(2-naphthalenylmethyl)-2-oxoethyl]-3-oxo-2-piperazinyl]propyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)